J. Jack Lee, Ph.D., M.S., D.D.S.
Department of Biostatistics, Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Affiliate member, Department of Institute for Data Science in Oncology (IDSO), Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, TX
Adjunct Professor of Biostatistics, Department of Biostatistics and Data Science, University of Texas School of Public Health, Houston, TX
Professor of Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member of the Graduate Faculty, The University of Texas MD Anderson Cancer Center and UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX
Dual/Joint/Adjunct Appointment
Visiting Professor, Department of Institute of Epidemiology and Preventive Medicine, National Taiwan University, College of Public Health, Taipei, Taiwan
Director, Department of Biostatistics Resource Group, Cancer Center Support Grant, The University of Texas MD Anderson Cancer Center Support Grant, Houston, TX
John G. & Marie Stella Kenedy Foundation Chair in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor of Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Adjunct Professor of Biostatistics, Department of Biostatistics and Data Science, University of Texas School of Public Health, Houston, TX
Regular Member of the Graduate Faculty, The University of Texas MD Anderson Cancer Center and UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX
Research Interests
Dr. Lee’s areas of research interest include design and analysis of clinical trials, survival analysis, longitudinal data analysis, statistical computation/graphics, statistical methods for determining drug interaction in combination studies, and cancer chemoprevention. Dr. Lee has been working on the development and application of innovative Bayesian methods for cancer clinical trials. He also actively participates in many multidisciplinary translational research in head/neck and lung cancer teams funded by National Institute of Health (NIH) and the Department of Defense (DoD). He has particular interests in incorporating multiple biomarkers and adaptive designs to develop more efficient and ethical clinical trials.
Dr. Lee is a Statistical Editor for the Journal of the National Cancer Institute and Cancer Prevention Research. He is a Fellow of the American Statistical Association.
Education & Training
Degree-Granting Education
| 1989 | University of California, Los Angeles, Los Angeles, California, US, Biostatistics, Ph.D |
| 1984 | University of California, Los Angeles, Los Angeles, California, US, Biostatistics, M.S |
| 1982 | National Taiwan University, Taipei, Taiwan, Dentistry, DDS |
Postgraduate Training
| 2018-2023 | LEADing Leaders & LEADing Institution, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2003-2004 | Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Adjunct Professor of Statistics, Rice University, Houston, TX, 2004 - 2016
Stanley Schor Visiting Scholar, Merck Research Laboratories, Rahway, NJ, 1998 - 1999
Adjunct Associate Professor of Biostatistics, University of Texas School of Public Health, Houston, TX, 1997 - 2001
Associate Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997 - 2001
Adjunct Assistant Professor of Biometry, University of Texas School of Public Health, Houston, TX, 1995 - 1997
Assistant Professor and Assistant Biomathematician, Department of Biomathematics, The University of Texas MD Anderson Cancer Center, Houston, TX, 1991 - 1997
Adjunct Assistant Professor, Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, 1989 - 1991
Senior Consulting Statistician, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 1987 - 1988
Senior Statistician, Base Unit, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, 1987 - 1989
Statistician and Senior Statistician, Base Unit, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, 1984 - 1989
Postgraduate Researcher, Department of Division of Biostatistics, University of California, Los Angeles, Los Angeles, CA, 1984
Teaching Assistant, Department of Division of Biostatistics, University of California, Los Angeles, Los Angeles, CA, 1983 - 1984
Statistical Assistant, Department of Statistical Biomathematical Consulting Clinic, University of California, Los Angeles, Los Angeles, CA, 1983 - 1984
Administrative Appointments/Responsibilities
Associate Vice President, Department of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2022
Associate Vice Provost, Department of Quantitative Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2017
Past Chair, Faculty Senate, University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2006
Chair, Faculty Senate, University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2005
Chair Elect, Faculty Senate, University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2004
Associate Director of Biostatistics, Department of Community Clinical Oncology Program, University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2005
Other Professional Positions
Member, Committee for AACR Waun Ki Hong Award for for Outstanding Achievement in Translational and Clinical Cancer Research, Philadelphia, PA, 2025 - Present
Member, External Advisory Board, Fred and Pamela Buffet Cancer Center, Omaha, NE, 2024 - Present
Expert Statistical Advisor, U.S. Food and Drug Administration, Silver Spring, MA, 2023 - 2025
Member, Evaluating the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union: A Consensus Study, National Academies of Science, Engineering and Medicine, Washington, DC, 2023 - 2024
Member, Committee for AACR Lifetime Achievement Award in Cancer Research, Philadelphia, PA, 2022 - 2024
Member, American Association for the Advancement of Science (AAAS) Review Committee for Andy Hill Cancer Research Endowment (CARE) Fund, Distinguished Researchers Program, Washington DC, 2021
Member, American Association for Cancer Research (AACR) Cancer Prevention Working Group Steering Committee, Philadelphia, PA, 2021 - Present
Member, NCI Thoracic Malignancy Steering Committee, Bethesda, MD, 2019 - 2022
Member, AbbVie Statistical Advisory Board, Chicago, IL, 2018
Member, AACR-Johnson & Johnson Lung Cancer Innovation Science Grants Scientific Review Committee, Philadelphia, PA, 2018 - 2019
Member, Assessment Committee, National Taiwan University School of Dentistry, Graduate Institute of Clinical Dentistry, Graduate Institute of Oral Biology, Taipei, Taiwan, 2018
Member, University of Arizona Cancer Center's External Advisory Board, Tucson, AZ, 2017 - Present
Consultantships, Workshop on Bayesian Methods for Clinical Trials, Roche-China, Shanghai, China, 2016
Member, Cancer Prevention Summit, American Association for Cancer Research, Leesburg, VA, 2016
Member, Search Committee, Chair of Department of Biostatistics, University of Texas School of Public Health, Houston, TX, 2015 - 2017
Member, Emory University, External Advisory Board to Dr. Haian Fu's program project grant entitled "Targeting LKB1-associated tumor vulnerability in lung cancer", Atlanta, GA, 2015 - Present
Member, Cancer Prevention Think Tank, National Cancer Institute, NCI Shady Grove, Rockville, MD, 2015
Member, Expert Advisory Panel of "Methodological Study to Address Two Major Gaps in the Analysis of Heterogeneity of Treatment Effect (HTE)" grant (PI: Ravi Varadhan, PhD) funded by Patient-Centered Outcomes Research Institute (PCORI), John Hopkins University, Baltimore, MD, 2014 - 2015
Member, AACR Clinical and Translational Cancer Research Committee, Philadelphia, PA, 2013 - 2015
Member, AACR Science Education Committee, Philadelphia, PA, 2013 - 2015
Member, External Advisory Board (Dr. Herbst's Lung SPORE Grant), Yale University, New Haven, CT, 2013 - Present
Ad-hoc Member, Harvard Cancer Center External Advisory Board, Dana-Farber Cancer Institute, Boston, MA, 2013
Member, Ad-hoc Site-Visit Committee of Endostar and M2ES, New Haven, CT, 2012
Member, LUNGEVITY Career Development Award Review Committee, Chicago, IL, 2012
Member, External Advisory Board to Dr. Everett Vokes’ Head and Neck SPORE grant application. University of Chicago, Chicago, IL, 2012
Consultantships, Lung Cancer Advisory Board, Tragara Pharmaceuticals, Santa Monica, CA, 2011
Member, The WINTHER Trial Steering Committee, A study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in Subjects with Advanced malignancies. The WIN Consortium, Paris, 2011 - 2014
Member, University of Wisconsin, Madison, External Advisory Board to Dr. Paul Harari’s Head and Neck SPORE grant application, Madison, WI, 2011 - Present
Chair, David P. Byar Young Investigator Award selection committee, Biometrics Section, American Statistical Association, Anaheim, CA, 2011 - 2012
Member, AACR Clinical and Translational Cancer Research Think Tank, San Francisco, CA, 2010
Member, Steering Committee for The Canadian Optically Guided Approach for Oral Lesions Surgical Trial (COOLS Study), British Columbia Cancer Agency, Vancouver, 2010 - 2016
Member, University of Pennsylvania, External Advisory Board to Dr. External Advisory Board to Dr. Anil Rustgi’s Program Project grant “Mechanisms of Esophageal Carcinogenesis”, Philadelphia, PA, 2010 - 2019
Member, Scientific Advisory Board, LUNGevity Foundation, Alexandria, VA, 2010 - 2015
Member, David P. Byar Young Investigator Award selection committee, Biometrics Section, American Statistical Association, Miami, FL, 2010 - 2011
Mentor, Special Session for High School Students, American Association for Cancer Research, Eighth Annual International Conference on Frontiers in Cancer Prevention Research, Houston, TX, 2009
Member, Publication Committee, American Association for Cancer Research, Philadelphia, PA, 2009 - 2011
Member, Emory University, External Advisory Board to Dr. Fadlo Khuri's program project grant entitled "Targeting cells signaling in lung cancer to enhance therapeutic efficacy", Atlanta, GA, 2009 - 2015
Member, ASCO YIA and CDA Grant Selection Committee, Alexandria, VA, 2009 - 2011
Member, External Advisory Board to Dr. Dong Shin's Head and Neck SPORE. Emory University, Atlanta, GA, 2009 - Present
Member, Scientific Advisory Board, Protect Your Lungs, Prevent Cancer Foundation, Alexandria, VA, 2009 - 2010
Consultantships, Scientific Input Engagement on “Biomarker Adaptive Designs in Oncology Development” Merck & Co., Inc, Upper Gwynedd, PA, 2008
Member, Advisory Council on Lung Cancer Early Detection Research, Prevent Cancer Foundation, Washington, DC, 2008
Member, Head and Neck Cancer Metastasis/Recurrence Disease Task Force, National Cancer Institute, Bethesda, MD, 2007 - 2015
Member, ASCO Cancer Prevention Curriculum, Alexandria, VA, 2005 - 2006
Member, Third Program for the Assessment of Clinical Cancer Tests (PACCT) 13. Working Group, National Cancer Institute, Bethesda, 2005 - 2006
Member, Data Safety Monitoring Board/Scientific Steering Committee for "A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib in the Prevention of Colorectal Sporadic Adenomatous Polyps" (PIs: B. Levin, MD and N. Arber, MD), Houston, TX, 2001 - 2006
Member, Data Safety Monitoring Board/Steering Committee for "A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients, N01-CN-90540 (NCI)" Study PI: Frank Sinicrope, M.D, Houston, TX, 2001 - 2002
Member, Head and Neck Committee of the American Joint Committee on Cancer, Chicago, 2000 - 2007
Member, Statistical Committee of the American Joint Committee on Cancer, Chicago, 2000 - 2007
Extramural Institutional Committee Activities
Member, Ziyi Li Pre-PTC Advance Committee, The University of Texas MD Anderson Cancer Center, 2025
Member, Research Integrity Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Suyu Liu Pre-PTC Advance Committee, The University of Texas MD Anderson Cancer Center, 2025
Member, Chong Wu Pre-PTC Advance Committee, The University of Texas MD Anderson Cancer Center, 2025
Member, Institutional Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Member, Data Science Faculty Recruitment Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Clinical Research Technology Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Context Engine Program Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Scientific Review Committee 2, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Senior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Committee on Faculty Awards, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Clinical Trial Management System (CTMS) Executive Program Governance Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, Advisory Council of Clinical Research Leaders (ACCRL), The University of Texas MD Anderson Cancer Center, 2021 - 2024
Chair, Data Management Initiative (DMI) Advisory Board, The University of Texas MD Anderson Cancer Center, 2020 - 2022
Member, Stiefel Research Fund Steering Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
ex-officio, Executive Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2022
Member, Internal Advisory Board, MD Anderson Breast Cancer SPORE, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, COVID Research Working Group, The University of Texas MD Anderson Cancer Center, 2020 - 2022
Member, Research Leadership Team Data Management, The University of Texas MD Anderson Cancer Center, 2020 - 2022
Member, Clinical Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Member, Executive Committee of IRB, The University of Texas MD Anderson Cancer Center, 2019 - 2022
Member, Graduate School of Biomedical Sciences, Membership Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022
Member, Research Investigation Committee, MD Anderson, Houston, TX,, The University of Texas MD Anderson Cancer Center, 2019 - 2022
Member, Information Technology Executive Team (ITEC), The University of Texas MD Anderson Cancer Center, 2019 - 2022
Co-Chair, Data Safety and Monitoring Board, The University of Texas MD Anderson Cancer Center, 2019 - 2022
Co-Chair, Research and Academic Information (RAI) Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022
Member, Office of Clinical Research Administration Reorganizing Committee, The University of Texas MD Anderson Cancer Center, 2018
Member, Patient History Database (PHDB) Access Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2022
Member, Across Cancer Spectrum Working Group of the Operational Priority: “Achieve Decisive Discoveries”, The University of Texas MD Anderson Cancer Center, 2017 - 2019
Co-Chair, Click IRB Executive Steering Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2019
Member, Clinical Trials Activation Retreat Organizing Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2020
Co-Chair, Clinical Trials Activation Biostatistics Working Group, The University of Texas MD Anderson Cancer Center, 2017 - 2020
Member, K12/Calabresi Scholar Program, Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Internal Advisory Committee, MD Anderson Ovarian SPORE, The University of Texas MD Anderson Cancer Center, 2017 - Present
Co-Chair, Research Database Steering Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2018
Member, Research Informatics Subcommittee of the Informatics Governance Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2018
Member, Information Security Compliance Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present
Co-Chair, TissueStation Review Committee, The University of Texas MD Anderson Cancer Center, 2015
Co-Chair, Sabin Family Fellow Award, Population and Quantitative Science Panel, The University of Texas MD Anderson Cancer Center, 2015 - 2022
Member, Research IS Consortium Advisory Board, The University of Texas MD Anderson Cancer Center, 2014 - 2018
Member, Electronic Health Record Integrated Research Team, The University of Texas MD Anderson Cancer Center, 2014 - 2016
Member, Electronic PRMS Accrual Audit Committee (ePAAC), The University of Texas MD Anderson Cancer Center, 2014 - 2019
Co-Chair, Consortium for Research Data Management System, The University of Texas MD Anderson Cancer Center, 2014 - 2018
Member, Information System Executive Team (ISET), The University of Texas MD Anderson Cancer Center, 2014 - 2019
Member, eResearch Executive Steering Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2017
Member, Data Governance Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2022
Member, Mentor Committee for Chad Huff, Ph.D., Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 2013 - 2016
Member, Endowed Positions and Awards Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2015
Co-Chair, Research and Education Information System Steering Team, The University of Texas MD Anderson Cancer Center, 2013 - 2019
Co-Chair, Clark Fellows Award, Clinical Innovator Panel, The University of Texas MD Anderson Cancer Center, 2013 - 2014
Member, Planning Committee, 2014 MD Anderson Methods & Design Workshop for Junior Faculty, The University of Texas MD Anderson Cancer Center, 2013 - 2014
Member, Mentor Committee for Yuanging Ye, PhD, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 2013 - 2016
Member, Institutional Research Executive Committee (IREC), The University of Texas MD Anderson Cancer Center, 2013 - 2017
Chair, Statistical Computing Committee, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 2012 - 2014
Member, Internal Advisory Committee, MD Anderson Leukemia SPORE, The University of Texas MD Anderson Cancer Center, 2012
Member, Internal Advisory Committee, MD Anderson Melanoma SPORE, The University of Texas MD Anderson Cancer Center, 2012
Member, Vice Provost Advisory Council - Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2017
Member, CPRIT MIRA Internal Advisory Board, PI: Jonathan Kurie, MD, The University of Texas MD Anderson Cancer Center, 2012
Member, Department of Epidemiology Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2015
Member, Clinical Research Subcommittee of the Institutional Clinical Executive Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012
Chair, Department of Biostatistics Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2011
Reviewer, Sister Institution Network Fund Grant Review Committee, The University of Texas MD Anderson Cancer Center, 2011
Member, Institutional Clinical Executive Committee - Clinical Research Subcommittee, The University of Texas MD Anderson Cancer Center, 2011 - 2012
Member, Molecular Testing Task Force Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2019
Member, Ph.D. Qualify Examine Committee, University of Texas Graduate School of Biomedical Sciences, Program of Biomathematics and Biostatistics, The University of Texas MD Anderson Cancer Center, 2008 - 2014
Member, Institute of Personalized Cancer Therapy Steering Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2022
Member, Faculty Achievement Award, Selection Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2009
Member, Department of Bioinformatics and Computational Biology Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2008
Member, Faculty Senate Salary Review Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2009
Member, Faculty Ad-hoc Committee on Animal Protocols, The University of Texas MD Anderson Cancer Center, 2006 - 2009
Member, Extramural Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2006
Faculty Senate Representative, Bridge Funding Advisory Panel, The University of Texas MD Anderson Cancer Center, 2005 - 2006
Member, Division of Cancer Medicine ASCO - Young Investigator Award and Career Development Award Review Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2022
Member, Faculty Salary Equity Study Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2007
Faculty Senate Representative, Faculty Salary Diversity Review Panel, The University of Texas MD Anderson Cancer Center, 2005 - 2006
Alternate Member, Data Safety and Monitoring Board (Data Monitoring Committee), The University of Texas MD Anderson Cancer Center, 2004 - 2015
Chair, Mid-tenure Review Committee for E. Warwick Daw, Ph.D, The University of Texas MD Anderson Cancer Center, 2004
Member, Faculty Compensation Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2007
Faculty Senate Representative, Facility Steering Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2005
Faculty Senate Representative, UCF Funding Subcommittee, The University of Texas MD Anderson Cancer Center, 2004 - 2005
Faculty Senate Representative, Research Council, The University of Texas MD Anderson Cancer Center, 2004 - 2005
Member, Faculty Achievement Award, Parent Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2005
Faculty Senate Representative, President Advisory Board, The University of Texas MD Anderson Cancer Center, 2004 - 2005
Faculty Senate Representative, Conflict Management Advisory Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2006
Member, Data Safety Monitoring Board, Clinical Community Oncology Program, The University of Texas MD Anderson Cancer Center, 2004 - 2005
Member, University of Texas Faculty Advisory Council, The University of Texas MD Anderson Cancer Center, 2003 - 2005
Member, Faculty Oversight Committee for Database Development, The University of Texas MD Anderson Cancer Center, 2002 - 2005
Member, Executive Committee of Faculty Senate, The University of Texas MD Anderson Cancer Center, 2002 - 2006
Member, Faculty Achievement Award, Cancer Prevention Subcommittee, The University of Texas MD Anderson Cancer Center, 2002
Faculty Senate Representative, Executive Committee of Science Faculty, The University of Texas MD Anderson Cancer Center, 2002 - 2004
Member, Search Committee, Chair of Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, 2002
Member, Institutional Blue Ribbon Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2003
Member, Advisory Committee of Dr. Benedict's Bladder Cancer P01, The University of Texas MD Anderson Cancer Center, 2001
Alternate Member, Institutional Surveillance Committee (IRB), The University of Texas MD Anderson Cancer Center, 2001 - 2002
Member, Carl de Moor's Mid-Tenure Review Committee for Ph.D, The University of Texas MD Anderson Cancer Center, 2000
Member, Department of Biostatistics Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2000
Member, Department of Biostatistics Statistical Analyst Search Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2005
Member, Advisory Committee of Biology of Non-Melanoma Skin Cancer: Growth and Progression-PI, Margaret Kripke, PhD, The University of Texas MD Anderson Cancer Center, 1999
Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1998
Member, Faculty Achievement Award, Cancer Prevention Subcommittee, The University of Texas MD Anderson Cancer Center, 1994
Editorial Activities
Editor/Service on Editorial Board(s), Editorial Board, Journal of Clinical Oncology – Precision Oncology, 2020 - Present
Special Issue Co-Editor, The Collection of Statistical Methods for Precision Oncology, Journal of Clinical Oncology – Precision Oncology, 2019
Member, Editorial Board, Chinese Clinical Oncology, 2012 - 2020
Statistics Section Co-Editor, Clinical Cancer Research, 2007 - 2013
Statistical Editor, Cancer Prevention Research, 2007 - Present
Statistical Editor, Journal of the National Cancer Institute, 2001 - Present
Honors & Awards
| 2023 | Hall of Fame Award, School of Public Health, University of California, Los Angeles |
| 2019 | Fellow, American Association for the Advancement of Science |
| 2017 | Fellow, Society for Clinical Trials |
| 2010 | Excellence in Team Science Award, Division of Cancer Medicine (with Roy Herbst, Edward Kim, Scott Lippman, and Ignacio Wistuba on the BATTLE Program), UTMDACC |
| 2010 | Excellence-in-CE Award (with Donald Berry, Scott Berry, & Brad Carlin on "Bayesian Adaptive Methods for Clinical Trials."), Joint Statistical Meetings, American Statistical Association |
| 2009 | John G. & Marie Stella Kenedy Foundation Chair in Cancer Research, UTMDACC |
| 2008 | Fellow, American Statistical Association |
| 2007 | Margaret & James A. Elkins, Jr. Faculty Achievement Award in Cancer Prevention, UTMDACC |
| 2006 | Julie and Ben Rogers Award for Excellence in Prevention, Finalist |
| 1998 - 1999 | Stanley Schor Scholar, Merck Research Laboratories |
| 1988 | Associate Member of Delta Omega |
| 1988 | Associate Member of Sigma Xi |
| 1982 - 1983 | Book Coupon Awards, National Taiwan University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Informal Biostatistics Lunch Discussion Series: Context Engine and Foundry for Biostatisticians. Conference. Houston, Texas, US.
- 2024. Rigor and Reproducibility in Research: FY25 Responsible Conduct of Research Class for Postdocs. Conference. Houston, Texas, US.
- 2024. Clinical Trial Overview and Bayesian Basic Image Guided Cancer Therapy/IDBT Workshop. Houston, Texas, US.
- 2024. MD Anderson Cancer Center Support Group (CCSG) Biostatistics Resource Group (BRG) Progress Report to Core Facilities Oversight Board Monthly Meeting. Conference. Houston, TX, US.
- 2023. Power of Statistics. Discussion Series for Fellows at the Institute of Data Science in Oncology. Conference. Houston, TX, US.
- 2023. Rigor and Reproducibility in Research. FY24 Responsible Conduct of Research Course for Fellows. Conference. Houston, TX, US.
- 2023. Rigor and Reproducibility for Statistical Analysis. Safety Moment at Research Townhall, Division of Science. Conference. Houston, TX, US.
- 2023. Sharpening Your Quantitative Reasoning Skills. Keynote Speaker of Quantitative Science Program Retreat. Conference. Houston, TX, US.
- 2022. We Are All Bayesians: Bayes 101, 102, and Model-Assisted Designs. Conference. Houston, TX, US.
- 2022. A New Data Science Platform at MDA: Context Engine and Foundry (with Scott Woodman and James Long). Conference. Houston, TX, US.
- 2022. We Are All Bayesians: From Bayes 101 to Novel Adaptive Designs. Conference. Houston, TX, US.
- 2021. My Journey in Biostatistics. Conference. QS Faculty Insight Series. Houston, TX, US.
- 2021. Statistical Considerations for Later Stage Clinical Trials. Conference. Houston, TX, US.
- 2021. Biostatistics and Data Integration Core Presentation, Oropharyngeal Program. Conference. Houston, TX, US.
- 2021. Informal Biostatistics Lunch Discussion Series: Introduce a reproducible software: StatTag for PC/Mac. Conference. Houston, TX, US.
- 2021. Biostatistics and Data Integration Core Presentation. Conference. Oropharyngeal Program. Houston, TX, US.
- 2021. Mentoring Day, Panelist. Conference. Houston, TX, US.
- 2021. Progress Report of Biostatistics and Bioinformatics Core. Conference. MD Anderson Melanoma SPORE External Advisory Committee Meeting. Houston, TX, US.
- 2020. COVID-19 Vaccine Trials. Informal Biostatistics Lunch Discussion Series. Conference. Houston, TX, US.
- 2020. Informal Biostatistics Lunch Discussion Series: Research Databases in Biostat: DMI and REDCap. Conference. Houston, TX, US.
- 2020. Informal Biostatistics Lunch Discussion Series: Panel discussion of COVID-19 related projects – designs, reviews, and experiences. Conference. Houston, TX, US.
- 2019. Discussions on Potential Collaborations between Taiwan Ministry of Science and Technology and MD Anderson. Conference. Houston, TX, US.
- 2019. Joy of Statistics – A Great Time To Be a Biostatistician! Quantitative Science Program Retreat. Conference. Houston, TX, US.
- 2019. Discussions on Potential Collaborations between Taiwan Ministry of Science and Technology and MD Anderson. Conference. Houston, TX, US.
- 2019. Informal Biostatistics Lunch Discussion Series: MD Anderson Cancer Center Support Grant (CCSG) Biostatistics Resource Group (BRG). Conference. Houston, TX, US.
- 2017. Informal Biostatistics Lunch Discussion Series: Searching & Validating Biomarkers in Cancer Immunotherapy. Conference. Houston, TX, US.
- 2017. Streamlining Clinical Trial Activations. Conference. Clinical Trial Activation Retreat. Houston, TX, US.
- 2017. Informal Biostatistics Lunch Discussion Series: Rigor and Reproducibility in Research Initiative. Conference. Houston, TX, US.
- 2016. Informal Biostatistics Lunch Discussion Series: Learning Bayesian Update via Shiny - Understanding How Bayesian Method Works Through Visualization. Conference. Houston, TX, US.
- 2015. Panel Discussion: Academic Career Development. Conference. 1st Annual Biotechnology Conference. Houston, TX, US.
- 2015. Novel Clinical Trial Designs. Conference. University of Texas MD Anderson Clinical Trial Methods & Design Workshop for Junior Faculty. Houston, TX, US.
- 2015. Are Outcome-Adaptive Randomization Trials Ethical?. Conference. Houston, TX, US.
- 2014. Extending the Cancer Prevention Frontier: Personalizing Prevention via Risk Modeling, Molecular Targets and Novel Trial Designs. Conference. Houston, TX, US.
- 2014. CMS400 Pilot Study. Conference. Molecular Tumor Board. Houston, TX, US.
- 2014. Biostatistics 101: Essential Statistical Considerations in Clinical Trials and More. Conference. University of Texas MD Anderson Clinical Trial Methods & Design Workshop for Junior Faculty. Houston, TX, US.
- 2012. Informal Biostatistics Lunch Discussion Series: Outcome Adaptive Randomization – Is It Useful & How to Communicate Effectively to Statisticians and Non-statisticians. Conference. Houston, TX, US.
- 2010. Challenge and Promise for Breast Cancer Prevention Trials. Conference. Houston, TX, US.
- 2009. Predictive Probability and Adaptive Randomization Designs for Phase II Clinical Trials. Conference. Bayesian Clinical Trial Design Discussion Forum. Houston, TX, US.
- 2009. Database development for personalized medicine trials (part of the presentation of Institute of Personalized Cancer Therapy). Conference. Cancer Center Support Grant External Advisory Board Meeting. Houston, TX, US.
- 2008. Biomarker-based adaptive randomization for personalized medicine. Conference. MDACC - Institut de Carcerologie Gustave Roussy Workshop. Houston, TX, US.
- 2008. Overview of the Statistical Properties of Adaptive Randomization in the BATTLE Trial. Conference. Interdisciplinary Forum CCSG Lung Cancer Program. Houston, TX, US.
- 2006. Adaptive randomization design and implementation for the DoD-BATTLE trial. Conference. Houston, TX, US.
- 2005. Cut-point selection for evaluating biomarkers as prognostic variables. Conference. Biomarker Journal Club. Houston, TX, US.
- 2004. Surviving survival analysis on time varying covariates. Conference. Houston, TX, US.
- 2003. Statistical Design and Data Management of Clinical Trials to visitors from Korea National Cancer Center. Conference. Houston, TX, US.
- 2002. Web-based Clinical and Biomarker Databases in Chemoprevention Trials (Jointly given with Juan Posadas). Conference. Houston, TX, US.
- 2001. Intriguing or incidental? Subset analysis in cancer clinical trials, part of "What's CCOP and why is it important to cancer and MDACC?" (Archie Bleyer, M.D., Chair). Conference. Advances in Oncology Institutional Grand Rounds. Houston, TX, US.
- 2001. Design and estimation issues for multi-stage phase II trials, Biostatistics Workshop. Conference. Houston, TX, US.
- 2001. Lessons learned from analyzing the differential gene expression data between normal and tumor tissues in head and neck cancer patients. Conference. Bioinformatics Workshop. Houston, TX, US.
- 2000. Biostatistics and Data Management in Translational Cancer Research in the Upper Aerodigestive Tracts. Conference. Houston, TX, US.
- 2000. Approaches to the analysis of biomarkers. Conference. Chemoprevention Retreat. Houston, TX, US.
- 2000. Sample size calculation for historical control studies. Conference. Houston, TX, US.
- 1998. Design and statistical considerations for phase III chemoprevention trials, part of Intergroup lung second primary tumor prevention trial: A model for phase III chemoprevention trials (Scott M. Lippman, Chair). Conference. Houston, TX, US.
- 1997. Xgobi as a tool for exploratory data analysis in biomarker studies. Conference. Applied Biostatistics Workshop. Houston, TX, US.
- 1997. Updates and new features of survplot and bxplt functions. Conference. Applied Biostatistics Workshop. Houston, TX, US.
- 1996. Extensions of event charts. Conference. Applied Biostatistics Workshop. Houston, TX, US.
- 1996. Analysis of the correlated ordinal categorical data. Conference. Applied Biostatistics Workshop. Houston, TX, US.
- 1996. Adjusted correlation coefficient in measurement error models. Conference. Applied Biostatistics Workshop. Houston, TX, US.
- 1996. Stochastic curtailment and conditional power calculation for interim monitoring of clinical trials. Conference. Applied Biostatistics Workshop. Houston, TX, US.
- 1996. Correspondence analysis. Conference. Applied Biostatistics Workshop. Houston, TX, US.
- 1995. Statistics in action: measures of agreement and association. Conference. Applied Biostatistics Workshop. Houston, TX, US.
- 1995. The design of phase I cancer clinical trials. Conference. Houston, TX, US.
- 1995. Representative curves for longitudinal data via regression trees. Conference. Journal Club Meeting. Houston, TX, US.
- 1994. Design of phase I clinical trials. Conference. Houston, TX, US.
- 1994. A versatile one-dimensional distribution plot: the BLiP plot. Conference. Houston, TX, US.
- 1992. Design and analysis of group sequential trial: an overview and a review on EAST. Conference. Houston, TX, US.
- 1992. Unbalanced repeated-measures models with structured covariance matrices and BMDP5V. Conference. Houston, TX, US.
- 1992. New methodology in the design of phase I studies. Conference. Houston, TX, US.
- 1992. Review of recent developments on the design of phase I studies. Conference. Houston, TX, US.
- 1992. Application of the generalized estimating equations in the longitudinal study. Conference. Informal seminar series on the longitudinal design and analysis. Houston, TX, US.
Regional Presentations
- 2024. Career Panel: Statistical Leadership across Sectors. Conference. A Special Conference on Biostatistics in the New Era of Data-Driven Sciences. Houston, Texas, US.
- 2021. An Overview of Novel Model-Assisted Designs for Early Phase Oncology Trials: Simplicity Meets Superiority. Conference, US.
- 2020. Accomplishment and FY21 Scientific Proposal of Biostatistics and Data Integration Core in the Oropharynx Program. Conference. Annual Scientific Advisory Meeting of the Stiefel Oropharyngeal Research Program. Houston, TX, US.
- 2020. Data Management and Software Development Support for Clinical Research in the Department of Biostatistics, Research Leadership Team – Data Management. Conference. Houston, TX, US.
- 2020. Updates on Streamlining Clinical Trial Activations. Conference. Clinical Trial Activation Retreat. Houston, TX, US.
- 2018. Updates on Streamlining Clinical Trial Activations. Conference. Houston, TX, US.
- 2018. Quantitative Research at MD Anderson. Conference. Houston, US.
- 2018. Updates on Streamlining Clinical Trial Activations. Conference. Houston, TX, US.
- 2017. Clinical Trials Panel Discussion. Conference. Tampa, FL, US.
- 2008. From BATTLE-1 to BATTLE-2: Lessons learned and forge ahead. Conference. Interdisciplinary Forum CCSG Lung Cancer Program. Houston, TX, US.
- 1990. On re-censoring for censored paired data. Conference. Los Angeles, CA, US.
- 1990. Introduction to surgical research: statistics. Conference. Los Angeles, CA, US.
- 1989. Applied logistic regression. Conference. Los Angeles, CA, US.
National Presentations
- 2025. From Setbacks to Solutions: Experiences Gained in Complex Oncology Trials Invited Panelist. Invited. Stat4Onc Conference. Palo Alto, California, US.
- 2024. PSRC Data Sharing Platform in PASSCODE (Pancreatic Adenocarcinoma Stromal Reprogramming Consortium Coordination. Invited. Data Management and Education. San Diego, California, US.
- 2024. Integrated Analysis of Multi-omics Data. Invited. Joint Fall Meeting, Virtual, US.
- 2024. Updater on Data Management and Storage Unit in PASSCODE (Pancreatic Adenocarcinoma Stromal Reprogramming Consortium Coordination, Data Management and Education). Invited. PDAC Stromal Reprogramming Consortium (PSRC) Semi-annual Meeting. San Diego, CA, US.
- 2024. Boosting Bayesian Adaptive Platform Designs for Screening Safe and Efficacious Drugs via Particle Swarm Optimization. Invited. 45th Annual Meeting. Boston, MA, US.
- 2024. Model-Assisted Designs - Make Adaptive Clinical Trials Easy and Accessible, Short Course (co-taught with Ying Yuan). Invited. ENAR Spring Meeting. Baltimore, MD, US.
- 2024. Panel Member on "Advancing the Use of Complex Innovative Designs in Clinical Trials: From Pilot to Practice Public Meeting". Invited. Silver Spring, MD, US.
- 2024. Data Management and Storage Unit in PASSCODE (Pancreatic Adenocarcinoma Stromal Reprogramming Consortium Coordination, Data Management and Education). Invited. Semi-annual Meeting. Houston, TX, US.
- 2023. The Application of Model-Assisted Designs for Dose Optimization in Oncology Drug Development. Invited. Rockville, MA, US.
- 2023. Biostatistics and Bioinformatics Working Group Panel. Invited. Semi-Annual Meeting. Ann Arbor, MI, US.
- 2023. Efficient Evidence Synthesis for Evaluating Treatment Effects by Network Meta-Analysis and Combining Grouped Data and Individual Patient Data. Invited. 44th Annual Meeting. Baltimore, MA, US.
- 2023. Bayesian Adaptive Designs and Information Borrowing for Efficient and Accurate Statistical Inference in Rare Diseases. Invited. CERSI Rare Disease Virtual Workshop, US.
- 2023. Panel Discussions: Navigating Hybrid Work Models and Managing Expectations. Invited. Statistical Practice in Cancer Conference. Tampa, FL, US.
- 2022. Data Management and Storage Unit in PASSCODE (Pancreatic Adenocarcinoma Stromal Reprogramming Consortium Coordination, Data Management and Education). Invited. Kickoff Meeting. Houston, TX, US.
- 2022. Statistical Training on Dose Finding/Optimization, Amgen Training Workshop. Invited. Virtual Meeting, US.
- 2022. Statistical Considerations for Contemporary Clinical Trials and Software Demonstration. Invited. Virtual Meeting, US.
- 2022. Challenges and Solutions for Developing Combination Therapies in Cancer. Invited. Industry Statistics Workshop. Washington, DC, US.
- 2022. Statistical Considerations for Contemporary Clinical Trials, The 9th Clinical Research Skill Advancement Workshop. Invited. Virtual Meeting, US.
- 2022. Oncology Dose Optimization Policy Summit. Invited. Virtual Meeting, US.
- 2022. Model-Assisted Designs for Early Phase Oncology Trials –Where Simplicity Meets Superiority. Invited. New England Statistics Symposium, Virtual Meeting, US.
- 2022. Short Course on “Model-Assisted Designs - Make Adaptive Clinical Trials Easy and Accessible” (joined with Dr. Ying Yuan). Invited. 43rd Annual Meeting. San Diego, CA, US.
- 2022. “Seeing Is Believing” – Effective Data Visualization. Annual Meeting. Invited. New Orleans, LA, US.
- 2021. Statistical Approaches for Multivariable Data Analyses Across Platforms. Conference. Joint Fall Meeting, Virtual, US.
- 2021. Understanding and Applying Proper Statistics in Cancer Clinical Trials to Identify Better Treatments. Invited. Understanding and applying cancer clinical trials in the Era of evidence-based medicine, Virtual Meeting, US.
- 2021. Panelist on the “Study Design Panel” at Cancer Prevention and Risk Reduction: Barriers to Clinical Trial Participation. Invited. Endpoints and Future Drug Development Oncology Center for Excellence Mini-Symposium, US.
- 2021. Bayesian Hierarchical Models for Efficient Drug Development in Basket and Umbrella Trials. Invited. 4th Annual Symposium of Stat4Onc, Virtual Meeting, US.
- 2021. Statistical Considerations for Contemporary Clinical Trials. Invited. Education Program, Virtual Meeting, US.
- 2021. Software Demonstration for Clinical Trial Design and Conduct. Invited. Education Program, Virtual Meeting, US.
- 2021. Study Designs to Benefit Older Adults: Approaches to Early Phase Therapeutic Development: Statistical Perspective. Improving the Evidence Base for Treatment Decision-Making for Older Adults with Cancer: A Virtual Workshop. National Cancer Policy Forum. Invited. Virtual Meeting, US.
- 2020. Data Integration, Management, and Public/Secure Websites to Facilitate Collaborations in PATRec/PaCMEN. Invited. Annual Meeting, Virtual Meeting, US.
- 2020. Statistical Approaches for Multi-source Data and Cross-trial Analysis. Invited. Joint Fall Meeting, Virtual Meeting, US.
- 2020. Statistical Considerations for Contemporary Clinical Trials. Invited. The 8th Clinical Research Skill Advancement Workshop, Virtual Meeting via Zoom, US.
- 2020. Software Demonstration on Innovative Clinical Trials. Invited. The 8th Clinical Research Skill Advancement Workshop, Virtual Meeting via Zoom, US.
- 2020. Novel Bayesian Phase I/II Designs for Identifying Safe and Efficacious Treatments for Immunotherapy. Invited. ENAR Spring Meeting. Virtual Meeting via Zoom, US.
- 2020. Implementing Bayesian Adaptive Designs: From Theory to Practice. Invited. Short Course at ENAR Spring Meeting (co-taught with Ying Yuan). Virtual Meeting via Zoom, US.
- 2020. Memorial and Celebration of Life of Dr. Ken Hess. Invited. 2020 Statistical Practice in Cancer Conference. Tampa, FL, US.
- 2019. P-values in Medical Product Development. Conference. Podcast by American Statistical Association Biopharmaceutical Section, Episode 71 (with Lisa LaVange and Steve Ruberg), https://community.amstat.org/biop/media-contents/podcasts, US.
- 2019. Data Integration, Management, and Public/Secure Websites to Facilitate Collaborations in PATRec / PaCMEN. Conference. NCI U24 Face to Face Meeting and Cancer Moonshot Meeting. Rockville, MD, US.
- 2019. Efficient drug development with master protocols integrating platform design, adaptive randomization, early stopping for futility and/or efficacy, and information borrowing in the Bayesian framework. Invited. Regulatory-Industry Statistics Workshop. Washington, DC, US.
- 2019. Seamless drug development with platform trials, adaptive randomization, information borrowing and early stopping for futility and/or efficacy in the Bayesian framework. Invited. 2019 Duke Industry Statistics Symposium. Durham, NC, US.
- 2019. Short Course on "Tutorial on Bayesian Methods for Design and Analysis for Clinical Trials". Invited. 2019 Duke Industry Statistics Symposium. Durham, NC, US.
- 2019. Operating Characteristics of A Clinical Trial Design, Part II: Bayesian Toxicity and Efficacy Monitoring Using Posterior Probability. Conference. Statistical Practice in Cancer Conference. Tampa, FL, US.
- 2018. Multi-Arm Platform Designs for Efficient Drug Development. Invited. 39th Annual Meeting. Portland, OR, US.
- 2018. Novel Clinical Trials for Cancer Therapy in the Precision Medicine and Immuno-Oncology Era. Invited. The 23rd Taiwan Joint Cancer Conference. Taipei, Taiwan, US.
- 2018. Statistics Helps! Avoid Common Pitfalls and Build a Solid Foundation on Quantitative Reasoning in the Big Data Era. Invited. Annual Meeting. Washington, DC, US.
- 2018. Panel Member on “Promoting the Use of Complex Innovative Designs in Clinical Trials Public Meeting". Invited. Silver Spring, MD, US.
- 2017. Panel Member on “Decision-Making for 21st Century Drug Development and Approval”. Invited. Symposium on Statistical Inference. Bethesda, MD, US.
- 2017. Short Course on “Bayesian Adaptive Designs – Promise and Progress". Invited. 2017 Duke Industry Statistics Symposium. Durham, NC, US.
- 2017. Shedding a Bayesian Light on the Evidence-based Medicine and Drug Development. Invited. Joint Statistical Meetings. Baltimore, MD, US.
- 2016. Learning Bayesian Update via Shiny – Understanding Bayesian Methods Through Visualization, Roundtable Discussion. Invited. Joint Statistical Meetings. Chicago, IL, US.
- 2016. P-value Overdose in Medical Research: Problems and Solutions. Conference. Joint Statistical Meetings. Chicago, IL, US.
- 2015. Worth Adapting? Revisiting the Usefulness of Response-Adaptive Randomization. Conference. Joint Statistical Meetings. Seattle, WA, US.
- 2015. Adaptive Middle Development: Three Good Designs. Invited. Third Cancer Biostatistics Workshop. Lake Tahoe, CA, US.
- 2015. We learn as we go: Bayesian adaptive designs for efficient and flexible clinical trials. Invited. Annual Meeting. Philadelphia, PA, US.
- 2014. Design and Implementation of Bayesian Adaptive Designs for Biomarker-based Target Agent Development. Symposium on Personalized Medicine with Biomarkers: The Role of Statistics. Invited. Amgen Inc. Thousand Oaks, CA, US.
- 2014. Strategies and Implications for Establishing Biostatistics Entities in Medical Centers: Expectations and Measures of Productivity. Invited. Invited Panel, Joint Statistical Meetings. Boston, MA, US.
- 2014. Adaptive Clinical Trials with Multiple Signatures and Multiple Targets: Design, Conduct, and Inference. Invited. 35th Annual Meeting. Philadelphia, PA, US.
- 2014. Adaptive Designs and Adaptive Learning for Biomarker-Based Clinical Trials for Targeted Therapies. Invited. MD Anderson Global Academic Oncology Conference. Seoul.
- 2014. Adaptive Designs and Adaptive Learning for Biomarker-Based Clinical Trials for Targeted Therapies, Plenary Session 2. Invited. AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer. San Diego, CA, US.
- 2013. MDA – IBM Discussion Meeting on Watson – Development of MDACC Oncology Expert Advisor and Genomic Medicine. Conference. Armonk, NY, US.
- 2013. Provocative Questions Workshop. Conference. National Cancer Institute. Bethesda.
- 2013. Novel clinical trial designs. 2013 AACR/ASCO Presidential Symposium: Current Challenges in Clinical Trials. Invited. Annual Meeting. Washington, DC, US.
- 2013. External Advisory Board Meeting for Dr. Fadlo Khuri’s Lung Cancer P01. Conference. Atlanta, GA, US.
- 2013. External Advisory Board Meeting for BATTLE-2. Conference. External Advisory Board Meeting for BATTLE-2. Santa Monica.
- 2013. AACR Translational Research Committee Meeting. Conference. Philadelphia.
- 2013. MDA-FDA Discussion on the BATTLE-2 Trial. Conference. MDA-FDA Discussion on the BATTLE-2 Trial. Silver Spring, MD, US.
- 2012. Novel trial designs from the clinical and translational research perspectives – How to design a prospective study?. Invited. The 1st Clinical Research Skill Advancement Workshop. Tokyo.
- 2012. Report card for chemoprevention trials: The good, the bad and the ugly – How can we do better?. Invited. 11th Frontiers in Cancer Prevention Research. Anaheim, CA, US.
- 2012. Analysis of TCGA Clinical Data in Head/Neck Cancer. Conference. Head/Neck TCGA Working Group. Chapel Hill, NC, US.
- 2012. Bayesian Adaptive Designs for Efficient Targeted Agent Development. Invited. Industry Statistics Workshop. Washington, DC, US.
- 2012. Overview of adaptive clinical trial designs in oncology. Invited. MD Anderson Cancer Center and iRICE (Taiwan) Joint Symposium. Houston, TX, US.
- 2012. Statistical Challenges In Drug Combination Studies. Invited. First Texas Screening Alliance for Cancer Therapeutics Conference - Drug Combinations for Cancer Therapy: New Pathways to Discovery. Houston, TX, US.
- 2012. Biomarker Adaptive Designs for Personalized Medicine – Lessons Learned from the BATTLE Trial and Beyond. Invited. Pediatric Cancer Translational Genomics Conference. Scottsdale, AZ, US.
- 2011. Biomarker-Based Bayesian Adaptive Designs for Targeted Agent Development – Implementation and Lessons Learned from the BATTLE Trial. Invited. DIA/FDA Tailored Therapeutics: Practical Issues and Methodologies for Selecting the Right Patients. North Bethesda, MD, US.
- 2011. Biologic Risk Models for Predicting Recurrence for Patients with Resected Non-Small Cell Lung Cancer. Invited. Conference on Risk Assessment and Evaluation of Predictions. Silver Spring, MD, US.
- 2011. Pick the Winner Trials and Other Winning Strategies. Invited. 5th Clinical Research Methodology Workshop. Seoul.
- 2011. Clinical Trial Designs to Test for Actionable Mutations and Druggable Genome. Invited. 102nd Annual Meeting. Orlando, FL, US.
- 2010. Endpoint selection and adaption in oncology trials – How can we do better?. Invited. The 2nd Yonsei-MD Anderson R&D Symposium. Seoul, KR.
- 2010. Efficient designs for lung cancer prevention trials: Lessons learned and moving forward. Invited. Philadelphia, PA, US.
- 2010. Bayesian Clinical Trials in Action. Workshop on “Clinical trials: past, present and future”. Invited. Bethesda, MD, US.
- 2010. Methodological Issues in Adaptive Clinical Trial Designs. Methods and Issues for Adaptive QA and Trial Designs in Radiation Therapy Workshop. Invited. Bethesda, MD, US.
- 2010. New Statistical Methodologies Applicable to Head and Neck Cancer Clinical Trials. Invited. Multidisciplinary Head and Neck Cancer Symposium. Chandler, AZ, US.
- 2010. Novel Trial Designs for Biomarker Studies. Conference. Novel Trial Designs for Biomarker Studies. Science Day. Houston, TX, US.
- 2010. Bayesian Adaptive Designs for Personalized Medicine: Promise, Progress, and Challenge. Invited. Bayesian Biostatistics Conference 2010. Houston, TX, US.
- 2009. Database Development for the Head and Neck SPORE/HIV Collaboration. Invited. SPORE Investigators' Workshop. Tyson Corner, VA, US.
- 2009. Novel Designs in Phase II Studies. Invited. AACR Cancer Biostatistics Workshop. Sonoma, CA, US.
- 2009. Randomized Phase II Trials. Invited. 4th Clinical Research Methodology Workshop. Seoul, KR.
- 2009. Applying Predictive Probability to Enhance the Design and Conduct of Cancer Clinical Trials. Invited. Korean Statistics and Health Information System Annual Meeting. Seoul.
- 2009. Bayesian Adaptive Designs for Targeted Therapy Development for Cancer and Beyond. Invited. Annual Conference on Statistical Issues in Clinical Trials: Statistical Issues in Targeted Therapies. Philadelphia, PA, US.
- 2009. A 50-year Journey of Phase II Designs for Cancer Clinical Trials – From Multi-stage Designs to Bayesian Predictive Probability Approach. Invited. Symposium in Honor of Dr. Edmund Gehan. Department of Biostatistics. Washington, DC, US.
- 2009. Adaptive designs for speeding up drug discovery. Invited. 100th Annual Meeting. Denver, CO, US.
- 2009. Careers in Clinical and Translational Cancer Research, Mentor in Roundtable Session. Conference. 100th Annual Meeting. Denver, CO, US.
- 2008. Biomarker Based Adaptive Designs for Targeted Agent Development – A Step Toward Personalized Medicine. Invited. Seoul.
- 2008. Adaptive Designs for Clinical Trials. Invited. Seoul, KR.
- 2008. Bayesian Adaptive Randomization Designs Versus Frequentist Designs For Targeted Agent Development. Invited. AACR Molecular Diagnostic Conference. Philadelphia, PA, US.
- 2008. Novel Designs in Phase II Studies. Invited. AACR Cancer Biostatistics Workshop. Sonoma, CA, US.
- 2008. Designs for Targeted Therapy: Statistical Considerations. Invited. 3rd Clinical Research Methodology Workshop. Seoul.
- 2008. Adaptive designs for efficacy and toxicity endpoints for early drug development. Invited. 99th Annual Meeting. San Diego, CA, US.
- 2007. Stacking the Odds for Success: Choosing Biomarkers, Endpoints, and Designs for Mid- to Late- Phase Prevention Trials. Invited. Frontiers in Cancer Prevention Research. Philadelphia, PA, US.
- 2007. Design for Targeted Therapies in Lung Cancer: Statistical Considerations. Invited. National Cancer Policy Forum. Washington, DC, US.
- 2007. Bayesian Clinical Trial in Action - MDA Experience. Conference. Joint Statistical Meetings. Salt Lake City, UT, US.
- 2007. Past, Present, and Future of the Data Acquisition and Management of the MD Anderson Head and Neck Tissue Bank. Conference. 15th SPORE Investigators' Workshop. Baltimore, MD, US.
- 2006. Early Phase Trials Bridging the Gap between Prevention and Treatment. Invited. 5th Annual AACR Frontiers in Cancer Prevention Research. Boston, MA, US.
- 2006. Progress in biostatistics and database development. Conference. Winter Inter-SPORE Meeting. Houston, TX, US.
- 2006. Innovative Designs for Incorporating Biomarkers in Cancer Prevention Studies. Invited. 30th Annual Meeting. Bethesda, MD, US.
- 2005. More Bang for the Bucks: Statistical Properties of Efficient and Flexible Designs for Cancer Prevention Trials. Invited. 4th AACR International Conference Frontiers in Cancer Prevention Research. Baltimore, MD, US.
- 2005. Bayesian Clinical Trials, Approaches and Implementation, Short Course (Joined with Dr. Peter Mueller). Invited. Joint Statistical Meetings. Minneapolis, MN, US.
- 2004. Web-based Database Applications at MD Anderson, (with Dan Ayers and Juan Posadas). Conference. Research Collaboration Meeting. Seattle, WA, US.
- 2004. Clinical and tissue bank databases for head and neck SPORE, (with Dan Ayers and Juan Posadas). Conference. Head and Neck Breakout Session, 12th SPORE Investigators' Workshop. Baltimore, MD, US.
- 2003. Statistical designs for head and neck prevention studies. Conference. Head and Neck Breakout Session, 11th SPORE Investigators' Workshop. Baltimore, MD, US.
- 2002. Innovative Designs for Translational Prevention Trials. Invited. Frontiers in Cancer Prevention Research, Third Annual AACR International Conference. Boston, MA, US.
- 2002. Statistical Methods for Multiple Biomarkers on Prevention. Invited. Sunrise Session, 93rd Annual Meeting. San Francisco, CA, US.
- 2001. Lessons learned from analyzing the differential gene expression data between normal and tumor tissues in head and neck cancer patients. Conference. 33rd Symposium on the Interface. Costa Mesa, CA, US.
- 2000. Mixed models and hierarchical Bayes models for analyzing biomarker data with multiple measurement. Conference. Joint Statistical Meetings. Indianapolis, IN, US.
- 1999. Monitoring and analyzing multiple intermediate endpoint biomarkers. Invited. Strategies for developing new clinical trials for Prostate Cancer Chemoprevention Workshop. Baltimore, MD, US.
- 1999. Statistical considerations for incorporating multiple biomarkers in the design and analysis of cancer chemoprevention studies. Conference. Annual Meeting. Philadelphia, PA, US.
- 1999. Biomarker analyses in Plenary session III, Translational Research Infrastructure. Invited. Head and Neck Cancer Priority Setting Workshop. Bethesda, MD, US.
- 1998. Statistical design and analysis issues for intermediate markers. Invited. Fifth Research Workshop. McLean, VA, US.
- 1998. Spatial statistics for analyzing genetic instability in tumorigenesis. Conference. American Society of Preventive Oncology. Bethesda, MD, US.
- 1997. Design and analysis considerations of using biomarkers in cancer prevention trials. Conference. Joint Statistical Meetings. Anaheim, CA, US.
- 1997. Applications of spatial statistics to the quantitative analysis of genetic instability in carcinogenesis. Conference. 29th Symposium on the Interface: Computing Science and Statistics. Houston, TX, US.
- 1995. Repeated confidence intervals and Bayesian implementation of equivalence trials. Conference. Joint Statistical Meetings. Orlando, FL, US.
- 1995. Performance evaluation for frequentist, Bayesian, and unified group sequential boundaries. Conference. Joint Statistical Meetings. Orlando, FL, US.
- 1995. How many readings are needed for the bleomycin sensitivity assay? A statistical analysis of the reliability and classification errors. Conference. American Society of Preventive Oncology. Houston, TX, US.
- 1994. Evaluations of designs for phase I clinical trials. Conference. 15th Annual Meeting. Houston, TX, US.
- 1993. A better confidence interval estimation for Kappa statistics. Conference. Annual Joint Statistical Meetings. San Francisco, CA, US.
- 1992. A note on modeling baseline information in longitudinal studies. Conference. Annual Joint Statistical Meetings. Boston, MA, US.
- 1991. Analysis of censored paired data through re-censoring. Invited. Joint Statistical Meetings. Atlanta, GA, US.
- 1990. On re-censoring for censored paired data. Conference. Joint Statistical Meetings. Anaheim, CA, US.
- 1989. Prenatal Down Syndrome screening using a combination analysis of maternal age, serum alphafetoprotein and serum human chorionic gonadotropin. Conference. American Society of Human Genetics. Baltimore, MD, US.
- 1987. Conditional confidence level in calibration problems. Conference. Joint Statistical Meetings. San Francisco, CA, US.
- 1986. Sample size calculations for complex survival analysis. Conference. Annual Meeting. Las Vegas, NV, US.
International Presentations
- 2025. Implementing Model-Assisted Designs to Enhance the Success of Clinical Trials. Panelist. Vancouver, CA.
- 2025. Significance, Innovation, and Challenges of Biostatistics in Preclinical Studies, Clinical Trials, and Beyond. Invited. Chicago, US.
- 2025. Statistics Made Simple, Engaging, and Practical: A Primer for Non-Statisticians. Invited. Chicago, US.
- 2025. Locally Advanced and Early Stage NSCLC. Panelist. International Association for the Study of Lung Cancer. Huntington Beach, US.
- 2024. Bayesian Model-Assisted Designs for Dose Optimization in Oncology Drug Development. Invited. Atlanta, US.
- 2024. Model-Assisted Designs: Make Bayesian Adaptive Clinical Trials Easy and Accessible. Invited. World Congress on Lung Cancer 2024. San Diego, US.
- 2024. Augmenting control arm of randomized controlled trials (RCT) by incorporating information across multiple external sources with stratified propensity score and data-driven mixture prior. Conference. 45th Annual Conference of the International Society for Clinical Biostatistics. Thessaloniki, GR.
- 2023. Novel model-assisted designs for dose optimization in efficient and effective oncology drug development. Conference. AACR-KCA Joint Conference on Precision Medicine in Cancer. Seoul, KR.
- 2023. The Nuts and Bolts of Combination Dosage Optimization: Clinical Trial Statistical Considerations. Invited. Second Annual Workshop on Getting the Dose Right: Optimizing Dose Selection Strategies in Combination Anticancer Therapies An FDA-ASCO Virtual Workshop. Houston, US.
- 2023. Optimizing Information Borrowing for Bayesian Hierarchical Model in Subgroup Analysis. Invited. Annual Meeting of International Society for Clinical Biostatistics, IT.
- 2023. Model-Assisted Designs for Dose Optimization in Oncology Drug Development. Invited. Taipei, TW.
- 2023. Efficient Data Synthesis for Evaluating Survival Effects by Combining Aggregate Data and Individual Patient Data in Network Meta-Analysis. Invited. 2023 Joint Statistical Meeting. Toronto, CA.
- 2023. Informative Prior Elicitation for Complex Innovative Clinical Trials (Discussant). Invited. 2023 Joint Statistical Meeting. Toronto, CA.
- 2023. Optimizing Information Borrowing for Bayesian Hierarchical Model in Subgroup Analysis. Invited. 12th ICSA International Conference. Hong Kong, CN.
- 2023. From Finding Maximum Tolerated Dose (MTD) to Determining Optimal Biological Dose (OBD) in Oncology Drug Development. Invited. ICSA China Conference. Chengdu, CN.
- 2023. Remembrance and Honor of Dr. Ed Gehan - A Pioneer Biostatistician, Trail Blazer, and Mentor. Invited. Spring Meeting, Eastern North American Region (ENAR). Nashville, US.
- 2023. Mentor of Posters at IASLC. Conference. 2023 Targeted Therapies of Lung Cancer Meeting. Santa Monica, US.
- 2021. Network Meta-analysis and Bayesian Hierarchical Model for Synthesizing Information in Dental Research. Invited. Annual Meeting of the International Conference of Asian Academy of Preventive Dentistry. Seoul, US.
- 2021. Short Course on “Bayesian adaptive clinical trial designs” (co-taught with Ying Yuan). Invited. International Society for Bayesian Analysis. Virtual Meeting, US.
- 2020. Comparing effect of IO combinations. Invited. IASLC 2020 Targeted Therapies of Lung Cancer Meeting. Santa Monica, US.
- 2019. Bayesian Model-Assisted Designs for the Easy Conduct and Efficient Design of Phase I/II Trials: Keep It Simple and Smart. Invited. 11th ICSA International Conference. Hangzhou, CN.
- 2019. Short Course on “Learning and Implementing Bayesian Adaptive Designs”. Invited. ICSA Midwest & NIC-ASA Joint Fall Meeting. Chicago, US.
- 2019. Journey of Bayesian Inference and Decision Making on Drug Development and Approval. Invited. 6th International Symposium on Biopharmaceutical Statistics. International Society for Biopharmaceutical Statistics. Kyoto, JP.
- 2019. Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials. Invited. International Symposium in Statistics and Biostatistics, University of Pretoria. Pretoria, ZA.
- 2019. Model-Assisted Adaptive Designs in Oncology: When Simplicity Meets Superiority. Invited. 3rd International Conference on Econometrics and Statistics (EcoSta 2019). Taichung.
- 2019. Bayesian Model-Assisted Designs and Their Applications for Early Phase Clinical Trials – When Simplicity Meets Superiority. Invited. Bayes 2019 Bayesian Biostatistics Conference. Lyon, FR.
- 2019. Statistical Considerations for Contemporary Clinical Trials. Invited. The 7th Clinical Research Skill Advancement Workshop. Tokyo, JP.
- 2018. Bayesian Adaptive Designs for Phase I Trials: Workshop of Early Phase Clinical Trials Methodology for Drug Development in Oncology. Invited. Shanghai, CN.
- 2018. Guidance and Software for Implementing Bayesian Adaptive Designs. Conference. Institute of Mathematical Statistics. Melbourne, AU.
- 2018. Practical Guidelines and User-Friendly Software for Bayesian Adaptive Designs. Invited. Roundtable Discussion: Joint Statistical Meeting. Vancouver, CA.
- 2018. Bayesian Hierarchical Models in the Design and Analysis of Clinical Trials. Invited. International Chinese Statistical Association China Conference. Qingdao, CN.
- 2018. Bayesian Adaptive Designs – from Theory to Practice. Invited. Keynote Speaker of Bayes 2018. Cambridge, GB.
- 2018. Tutorial for Bayesian Methods and Practical Guidelines for Bayesian Adaptive Designs. Invited. Taiwan Genomics and Genetics Society Workshop. Taipei, Taiwan.
- 2018. Introduction to Tools for Leaning and Implementing Bayesian Adaptive Designs. Invited. Spring Meeting, Eastern North American Region (ENAR). Atlanta, US.
- 2018. Statistical Considerations for Contemporary Clinical Trials. Invited. The 6th Clinical Research Skill Advancement Workshop. Chiba, JP.
- 2017. Bayesian Adaptive Designs – from Theory to Practice. Invited. International Indian Statistical Association (IISA) 2017 International Conference on Statistics. Hyderabad, IN.
- 2017. Searching & Validating Biomarkers – Are we Categorizing Biomarkers too Quickly?. Invited. 18th World Conference on Lung Cancer. Yokohama, JP.
- 2017. Bayesian Adaptive Designs – from Theory to Practice. Invited. Joint Conference of the Central European Network (CEN) and the International Society for Biopharmaceutical Statistics (ISBS). Vienna, AT.
- 2017. Bayesian Adaptive Designs in the Era of Personalized Medicine – Promise and Progress. Invited. Workshop on Perspectives and Analysis Methods for Personalized Medicine, SG.
- 2017. Bayesian Adaptive Designs for Precision Medicine: Promise, Progress, and Challenge. Invited. WIN Symposium. Paris, FR.
- 2017. Bayesian Adaptive Designs for Efficient Drug Development and Precision Oncology. Invited. Annual Meeting. Winnipeg, CA.
- 2017. Learning Bayesian Methods and Adaptive Designs: Concepts, Tools, and Applications, Short Course (joined with Dr. James Wason). Invited. Annual Meeting of Society for Clinical Trials. Liverpool, GB.
- 2017. Statistical Considerations for Contemporary Clinical Trials. Invited. The 5th Clinical Research Skill Advancement Workshop. Tokyo, JP.
- 2016. Bayesian Adaptive Designs From Theory to Practice: How Can We Turn Promise to Progress in Designing and Conducting Better Clinical Trials?. Conference. 10th ICSA International Conference. Shanghai, CN.
- 2016. Hierarchical Bayesian Classification and Information Sharing for Clinical Trials Containing Subgroups. Invited. Shanghai, CN.
- 2016. Bayesian Classification and Information Sharing for Clinical Trials With Subgroups and Binary Outcomes. Conference. International Biometric Society Meeting. Birmingham, GB.
- 2016. Adaptive multi-arm platform designs for screening effective treatments via predictive probability. Invited. 5th Institute of Mathematical Statistics Asia Pacific Rim Meeting. Hong Kong, CN.
- 2016. Multi-arm Platform Designs for Screening Effective Treatments via Predictive Probability. Invited. Spring Meeting, Eastern North American Region (ENAR). Austin, US.
- 2016. Statistical Considerations for Biomarker-Based Clinical Trials. Invited. The 4th Clinical Research Skill Advancement Workshop. Tokyo, JP.
- 2015. Novel Clinical Trial Design, Computation, and Implementation for Cancer Therapy in the Precision Medicine Era. Invited. 9th Conference of the Asian Regional Section, SG.
- 2015. Novel Clinical Trials for Cancer Therapy in the Precision Medicine Era. Invited. 53rd Annual Meeting. Kyoto, JP.
- 2015. Panel Discussion: Career Development – Knowing Your Strength and Weakness. Conference. Taipei City, TW.
- 2015. Meaningful Applications of Statistics in Decision Analysis and Dental Research in the Big-Data Era. Invited. 38th Annual Scientific Meeting. Taipei, TW.
- 2015. Multi-Arm Platform Designs for Screening Effective Treatments via Predictive Probability. Conference. Utrecht, NL.
- 2015. Worth Adapting? When and How to Apply Adaptive Randomization to Make More Bang for the Buck. Invited. Graybill Conference and ICSA Applied Statistics Symposium. Fort Collins, US.
- 2015. Statistical Considerations for Biomarker-Based Clinical Trials. Invited. The 3rd Clinical Research Skill Advancement Workshop. Tokyo, JP.
- 2014. Phase III Biomarker Driven Bridging Clinical Trials: Design Considerations and Real World Examples. Invited. Advanced Clinical Trials - China Workshop. Shenzheng, CN.
- 2014. Pharmacokinetics, Pharmacodynamics, Drug-target Interactions, and Identifying Adverse Events in Phase II Biomarker Driven Clinical Trials. Invited. Advanced Clinical Trials - China Workshop. Shenzheng, CN.
- 2014. Statistical Considerations for Phase II Biomarker Driven Trials and Adaptive Design. Invited. Advanced Clinical Trials - China Workshop. Shenzheng, CN.
- 2014. Adaptive Designs and Adaptive Learning for Biomarker-Based Clinical Trials for Targeted Therapies. Conference. Florence, IT.
- 2014. Bayesian Adaptive Designs For Biomarker Selection And Adaptive Randomization - From Theory To Practice. Invited. The 3rd Institute of Mathematical Statistics Asia Pacific Rim Meeting. Taipei, TW.
- 2014. Clinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents. Invited. 2014 Symposium. Paris, FR.
- 2014. Statistical Considerations for Phase I/II, Single-Arm Phase II, and Randomized Phase II Studies. Invited. The 2nd Clinical Research Skill Advancement Workshop. Tokyo, JP.
- 2013. Statistical Considerations for Phase III Biomarker-Based Trials, Interim Analysis, and Data Monitoring. Invited. Advanced Clinical Trials - China Workshop. Guangzhou, CN.
- 2013. Adaptive Designs and Biomarker-Based Phase I, Phase II Trials. Invited. Advanced Clinical Trials - China Workshop. Guangzhou, CN.
- 2013. "Adaptive?" "YES!" Rational and Efficient Learning Through Adaptive Designs. Invited. 15th World Conference on Lung Cancer. Sydney, AU.
- 2013. Biomarker Based Clinical Trial Design and Analysis. Invited. Fifth International Forum. Beijing, CN.
- 2013. Introducing Bayesian thinking and applications to Health Science Researchers. Invited. Roundtable Discussion: Joint Statistical Meeting. Montreal, CA.
- 2013. Bayesian adaptive designs for efficient drug development and improving patient outcomes. Invited. ICSA-Canada Chapter 2013 Symposium, Special Invited Lecture. Toronto, CA.
- 2013. Enhance Efficiency and Ethics of Clinical Trials Via Bayesian Outcome-Adaptive Randomization and Early Stopping. Conference. 29th European Meeting of Statisticians. Budapest, HU.
- 2013. Statistical design of the WINTHER Trial. Conference. WIN Symposium. Paris, FR.
- 2013. Design and Implementation of Bayesian Adaptive Trials for Personalized Treatment. Invited. Annual Meeting. Los Angeles.
- 2012. Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring. Invited. Advanced Clinical Trials - China Workshop. Guangzhou, CN.
- 2012. Statistical considerations for Phase II Trials and Adaptive Designs. Invited. Advanced Clinical Trials - China Workshop. Guangzhou, CN.
- 2012. Bayesian Statistics in Clinical Research. Expand Your Thinking Lecture. Invited. 5th Asia Pacific Lung Cancer Conference (APLCC) and 3rd International Thymic Malignancy Interest Group Annual Meeting (ITMIG). Fukuoka, JP.
- 2012. How to Design Clinical Trials in Non‐small Cell Lung Cancer in 2012 with Omics Data? Keynote III. Invited. Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago, US.
- 2012. Bayesian Outcome-Adaptive Randomization in Clinical Trials. Conference. Bergen, NO.
- 2012. Selecting biomarkers for personalized medicine in randomized clinical trials via statistical learning methods. Invited. The 2nd Institute of Mathematical Statistics Asia Pacific Rim Meeting. Tsukuba, JP.
- 2012. WINTHER: A study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. Conference. WIN Symposium. Paris, FR.
- 2012. Adaptive? “YES!” Rational and Efficient Learning Through Adaptive Designs. Invited. Annual Meeting of the American Society of Clinical Oncology. Chicago, US.
- 2012. Biomarker-based Bayesian Adaptive Designs for Selecting Treatments, Biomarkers, and Patients in Targeted Agent Development. Invited. 24th Annual EuroMeeting. Copenhagen, DK.
- 2012. Novel Trial Designs. Invited. 12th Annual Targeted Therapies for Treatment of Lung Cancer. Santa Monica, US.
- 2011. Worth Adapting? Outcome-Adaptive Randomization in Clinical Trials HYPE or HOPE?. Invited. Academia Sinica. Taipei, TW.
- 2011. Statistical Considerations for Phase II Trials and Adaptive Designs. Invited. Advanced Clinical Trials - China Workshop. Taicang, CN.
- 2011. Statistics in Evidence-Based Medicine. Invited. Fifth Japan Team Oncology Program. Tokyo, JP.
- 2011. Adaptive Clinical Trial Design for Personalized Medicine: Are we there?. Invited. 33rd Annual Meeting of the Society for Medical Decision Making. Chicago, US.
- 2011. Biomarker-Based Bayesian Adaptive Designs for Targeted Agent Development – Implementation and Lessons Learned from the BATTLE Trial. Invited. Design of Experiments in Healthcare Workshop. Cambridge, GB.
- 2011. Bayesian Adaptive Methods for Clinical Trials - Short Course (Joined with Drs. Donald Berry, Scott Berry, and Bradley Carlin). Invited. 2011 Joint Statistical Meeting. Miami Beach, US.
- 2011. Biomarker-based Bayesian Adaptive Designs for Targeted Agent Development – Implementation and Lessons Learned from the BATTLE Trial. Invited. 14th Annual Focus on Lung Conference, World Conference on Lung Cancer. Amsterdam, NL.
- 2011. Bayesian Adaptive Designs for Targeted Agent Development – Implementation and Lessons Learned from the BATTLE Trial. Invited. ICSA Applied Statistics Workshop. New York, US.
- 2011. Bayesian Adaptive Designs for Targeted Agent Development – Implementation and Lessons Learned from the BATTLE Trial. Invited. Annual Meeting, Western North American Region (WNAR). San Luis Obispo, US.
- 2011. Grant Writing Workshop II: Improving your Grant Writing Skills. Invited. Annual Meeting. Chicago, US.
- 2011. Bayesian Adaptive Designs for Targeted Agent Development in Cancer Clinical Trials. Invited. Spring Meeting, Eastern North American Region (ENAR). Miami, US.
- 2010. Bayesian Adaptive Designs for Biomarker Guided Trials for Personalized Medicine. Invited. 8th ICSA International Conference: Frontiers of Interdisciplinary and Methodological Statistical Research. Guangzhou, CN.
- 2010. Bayesian Two-step Lasso for Selecting Biomarkers in Targeted Agent Development. Invited. The International Workshop on Emerging Issues and Challenges to Statistics. Xiamen, CN.
- 2010. Predictive probability approach for the design and analysis of response data in cancer clinical trials. Conference. 2010 Joint Statistical Meeting. Vancouver, CA.
- 2010. Bayesian Adaptive Methods for Clinical Trials - Short Course (Joined with Drs. Donald Berry, Scott Berry, and Bradley Carlin). Invited. 2010 Joint Statistical Meeting. Vancouver, CA.
- 2010. Predictive probability and adaptive randomization designs for phase II clinical trials. Invited. ICSA Applied Statistics Symposium. Indianapolis, US.
- 2010. Bayesian methods for tailored therapeutics. - discussant. Conference. ICSA Applied Statistics Symposium. Indianapolis, US.
- 2010. Randomized Phase II Trial Design with Bayesian Adaptive Randomization and Predictive Probability. Conference. 2010 World Meeting. Benidorm, ES.
- 2009. Multidisciplinary Approach – Why are Statistics important?. Invited. Tokyo, JP.
- 2009. Adaptive designs based on biomarkers. Invited. 13th World Conference on Lung Cancer. San Francisco, US.
- 2009. Selecting and Evaluating Efficacy Endpoints for Lung Cancer Trials: What the Investigator and Clinician Should Know About the Statistics. Invited. 13th Conference, Satellite Symposium on Lung Cancer Efficacy Endpoints, World Conference on Lung Cancer. San Francisco, US.
- 2009. Biomarker Based Adaptive Designs for Targeted Agent Development - A Step Toward Personalized Medicine. Invited. Biostatistics Workshop in Cancer Research. Toronto, CA.
- 2009. Biomarker Based Adaptive Designs for Targeted Agent Development. Invited. Annual Meeting, International Biometric Society Western North American Region (WNAR). Portland, US.
- 2008. Multidisciplinary Approach – Why are Statistics important?. Invited. Second Japan Team Oncology Program. Sapporo, JP.
- 2008. Risk Factors, Risk Models, and Statistical Methods for Predicting the Development of Oral Cancer. Invited. The 8th International Conference of Asian Academy of Preventive Dentistry. Jeju, KR.
- 2008. Response Adaptive Randomization for Personalized Medicine. Invited. International Symposium on Biopharmaceutical Statistics. Shanghai, CN.
- 2008. Response Adaptive Randomization for Personalized Medicine. Are We There Yet?. Invited. ICSA Applied Statistics Workshop. Piscataway, US.
- 2008. Progress and Challenge of Applying Biomarkers and Adaptive Designs for Personalized Medicine. Invited. Annual Meeting. Chicago, US.
- 2008. Novel Trial Designs for Targeted Therapy. Invited. IASLC 8th Targeted Therapy of Lung Cancer Meeting. Santa Monica, US.
- 2007. Design for Targeted Therapies: Statistical Considerations. Invited. 12th Annual Focus on Lung Cancer, World Congress on Lung Cancer. Seoul, KR.
- 2007. Adaptive Randomization for Personalized Medicine in Cancer Clinical Trials. Invited. 2007 Taiwan International Statistical Symposium and ICSA International Conference. Taipei, TW.
- 2007. Adaptive Randomization Designs for Targeted Therapy. Invited. 7th Annual Targeted Therapies for Treatment of Lung Cancer. Santa Monica, US.
- 2006. Power of Statistics. Invited. Fifth Educational Seminars in Japan. Kyoto, JP.
- 2006. Methods in clinical cancer research, (faculty member), Common Mistakes in Phase I Designs. Invited. Eighth Annual Workshop. Flims, CH.
- 2006. Do Surrogate Marker Results Transform to Clinical Prevention Success?. Invited. 4th International Conference on Cancer Prevention. St. Gallen, CH.
- 2005. Adaptive Study Designs for Clinical Trials. Invited. DIA Congress on the Development and Utilization of Pharmaceuticals: The First Multi-track Workshop. Tokyo, JP.
- 2005. Power of Statistics. Invited. The Fourth Educational Seminar in Japan. Osaka, JP.
- 2005. Model selection for repeated measures biomarkers from multiple sites in cancer prevention trials. Conference. The Joint Meeting. Beijing, CN.
- 2005. Methods in clinical cancer research, (faculty member), Common Mistakes in Phase I Designs. Invited. Seventh Annual Workshop. Flims, CH.
- 2005. Methods in clinical cancer research, (faculty member). Present a lecture on “Common Mistakes in Phase I Designs. Conference. Seventh Annual Workshop. Flims, CH.
- 2005. A response surface model for assessing drug interaction as synergy, additivity, or antagonism. Conference. Applied Statistics Symposium. White Flint, US.
- 2004. Methods in clinical cancer research, (faculty member), Common Mistakes in Phase I Designs. Invited. Sixth Annual Workshop. Flims, CH.
- 2003. Application of predictive probability in phase II cancer clinical trials. Conference. Joint Meeting. London, GB.
- 2003. Methods in clinical cancer research, (faculty member), Phase I Designs – Statistics. Invited. Fifth Annual Workshop. Flims, CH.
- 2003. Long-term adherence, toxicity, and dose-intensity in a head and neck chemoprevention trial. Conference. 39th Annual Meeting. Chicago, US.
- 2002. Methods in clinical cancer research, (faculty member). Comparative Clinical Trials. Invited. Fourth Annual Workshop. Vail, US.
- 2002. Long-term adherence in a head and neck chemoprevention trial. Conference. 38th Annual Meeting. Orlando, US.
- 2000. Methods in clinical cancer research, (faculty member). Invited. Fourth Annual Workshop. Vail, US.
- 2000. The use and misuse of randomized phase II design in cancer clinical trial. Conference. Berkeley, US.
- 1999. Methods in clinical cancer research, (faculty member). Invited. Fourth Annual Workshop. Vail, US.
- 1999. Analysis of biomarker modulation in multiple biopsy data. Conference. Applied Statistics Symposium. Washington, US.
- 1999. Analysis of biomarker modulation in multiple biopsy data. Conference. Spring Meeting, Eastern North American Region (ENAR). Atlanta, US.
- 1998. Biomarkers for risk assessment in aerodigestive cancers. Invited. Carcinogenesis Modeling and Risk Assessment, An International Conference. Park City, US.
- 1998. Methods in clinical cancer research, (faculty member). Invited. Third Annual Workshop. Vail, US.
- 1998. Auxiliary variables in clinical trials, (discussant). Invited. Annual Meeting. San Diego, US.
- 1998. Sample size calculations for historical control studies. Conference. Spring Meeting, Eastern North American Region (ENAR). Pittsburgh, US.
- 1997. Pharmacologic effect of 13-cis-retinoic acid, beta-carotene, and retinyl palmitate on serum retinol in phase III chemoprevention trial. Conference. Thirty-third Annual Meeting. Denver, US.
- 1997. Extensions and applications of event charts. Conference. Spring Meeting, Eastern North American Region (ENAR). Memphis, US.
- 1997. Non-parametric regression analysis of longitudinal data (joint work with Joan G. Staniswalis). Invited. Spring Meeting, Eastern North American Region (ENAR). Memphis, US.
- 1995. Computation aspects for nonparametric analysis of longitudinal data. Conference. Joint Meeting of the International Biometric Society, Eastern North American Region (ENAR). Birmingham, US.
- 1994. A versatile box and point plot for displaying sample distributions. Conference. Joint Statistical Meetings. Toronto, CA.
- 1993. The development and application of biostatistics in dental research. Conference. Department of Dentistry. Taipei, Taiwan.
- 1993. Likelihood weighted exact confidence intervals for the difference of two binomial probabilities. Conference. Joint Statistical Conference, The Taipei International Statistical Symposium. Taipei, TW.
- 1990. Estimation of the location parameter for censored paired data through re-censoring and M-estimation. Conference. Budapest, HU.
- 1986. Sample size in survival studies and The effective use of a local area network for the data management of clinical and nutritional data from a multicenter clinical trial. Conference. Seventh Annual Meeting. Montreal, CA.
Formal Peers
- 2025. Bayesian Hierarchical Models and Adaptive Platform Designs for Efficient Drug Screening and Testing. Louisville, Kentucky, US.
- 2025. Bayesian Clinical Trials for Efficient Drug Development via Model-Assisted Designs – Keep it Simple and Smart. Louisville, Kentucky, US.
- 2025. Information Borrowing and Synthesizing by Incorporating External Data to Clinical Trials, US.
- 2025. Bayesian Hierarchical Models and Adaptive Platform Designs for Efficient Drug Screening and Testing, US.
- 2025. Model-Assisted Design for Dose Finding, Evaluation, and Optimization, US.
- 2024. Novel Bayesian Adaptive Clinical Trial Designs: When Superiority Meets Simplicity. Honolulu, HI, US.
- 2024. Overview of augmenting randomized-controlled trials by incorporating information across multiple external sources of the control arm (Keynote Speech in Workshop entitled: "Advanced Statistical Designs to Empower Biomarker-driven Clinical Trials"). Invited. Bath, GB.
- 2024. Bayesian Hierarchical Models for Appropriate, Efficient, and Optimal Information Borrowing Among Subgroups in Clinical Trials. Invited. Sutton, GB.
- 2024. Bayesian Adaptive Design for Every Clinical Trialists: Its Elegancy, Eminence, and Easiness. Invited. Sutton, GB.
- 2023. Overview of Bayesian Hierarchical Models for Synthesizing Information in Subgroups of Basket Trials. Invited, Taipei, Taiwan.
- 2023. Workshop on “Bayesian Adaptive Designs for Clinical Trials From Theory to Practice”. Invited, Taipei, Taiwan.
- 2023. Bayesian Clinical Trials in Practice via Model-Assisted Designs – Keep it Simple and Smart. Invited. Westwood, CA, US.
- 2023. Short Course: "Bayesian Clinical Trial Designs and their Implementation,” (joined with Ying Yuan). Invited. Houston, TX, US.
- 2023. Optimizing Information Borrowing for Bayesian Hierarchical Model in Subgroup Analysis of Basket Trials. Invited, Tainan, Taiwan.
- 2023. Bayesian Model-Assisted Designs for Practical and Efficient Oncology Drug Development: Keep It Simple and Smart!. Invited. Baltimore, MA, US.
- 2022. Bayesian inference and model-assisted designs, Biostatistics and Bioinformatics seminar series. Invited, US.
- 2021. Statistics Clearly Explained: Avoid Common Pitfalls and Build a Solid Research Foundation in the Big Data Era. Invited. Houston, TX, US.
- 2020. Statistical and Practical Considerations for the Design and Conduct of Master Protocols. Invited, US.
- 2020. Bayesian Adaptive Designs for Phase 2 and Phase 3 Studies Including Adaptive Randomization, Interim Toxicity and Efficacy Monitoring, and Bayesian Hierarchical Models. Invited, US.
- 2019. Learning and Implementing Bayesian Adaptive Designs. Visiting. Taipei, Taiwan.
- 2019. Novel Biostatistical Methods in Clinical Trial Design & Analysis –Practice Considerations. Invited. Hangzhou, CN.
- 2019. Novel Biostatistical Methods in Clinical Trial Design & Analysis – From Theory to Practice. Invited. Hangzhou, CN.
- 2019. Bayesian Model-Assisted Designs and Their Applications for Early Phase Clinical Trials – When Simplicity Meets Superiority, Department of Statistics and Data Science. Invited. Dallas, TX, US.
- 2019. Bayesian Inference and Practical Considerations on Implementing Bayesian Clinical Trials at MD Anderson Cancer Center. Invited. Lyon, FR.
- 2018. Recent Advances in Bayesian Adaptive Designs and Applications. Invited. Lexington, KY, US.
- 2018. The Importance of Biostatistics and Clinical Trial Design. Invited. Jinan, CN.
- 2018. Introduction to Bayesian Methods and Bayesian Adaptive Designs for Clinical Trials. Invited. Jinan, CN.
- 2017. Bayesian Adaptive Designs – Promise and Progress. Visiting, US.
- 2017. Bayesian Adaptive Designs: from Theory to Practice. Invited. Tainan, Taiwan.
- 2017. Bayesian Adaptive Designs: From Theory to Practice. Invited. Philadelphia, PA, US.
- 2017. Bayesian Adaptive Designs in the Era of Precision Medicine – Promise and Progress. Invited. Indianapolis, IN, US.
- 2016. Bayesian Adaptive Design and Analysis for Contemporary Cancer Clinical Trials. Invited. Silver Spring, MD, US.
- 2016. Bayesian Adaptive Designs for Efficient Drug Development and Precision Oncology. Invited. Albuquerque, NM, US.
- 2016. Biostatistics Workshop on Designing Oncology Trials. Visiting. Taipei, Taiwan.
- 2016. Bayesian Update and Its Application in Adaptive Clinical Trials. Invited. Minneapolis, MN, US.
- 2015. Bayesian Update and the Use of Predictive Probability in Adaptive Clinical Trials. Invited. Taipei, Taiwan.
- 2015. My Journey to Statistics. 60th Anniversary Symposium of College of Dentistry. Invited. Taipei, Taiwan.
- 2015. Bayesian Update and Its Application in Adaptive Clinical Trials. Invited. Zhunan.
- 2015. Bayesian Adaptive Designs for Cancer Clinical Trials – from Theory to Practice. Visiting. Taipei, Taiwan.
- 2015. Bayesian Update and the Use of Predictive Probability in Adaptive Clinical Trial Designs. Invited. Ann Arbor, MI, US.
- 2015. Overview of Bayesian adaptive designs: introduction, tools, and implementation. Visiting. Houston, TX, US.
- 2015. Bayesian adaptive designs for cancer clinical trials – from theory to practice (Part II). Invited. Houston, TX, US.
- 2014. Bayesian adaptive designs for cancer clinical trials – from theory to practice (Part I). Invited. Houston, TX, US.
- 2014. Understand Bayesian Methods and Their Applications in Clinical Trials. Invited. Taipei, Taiwan.
- 2014. Concept, Design, and Implementation of Novel Clinical Trials. Visiting. Houston, TX, US.
- 2014. Bayesian adaptive designs for the development of targeted therapies – from theory to practice. Invited. Lebanon, NH, US.
- 2013. Statistics and Its Applications in Clinical Trials: Quantitative Reasoning via Frequentist and Bayesian Methods. Invited. Taipei, Taiwan.
- 2013. Risk Assessment and Risk Modeling for Cancer Prevention and Therapy. Invited. Tampa, FL, US.
- 2013. Bayesian Adaptive Designs for Biomarker Selection & Adaptive Randomization - from Theory to Practice. Invited. New Haven, CT, US.
- 2013. Design and Implementation of Bayesian Adaptive Trials for Personalized Treatment and Efficient Drug Development. Seminar for the Biostatistics/Epidemiology/Research Design (BERD) Core. Invited. Houston, US.
- 2013. Bayesian Adaptive Designs for Efficient and Personalized Drug Development. Grand Rounds in Population Science. Invited. Tampa.
- 2013. Bayesian Adaptive Designs for Efficient and Personalized Drug Development. Visiting. Houston, TX, US.
- 2012. Bayesian Outcome-Adaptive Randomization in Clinical Trials. Visiting. Houston, TX, US.
- 2012. Sharpening Your Quantitative Reasoning Skills – The Tale of Two Inferences: Bayesian versus Frequentist. Visiting. Houston, TX, US.
- 2012. Is the Outcome-Adaptive Randomization Useful in Clinical Trials? HYPE or HOPE?. Invited. Houston, TX, US.
- 2010. Bayesian Clinical Trials in Action. Invited. Hong Kong, CN.
- 2010. Bayesian Clinical Trials in Action. Invited. Illinois, IL, US.
- 2010. Biomarker Based Adaptive Designs for Targeted Therapies. Invited. Detroit.
- 2010. Bayesian Biomarker-Based Adaptive Designs for Targeted Therapies. Invited. Memphis, TN, US.
- 2010. Adaptive Designs for the Development of Targeted Therapies. Invited. Bronx, NY, US.
- 2009. Predictive Probability and Adaptive Randomization Designs for Phase II Clinical Trials. Invited. Ann Arbor, MI, US.
- 2009. Biomarker Based Adaptive Designs for Targeted Agent Development in Cancer. Invited. Ann Arbor, MI, US.
- 2009. Study Design for Pan-Canadian Network for Oral Cancer Control. Invited. Vancouver, CA.
- 2009. Switching from Counting to 32 to Counting between 0 and 1: My Personal Journey into Biostatistics. Invited. Taipei, Taiwan.
- 2009. Phase I and II Study Design For Targeted Agents. Invited. Seoul.
- 2008. Biomarker-based Adaptive Designs for Personalized Medicine, Radiation Therapy Oncology Group (RTOG). Invited. Philadelphia, PA, US.
- 2008. Biomarker Based Adaptive Designs for Targeted Agent Development – A Step Toward Personalized Medicine. Department of Biostatistics. Invited. Houston, TX, US.
- 2008. Biomarker-based Adaptive Designs for Personalized Medicine, Institutional Ground Round. Invited. Buffalo, NY, US.
- 2008. The Application of Biostatistics in Medical Research. Invited. Shanghai, CN.
- 2008. Response Adaptive Randomization for Personalized Medicine. Invited. Seoul.
- 2008. Adaptive Designs for Efficacy and Toxicity Endpoints in Drug Development. Invited. Seoul.
- 2008. Response adaptive randomization for personalized medicine: Are we there?. Invited. Philadelphia, PA, US.
- 2007. An Application of Adaptive Randomization and Hierarchical Bayes Model in Biomarker-Based Cancer Clinical Trials. Invited. Nashville, TN, US.
- 2007. Efficient and flexible designs for clinical trials. Invited. Houston, TX, US.
- 2006. Your way, my way, and the highway - flexible and adaptive designs in cancer clinical trials. Invited. Waterloo, CA.
- 2005. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and the Risk of Oral Cancer. Invited. Vancouver, CA.
- 2005. Applications of Event Charts in Multiple Time-to-Event Data. Visiting. Rockville, MD, US.
- 2005. Predictive Probability and Other Bayesian Methods in Cancer Clinical Trials. Invited. Birmingham, AL, US.
- 2004. Risk and mortality of oral leukoplakia and oral cancer. Invited. Vancouver, CA.
- 2004. Time varying covariates in survival analysis. Invited. Vancouver, CA.
- 2004. Statistical considerations for the risk assessment of oral leukoplakia to oral cancer. Invited. Vancouver, CA.
- 2000. Predicting cancer development in oral leukoplakia: an example of incorporating multiple biomarkers in the design and analysis of cancer chemoprevention studies. Invited. Baltimore, MD, US.
- 2000. Mixed models and hierarchical Bayes models for analyzing biomarker data with multiple measurements. Invited. Baltimore, MD, US.
- 1999. Event charts for multiple timed-event data. Invited. Los Angeles, CA, US.
- 1999. Event charts and their applications to survival analysis. Invited. New Brunswick, NJ, US.
- 1999. Event charts and their applications to multiple timed-event data in survival analysis. Invited. Branchburg, NJ, US.
- 1999. Design and statistical considerations for phase IIB cancer clinical trials -- seminar and software demonstration. Invited. Rahway, NJ, US.
- 1999. Extensions and applications of event charts. Invited. New York, NY, US.
- 1999. Design and statistical considerations for phase IIA cancer clinical trials -- seminar and software demonstration. Invited. Rahway, NJ, US.
- 1998. Design and statistical considerations for phase II cancer clinical trials. Invited. Rahway, NJ, US.
- 1998. Evaluation and comparison of statistical properties of phase I cancer clinical trials: A Workshop. Invited. Rahway, NJ, US.
- 1998. Design and statistical considerations for phase I cancer clinical trials: Part I - Overview of key elements and the conventional approach. Invited. Rahway, NJ, US.
- 1998. Design and statistical considerations for phase I cancer clinical trials: Part II - Recent advancements. Invited. Rahway, NJ, US.
- 1998. Biomarkers and intermediate endpoints in lung cancer chemoprevention trials. Invited. Dallas, TX, US.
- 1998. Spatial statistics for analyzing genetic instability in tumorigenesis. Invited. Houston, TX, US.
- 1994. A versatile one-dimensional distribution plot. Invited. Houston, TX, US.
- 1994. Longitudinal data analysis on head circumference data. Invited. Houston, TX, US.
- 1993. The Kappa Statistic. Invited. Houston, TX, US.
- 1992. A note on modelling baseline information in longitudinal studies. Invited. Houston, TX, US.
- 1992. Design and analysis of longitudinal data. Invited. Houston, TX, US.
- 1990. Survival Analysis. Invited. Sepulveda, CA, US.
Grant & Contract Support
| Date: | 2025 - 2028 |
| Title: | RAID-Lung Cancer: Rapid AI-Integrated Diagnosis of Lung Cancer |
| Funding Source: | Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2025 - 2030 |
| Title: | Ontology-based aPplications of mUlti-discipLinary knowlEdge on orodeNtal Conditions and outcomEs (OPULENCE) |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2025 - 2030 |
| Title: | Cancer Immunoprevention Network Data and Resource Coordinating Center (CIP-Net DRCC) |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-PI |
| ID: | #TBA |
| Date: | 2025 - 2030 |
| Title: | PRECISE-OPMD Trial: Preventing Cancer through Intratumoral Strategy and Early Biomarker Evaluation in Oral Potentially Malignant Disorders |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | PAR-24-072 |
| Date: | 2025 - 2030 |
| Title: | Reprogram innate immunity for lung cancer immunoprevention |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1UG3CA290311-01A1 |
| Date: | 2025 - 2030 |
| Title: | Elucidating roles of the CD24 ligand in lung cancer development, immune escape and response to immune-based therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2025 - 2029 |
| Title: | I-PROTECT - Intratumoral Prevention and Risk Outcomes in Targeted Early Cancer Treatment with Immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP250354 |
| Date: | 2024 - 2026 |
| Title: | Clinical-radiomic machine learning model predicts progression after RET TKI |
| Funding Source: | Lungevity Foundation |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2030 |
| Title: | BEGIN BATTLE: integrated biomarker-guided approaches for therapy selection, tailored early intensification, and targeting resistance mechanisms in lung cancer |
| Funding Source: | Advanced Research Project Agency |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | OPC SURVIVOR: Optimizing OroPharyngeal Cancer SURVIVORship |
| Funding Source: | NIH/NCI |
| Role: | Co-Core Director |
| ID: | 1P01 CA285249-01A1 |
| Date: | 2024 - 2026 |
| Title: | Accelerating Diagnosis and Personalized Treatment through Developing an Ethical Integrative Predictive Model for Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1OT2OD037949-01 |
| Date: | 2024 - 2029 |
| Title: | Ontology-based applications of multidisciplinary knowledge on orodental conditions and outcomes (OPULENCE) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | GRANT14057533 |
| Date: | 2024 - 2029 |
| Title: | Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA287734-01A1 |
| Date: | 2024 - 2028 |
| Title: | Enhancing immune responses in recalcitrant non-small cell lung cancer (NSCLC) |
| Funding Source: | Subaward-Subcontract via University of Texas at Austin |
| Role: | Principal Investigator-MDACC |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Other Significant Contributor |
| ID: | #TBA |
| Date: | 2024 - 2026 |
| Title: | Cancer Center Support (CORE) Grant - Biostatistics Resource Group (BRG) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P30CA016672 |
| Date: | 2024 - 2029 |
| Title: | Cancer Center Support (CORE) Grant |
| Funding Source: | NATIONAL CANCER INSTITUTE |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | Decipher the Evolution from Precancer to Invasive Lung Adenocarcinoma to Unravel Targets for Lung Cancer Interception and Prevention |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | GRANT14026815 |
| Date: | 2024 - 2029 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-Director |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | The Role of Intra-Tumor Heterogeneity in Lung Cancer Recurrence and Resistance to Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | Reprogram innate immunity for lung cancer immunoprevention |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | GRANT13925607 |
| Date: | 2024 - 2029 |
| Title: | Translating advanced approaches to precision targeting of KRAS mutated cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2026 |
| Title: | Optimize the Optimals: Global Optimality for Model-Assisted Dose-Finding Cancer Trials |
| Funding Source: | Subaward-Subcontract via Penn State University |
| Role: | PD/PI |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | Eradicating NOTCH1 mutant head and neck cancer with combination therapy targeting PI3K and Polo-like kinase |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | Synthetic lethality of Aurora kinase A and TRIP13 in Rb-deficient cancers |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2024 - 2027 |
| Title: | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240117 |
| Date: | 2024 - 2027 |
| Title: | The Evolution of Intratumor Heterogeneity of Lung Cancers With or Without Immunotherapy and Its Impact on Patient Survival |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240112 |
| Date: | 2024 - 2028 |
| Title: | Eradicating NOTCH1 mutant head and neck cancer with combination therapy targeting PI3K and Polo-like kinase |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240124 |
| Date: | 2024 - 2027 |
| Title: | MD Anderson ACCESS Hub for Cancer Screening and Early Detection |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | GRANT13816531 |
| Date: | 2023 - 2028 |
| Title: | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor |
| Funding Source: | National Cancer Institute |
| Role: | Co-I |
| ID: | 1R01CA279452-01A1 |
| Date: | 2023 - 2025 |
| Title: | Intergovernmental Personnel Act (IPA) Agreement |
| Funding Source: | US Food and Drug Administration (FDA), Center for Drug Evaluation and Research |
| Role: | Expert Statistical Advisor |
| ID: | IPA Agreement |
| Date: | 2023 - 2028 |
| Title: | Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2023 - 2024 |
| Title: | CCSG Supplement: Identify multi-modal machine learning model to guide immunotherapy for non-small cell lung cancer through federated learning |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | OPC SURVIVOR: Optimizing OroPharyngeal Cancer SURVivorship - CORE B (CLINICAL INFORMATICS & ANALYTICS) |
| Funding Source: | NIH/NCI |
| Role: | Co Core Lead |
| ID: | 1P01CA285249-01 |
| Date: | 2023 - 2028 |
| Title: | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | IAB Member |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2U24CA224285-02 |
| Date: | 2023 - 2028 |
| Title: | Development of large-scale composite null hypothesis inference approaches to characterize translationally relevant germline genetic variants in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA284100-01 |
| Date: | 2023 - 2028 |
| Title: | Translating advanced approaches to precision targeting of KRAS mutated cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA283210-01 |
| Date: | 2023 - 2028 |
| Title: | Investigation of the molecular/immune cascade underlying evolution of intra-tumor heterogeneity during lung cancer progression and metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA282093-01 |
| Date: | 2023 - 2025 |
| Title: | Novel Model-Assisted Designs with Global Optimality for Dose-Finding Cancer Trials |
| Funding Source: | NIH/NCI subaward via Penn State |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | MD Anderson SPORE in KRASG12C |
| Funding Source: | NIH/NCI |
| Role: | Biostats & Bioinformatics Core Co-director |
| ID: | 1P50CA281788-01 |
| Date: | 2023 - 2025 |
| Title: | Investigating the Effect of FLASH-Radiotherapy on Tumor and Normal Tissue |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA273845-01A1 |
| Date: | 2023 - 2028 |
| Title: | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA279452-01 |
| Date: | 2023 - 2028 |
| Title: | MD Anderson Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program |
| Funding Source: | NIH/NCI |
| Role: | Biostatistics SPORE Mentor |
| ID: | 1U54CA280881-01 |
| Date: | 2023 - 2027 |
| Title: | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240160 |
| Date: | 2023 - 2026 |
| Title: | The evolution of intra-tumor heterogeneity of lung cancers with or without immunotherapy and its impact on patient survival |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2027 |
| Title: | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2026 |
| Title: | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2026 |
| Title: | The evolution of intra-tumor heterogeneity of lung cancers with or without immunotherapy and its impact on patient survival |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2026 |
| Title: | Investigating the effect of FLASH-Radiotherapy on tumors and normal tissues |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | Dissemination and implementation of DIGEST™ as an evidence-based measurement tool for dysphagia in cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA271223-01A1 |
| Date: | 2022 - 2027 |
| Title: | The evolution of intra-tumor heterogeneity of lung cancers with or without immunotherapy and its impact on patient survival |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA269469-01A1 |
| Date: | 2022 - 2024 |
| Title: | Biological, Imaging, and Dosimetric Markers of Enhanced Tumor Control and Preserved Normal-Organ Functions after Proton or X-Ray Radiation for Head and Neck Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA277327-01 |
| Date: | 2022 - 2027 |
| Title: | PASSCODE (Pancreatic Adenocarcinoma Stromal Reprograming ConSortium COordination, Data Management and Education |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1U24CA274274-01 |
| Date: | 2022 - 2029 |
| Title: | Biology and Function of Exosomes in Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R35CA263815-01A1 |
| Date: | 2022 - 2026 |
| Title: | Project 4: Developing a PARP inhibitor for breast cancer risk reduction in BRCA mutation carriers |
| Funding Source: | DOD subaward via DANA-FARBER CANCER INSTITUTE |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2022 - 2027 |
| Title: | Multicenter radiomic-pathomic study to guide the use of chemo-immunotherapy for non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA277612-01 |
| Date: | 2022 - 2027 |
| Title: | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA276860-01 |
| Date: | 2022 - 2027 |
| Title: | Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA269516-01 |
| Date: | 2022 - 2027 |
| Title: | State-of-the-art Pediatric Accelerator for Clinical Trial Excellence, Texas (SPACE TX) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Director (Biostatistics) |
| ID: | #TBA |
| Date: | 2022 - 2023 |
| Title: | Oral cavity carcinoma immune microenvironment and its impact on clinical outcome |
| Funding Source: | American Head and Neck Society |
| Role: | Consult |
| ID: | FP00015648 |
| Date: | 2022 - 2024 |
| Title: | Investigating the Effect of FLASH-Radiotherapy on Tumor and Normal Tissue |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA273845-01 |
| Date: | 2022 - 2027 |
| Title: | Investigating the functional heterogeneity of fibroblast in PDAC |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1U01CA274325-01 |
| Date: | 2022 - 2027 |
| Title: | OPC SURVIVOR: Optimizing OroPharyngeal Cancer SURVivorship through Informatics-based Cohort Validation and Maintenance for Research |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U01CA268336-01A1 |
| Date: | 2022 - 2027 |
| Title: | MD Anderson SPORE in KRASG12C |
| Funding Source: | NIH/NCI |
| Role: | Biostatistics and Bioinformatics Core Director |
| ID: | 1P50CA261607-01A1 |
| Date: | 2022 - 2024 |
| Title: | Radioimmunogenomic Analysis of Indeterminant Pulmonary Nodules for Precision Immunoprevention of Lung Cancer |
| Funding Source: | The Fund for Innovation in Cancer Informatics (ICI) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2022 - 2027 |
| Title: | Radioimmunogenomic analysis of indeterminant pulmonary nodules for precision immunoprevention of lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA269475-01 |
| Date: | 2022 - 2027 |
| Title: | The evolution of intra-tumor heterogeneity of lung cancers with or without immunotherapy and its impact on patient survival |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA269469-01 |
| Date: | 2022 - 2027 |
| Title: | Cancer Immune-Interception for Lynch Syndrome |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA271426-01 |
| Date: | 2022 - 2027 |
| Title: | Dissemination and implementation of DIGEST™ as an evidence-based measurement tool for dysphagia in cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA271223-01 |
| Date: | 2022 - 2026 |
| Title: | Radioimmunogenomic analysis of indeterminant pulmonary nodules for precision immunoprevention of lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2022 - 2026 |
| Title: | Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2022 - 2026 |
| Title: | OPC SURVIVOR: Optimizing OroPharyngeal Cancer SURVivorship through Informatics-based Cohort Validation and Maintenance for Research |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U01CA268336-01 |
| Date: | 2021 - 2026 |
| Title: | Cancer Immune-Interception for Lynch Syndrome |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5R01CA257375-02 |
| Date: | 2021 - 2026 |
| Title: | Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | OSC |
| ID: | 1R01CA262425-01 |
| Date: | 2021 - 2022 |
| Title: | Expanding Reach Moon Shot |
| Funding Source: | MD Anderson Moon Shot Program |
| Role: | Biostatistician, Co-investigator |
| ID: | 710499-80-123136-21 |
| Date: | 2021 - 2024 |
| Title: | Investigating the value of proton versus X-ray radiation for preserving taste function |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01DC019964-01 |
| Date: | 2021 - 2023 |
| Title: | Tissue Immune Cell Infiltration Index and Unbiased Discovery of Novel Immune Biomarkers Using CODEX |
| Funding Source: | Foundation for the Natl Inst of Health |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2021 - 2026 |
| Title: | MD Anderson Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | #TBA |
| Date: | 2021 - 2026 |
| Title: | Characterization and targeting of NOTCH1 activated Adenoid Cystic Carcinoma (ACC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA261958-01 |
| Date: | 2021 - 2026 |
| Title: | State-of-the-art Pediatric Accelerator for Clinical Trial Excellence, Texas (SPACE TX) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2021 - 2026 |
| Title: | Characterization of altered immunity in patients with inflammatory arthritis induced by immune checkpoint inhibitor therapy |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1K08AR079587-01 |
| Date: | 2021 - 2026 |
| Title: | Cancer Immune-Interception for Lynch Syndrome |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA257375-01A1 |
| Date: | 2021 - 2026 |
| Title: | MDACC KRAS G12C SPORE |
| Funding Source: | NIH/NCI |
| Role: | Core Director |
| ID: | 1P50CA261607-01 |
| Date: | 2021 - 2028 |
| Title: | Biology and Function of Exosomes in Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R35CA263815-01 |
| Date: | 2021 - 2024 |
| Title: | CA200674: Characterization and targeting NOTCH activated Adenoid Cystic Carcinoma (ACC) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH-20-PRCRP-IPA |
| Date: | 2021 - 2024 |
| Title: | Informatics for Functional Integration of Heterogeneous Cancer Genome and Transcriptome Sequencing Data |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | #TBA |
| Date: | 2020 - 2025 |
| Title: | Customizing precision high linear energy transfer radiation therapy via biomarker integrated relative biological effectiveness models |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA256843-01 |
| Date: | 2020 - 2022 |
| Title: | MD Anderson Oropharynx Program - Biostatistics and Data Integration |
| Funding Source: | Stiefel Research Fund |
| Role: | Core Leader |
| ID: | 600567-80-123263-21 |
| Date: | 2020 - 2027 |
| Title: | Biology and Function of Exosomes in Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R35CA232090-01A1 |
| Date: | 2020 - 2022 |
| Title: | Exploring the value of proton versus photon radiation for preserving taste function |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA240671-01 |
| Date: | 2020 - 2025 |
| Title: | Elucidation of Mechanisms Underlying Inflammatory Arthritis Associated with Immune Checkpoint Inhibitor Therapy |
| Funding Source: | Natl Inst Arth & Musc & Skin Diseases |
| Role: | Advisory Committee Mem |
| ID: | 1K08AR076496-01A1 |
| Date: | 2020 - 2022 |
| Title: | Targeting oncogenic Kras with iExosomes in Pancreatic cancer |
| Funding Source: | Pancreatic Cancer Action |
| Role: | Co-PI |
| ID: | #TBA |
| Date: | 2020 - 2025 |
| Title: | Harnessing Aurora kinase inhibition‐induced cell death to enhance immunotherapy in HPV‐driven cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5R01CA248205-03 |
| Date: | 2020 - 2025 |
| Title: | Predicting and Overcoming Chemoradioresistance in p53-Mutant Head and Neck Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2R01DE024601-06 |
| Date: | 2020 - 2025 |
| Title: | Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01DE029474-01 |
| Date: | 2020 - 2023 |
| Title: | Harnessing Aurora Kinase Inhibition-Induced Cell Death to Enhance Immunotherapy in HPV- Driven Cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2020 - 2023 |
| Title: | Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP# TBA |
| Date: | 2019 - 2024 |
| Title: | Core Infrastructure Support NN-2019 |
| Funding Source: | NIH/NCI |
| Role: | Lead Statistician |
| ID: | HHSN261201200034I |
| Date: | 2019 - 2024 |
| Title: | Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5R01CA235620-04 |
| Date: | 2019 - 2024 |
| Title: | Targeting Wild-Type p53 in Chemoresistant Rare Ovarian Cancers |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | 1R01CA244385-01 |
| Date: | 2019 - 2024 |
| Title: | Optimizing Precision Therapies in Immuno - oncology Core (OPTIC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | FP00007257 |
| Date: | 2019 - 2024 |
| Title: | Elucidation of Mechanisms Underlying Inflammatory Arthritis Associated with Immune Checkpoint Inhibitor Therapy |
| Funding Source: | Natl Inst Arth & Musc & Skin Diseases |
| Role: | Collaborator |
| ID: | 1K08AR076496-01 |
| Date: | 2019 - 2024 |
| Title: | iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| ID: | 5UG1CA242609-04 |
| Date: | 2019 - 2024 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in Melanoma: Administrative Core 1 |
| Funding Source: | NIH/NCI |
| Role: | Co-Leader |
| ID: | 5P50CA221703-04 |
| Date: | 2019 - 2024 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in Melanoma: Core 3 Biostatistics and Bioinformatics |
| Funding Source: | NIH/NCI |
| Role: | Director |
| ID: | 5P50CA221703-04 |
| Date: | 2019 - 2021 |
| Title: | Exploring the effect of proton versus photon radiation on human immune system |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA240671-01 |
| Date: | 2019 - 2021 |
| Title: | BREATHMD, a rapid, non-invasive, breath analysis diagnostic tool for the early detection of lung cancer utilizing differential mobility spectrometry (DMS) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | FP00006404 |
| Date: | 2019 - 2026 |
| Title: | Cancer Center Support (CORE) Grant - Biostatistics Resource Group (BRG) |
| Funding Source: | NIH/NCI |
| Role: | Core Director |
| ID: | 5P30CA016672-47 |
| Date: | 2019 - 2022 |
| Title: | Cell-free DNA (cfDNA) to detect minimal residual disease, predict therapeutic response, and characterize immunogenomic evolution in early-stage NSCLC treated with neoadjuvant immunotherapy |
| Funding Source: | Conquer Cancer Foundation ASCO CDA |
| Role: | Collaborator |
| ID: | FP00006364 |
| Date: | 2019 - 2022 |
| Title: | The molecular and immune evolution in the progression of lung preneoplasia to invasive adenocarcinoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | FP00005178 |
| Date: | 2019 - 2025 |
| Title: | The Molecular and Immune Evolution in the Progression of Lung Neoplasia to Invasive Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5R01CA234629-05 |
| Date: | 2019 - 2023 |
| Title: | Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA235620-01 / FP00004689 |
| Date: | 2018 - 2023 |
| Title: | Program for Artificial Intelligence (AI) -Radiology in Cancer Care (PAIR-CC) |
| Funding Source: | The Trustees of Columbia University in the City of New York |
| Role: | Co-I |
| ID: | GRANT12551143 / FP00004409 |
| Date: | 2018 - 2021 |
| Title: | Circulating biomarkers for combination immunotherapy in advanced NSCLC |
| Funding Source: | LUNGevity CDA |
| Role: | Co-I |
| ID: | FP00005308 |
| Date: | 2018 - 2019 |
| Title: | Engineered exosomes for precision pancreatic cancer therapy |
| Funding Source: | LUSTGARTEN FNDTN - PANCREATIC CANCER RES |
| Role: | Investigator |
| ID: | FP00005905 |
| Date: | 2018 - 2019 |
| Title: | Core Infrastructure Support - Task Order 10 (Cost Reimbursement) |
| Funding Source: | NIH/NCI |
| Role: | Lead Statistician |
| ID: | FP00005846 |
| Date: | 2018 - 2025 |
| Title: | The Biology of Exosomes in Cancer |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | 1R35CA232090-01 / FP00004193 |
| Date: | 2018 - 2023 |
| Title: | Harnessing the PDAC Tumor Stroma to enhance the efficacy of Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA234487 / FP00004752 |
| Date: | 2018 - 2023 |
| Title: | Exploiting Exosomes for Precision Medicine in Pancreatic Cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | 1R01CA231431-01 |
| Date: | 2018 - 2023 |
| Title: | MD Anderson Cancer Center Head & Neck SPORE – Biostatistics and Bioinformatics Core (Core B) |
| Funding Source: | NIH/NCI |
| Role: | Core Director |
| ID: | 1P50CA217669-01A1 |
| Date: | 2018 - 2023 |
| Title: | Targeted Development of Platinum Drug Combinations |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | 2R01CA160687-06 /FP00001837_Res1 |
| Date: | 2018 - 2021 |
| Title: | Cell-free tumor DNA velocity and peripheral T-cell invigoration as biomarkers |
| Funding Source: | Conquer Cancer Foundation of ASCO 2018 career Development Award |
| Role: | Co-I |
| ID: | 12942 |
| Date: | 2017 - 2021 |
| Title: | Detection, Characterization & Immunoprevention of Pre & Early Lung cancers |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Investigator |
| ID: | FP00002332 |
| Date: | 2017 - 2023 |
| Title: | Translational Cancer Immune Monitoring and Analysis Center (TCIMAC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5U24CA224285-05 |
| Date: | 2017 - 2022 |
| Title: | Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5U24CA224020-03 |
| Date: | 2017 - 2022 |
| Title: | Exploiting the Biology of Exosomes for Personalized PDAC Therapy |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | 1U01CA224157-01 |
| Date: | 2017 - 2022 |
| Title: | Targeted Development of Platinum Drug Combination |
| Funding Source: | NIH/NCI |
| Role: | Unknown |
| ID: | 2R01CA160687-06 |
| Date: | 2017 - 2022 |
| Title: | Cell Cycle Blockade and Therapeutic Sensitization |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 5R01CA211975-05 |
| Date: | 2017 - 2019 |
| Title: | Engineered exosomes for precision therapy of pancreatic cancer |
| Funding Source: | Pancreatic Cancer Action Network |
| Role: | Collaborator |
| ID: | FP00001671 |
| Date: | 2017 - 2022 |
| Title: | Optimizing precision oncology with systems biology |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01CA219109-01 |
| Date: | 2017 - 2022 |
| Title: | MD Anderson Cancer Center Head & Neck SPORE; Biostatistics and Bioinformatics Core (Core B) |
| Funding Source: | NIH/NCI |
| Role: | Core Director |
| ID: | 1P50CA217669-01 |
| Date: | 2017 - 2019 |
| Title: | Improving Quality of Life in Head and Neck Cancer Patients with Proton Therapy |
| Funding Source: | Gateway For Cancer Research |
| Role: | Statistical Analyst |
| ID: | FP00001583 |
| Date: | 2017 - 2021 |
| Title: | Decision Support for Genomic Sequencing in Academic and Community Setting |
| Funding Source: | NIH/HG |
| Role: | Co-I |
| ID: | 19599 |
| Date: | 2017 - 2022 |
| Title: | Personalizing NSCLC Therapy: Targeting immune escape and MEK pathways |
| Funding Source: | Yale University/NIH/NCI Subaward |
| Role: | Co-I |
| ID: | 00019107 |
| Date: | 2016 - 2021 |
| Title: | SCLC Team for Advancing Research (STAR) |
| Funding Source: | Beckman Research Institute of the City of Hope - NIH/NCI |
| Role: | Co-I |
| ID: | IP16073379 |
| Date: | 2016 - 2021 |
| Title: | Impact of PD-L1 Testing and PD-1/L1 Inhibitor Use on Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer at MD Anderson Comprehensive Cancer Center |
| Funding Source: | Merck Sharp & Dohme Corp |
| Role: | Statistician |
| ID: | PA13-0589 |
| Date: | 2016 - 2021 |
| Title: | Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015 and 2016 |
| Funding Source: | NIH/NCI |
| Role: | EAB (External Advisory Board) Member |
| Date: | 2016 - 2021 |
| Title: | Targeting tumor suppressors: exploiting LKB1 vulnerability in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | External Advisor |
| Date: | 2016 - 2022 |
| Title: | Defining and Defeating Mechanistic Subtypes of KRAS-mutant Lung Cancers - Core B: Clinical and Investigational Data Analytics |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Director |
| ID: | RP160652 |
| Date: | 2016 - 2022 |
| Title: | Pathogenesis and Early Progression of Lung Cancer - Core 2: Biostatistics and Computational Biology |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Director |
| ID: | RP160668 |
| Date: | 2016 - 2023 |
| Title: | THNMO BMS SIV Strategic Alliance: Strategic Collaboration Agreement (Lung Cancer) - NEOSTAR |
| Funding Source: | Bristol-Myers Squibb |
| Role: | Co-I |
| ID: | 52950 |
| Date: | 2016 - 2023 |
| Title: | THNMO BMS SIV Strategic Alliance: Strategic Collaboration Agreement (Lung Cancer) - LONESTAR |
| Funding Source: | Bristol-Myers Squibb |
| Role: | Co-I |
| ID: | 52950 |
| Date: | 2016 - 2018 |
| Title: | Platform-based Clinical Trial Designs for Phase II: Methodology and Software |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA205488-01 |
| Date: | 2016 - 2019 |
| Title: | Southwest Early Clinical Trials - Phase 2 Consortium |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5UM1CA186688-04 |
| Date: | 2015 - 2019 |
| Title: | Cancer Prevention Agent Development Program: Early Phase Clinical Research |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | N01-CN-05014-69 |
| Date: | 2015 - 2016 |
| Title: | Improving the Clinical Effectiveness and Understanding of the Biophysical Basis of Proton Therapy: Assessing and Understanding the Impact of Physical and Biological Factors: CORE D: Biostatistics & Data Management |
| Funding Source: | NIH/NCI (Subcontract from Massachusetts General Hospital) |
| Role: | Co-I |
| ID: | 5U19CA021239-36 |
| Date: | 2015 - 2020 |
| Title: | Targeting KRAS Mutant Lung Cancers |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Co-I |
| ID: | SU2C-AACR-DT-17-15 |
| Date: | 2015 - 2016 |
| Title: | Spore in Head and Neck Cancer |
| Funding Source: | John Hopkins University |
| Role: | Co-I |
| ID: | 3P50DE019032-14S2 |
| Date: | 2015 - 2016 |
| Title: | The impact of intra-tumor heterogeneity on disease-free survival after complete resection in patients with stage I lung adenocarcinomas |
| Funding Source: | Conquer Cancer Foundation of the American Society of Clinical Oncology |
| Role: | Collaborator |
| ID: | 13238 |
| Date: | 2015 - 2016 |
| Title: | Optical and Molecular Biomarkers for Oral Cancer Detection |
| Funding Source: | Red & Charline McCombs Institute |
| Role: | Co-I |
| Date: | 2015 - 2020 |
| Title: | Defining and Defeating Mechanistic Subtypes of KRAS-Mutant Lung Cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator - Core 2 "Clinical and Investigational Data Analytics" |
| ID: | RP150519 |
| Date: | 2015 - 2015 |
| Title: | Methods Training in Patient-Centered Cancer Outcomes Research |
| Funding Source: | Agency for Healthcare Research & Quality (AHRQ) |
| Role: | Co-I |
| ID: | 5R25HS023214-04 |
| Date: | 2015 - 2020 |
| Title: | Multi-ethnic Cancer Survivorship Cohort |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U01CA195566-01 |
| Date: | 2015 - 2019 |
| Title: | (PQA-4) Identification of Signaling Pathways that Promote Oral Cancer Progression |
| Funding Source: | NIH (Subcontract from Baylor College of Medicine) |
| Role: | Co-I |
| Date: | 2015 - 2016 |
| Title: | Integrative Genomic Modeling for Oral Cancer Progression |
| Funding Source: | CPRIT (Subcontract from Baylor College of Medicine) |
| Role: | Co-I |
| ID: | RP 15039 |
| Date: | 2015 - 2016 |
| Title: | Comprehensive Genomic Characterization of HNSCC Arising in HIV-Infected Individuals |
| Funding Source: | National Cancer Institute through Johns Hopkins |
| Role: | Subsite Co-Investigator |
| ID: | 00013550 HIV SPORE Admin Supplement |
| Date: | 2014 - 2020 |
| Title: | WINTHERapeutics: Development of a System Biology Method to predict Efficacy of Cancer Drugs to Optimize Individualized Therapeutic Decision and Improve Clinical Outcome for Cancer Patients |
| Funding Source: | Inst Gustave Roussy Tresorerie |
| Role: | Co-I |
| ID: | 7106 |
| Date: | 2014 - 2017 |
| Title: | MDACC Moon Shot Flagship |
| Funding Source: | MDACC Moon Shot Flagship |
| Role: | Biostatistician |
| ID: | 80-710499-111543-19 |
| Date: | 2014 - 2019 |
| Title: | Improving the Clinical Effectiveness and Understanding of the Biophysical Basis of Proton Therapy: Core D Biostatistics & Data Management |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5U19CA021239-38 |
| Date: | 2014 - 2015 |
| Title: | Myers Philanthropy Funds |
| Funding Source: | Philanthropy Funds |
| Role: | Biostatistician |
| ID: | 80-600382-112472-21 |
| Date: | 2014 - 2018 |
| Title: | (PQC2): Optical Hallmarks of Aggressive Clones Within Oral Field Cancerization |
| Funding Source: | NIH (Subcontract from Rice University) |
| Role: | Co-I |
| ID: | 5R01CA185207-04 |
| Date: | 2014 - 2019 |
| Title: | Profiling of Oral Pre-Malignant Lesions to Identify Targets for Chemoprevention |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA190903-01 |
| Date: | 2014 - 2017 |
| Title: | Next Generation Sequencing and Transcriptomic Profiling |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP140464 |
| Date: | 2014 - 2017 |
| Title: | GLOBAL ASSET – Global Longitudinal Observation and Bayesian Analysis Leading to A Scientifically Structured Evolution of Treatment |
| Funding Source: | PCORi (Subcontract from Yale University) |
| Role: | Co-PI |
| Date: | 2014 - 2015 |
| Title: | The Impact of Intra-tumor Heterogeneity on Disease-free Survival After Complete Resection in Non-small Cell Lung Cancer Patients |
| Funding Source: | Conquer Cancer Foundation of the American Society of Clinical Oncology |
| Role: | Co-I |
| Date: | 2014 - 2015 |
| Title: | Thymic Epithelial Malignancies Consortium |
| Funding Source: | The Valley Health System |
| Role: | Co-I |
| Date: | 2014 - 2017 |
| Title: | Liquid Biopsies in Advanced Cancers with BRAF V600 Mutations |
| Funding Source: | Conquer Cancer Foundation of the American Society of Clinical Oncology |
| Role: | Co-I |
| Date: | 2014 - 2016 |
| Title: | Molecular Understanding of Everolimus and Vorinostat Combination in Hodgkin Lymphoma |
| Funding Source: | Hope Foundation |
| Role: | Co-I |
| Date: | 2014 - 2014 |
| Title: | Novel Combined Immunotherapy Approaches for Targeting HPV Positive Cancers |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Co-I |
| Date: | 2014 - 2014 |
| Title: | Phase I & II Clinical Trials of Chemopreventive Agents |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | N01-CN-035159 07 |
| Date: | 2014 - 2019 |
| Title: | Targeted On-demand Chemo-Mechanical Therapy of Lung Cancer |
| Funding Source: | Subcontract from Rice University |
| Role: | Co-I |
| Date: | 2014 - 2018 |
| Title: | Molecular Genetics of Filed Cancerization in Oral Squamous Cell Carcinoma (PQD4) |
| Funding Source: | NIH (Subcontract from Baylor College of Medicine |
| Role: | Co-I |
| Date: | 2014 - 2019 |
| Title: | Southwest Early Clinical Trials Consortium |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 UM1 CA 186688 03S2 |
| Date: | 2014 - 2014 |
| Title: | Formalin-fixed paraffin-embedded (FFPE) based tumor tissue proteomics for cancer biomarker discovery, using proprietary and confidential discovery and analysis methods of OpDX |
| Funding Source: | OncoPlex Diagnostics |
| Role: | Co-I |
| Date: | 2013 - 2015 |
| Title: | Molecular Understanding of mTOR and HDAC Combination in Hodgkin Lymphoma |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-I |
| Date: | 2013 - 2018 |
| Title: | Personalized Cancer Therapy Studies in Head and Neck Squamous Cell Carcinomas (HNSCC) |
| Funding Source: | Kadoorie Charitable Foundation |
| Role: | Co-I |
| ID: | 14027706 |
| Date: | 2013 - 2018 |
| Title: | Targeting RXR and Signaling Pathways for Breast Cancer Prevention |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 2R01CA078480-13A1 |
| Date: | 2013 - 2016 |
| Title: | Overcoming Therapeutic Resistance to mTOR inhibition in Renal Cell Carcinoma with Autophagy Blockade |
| Funding Source: | Conquer Cancer Foundation of the American Society of Clinical Oncology |
| Role: | Biostatistician |
| ID: | 2013_cda_rfp_120524 |
| Date: | 2013 - 2016 |
| Title: | Late Effects and Intervention Needs in Head & Neck Cancer Survivors |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| ID: | Coeus #6351 |
| Date: | 2013 - 2014 |
| Title: | Statistics – Sharpening your knowledge of evidence-based medicine through quantitative reasoning |
| Funding Source: | UTMDACC Academy of Health Science Education |
| Role: | PI |
| Date: | 2012 - 2015 |
| Title: | Global molecular analysis of airway field cancerization in early-stage lung squamous cell carcinomas |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2012 - 2014 |
| Title: | Oncogenic mutations in circulating tumor DNA in personalized cancer therapy |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | Statistician |
| Date: | 2012 - 2015 |
| Title: | Personalizing NSCLC Therapy: Applying Next-Generation Sequencing in the BATTLE-2 Trial |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | LC110259 |
| Date: | 2012 - 2013 |
| Title: | Overcoming therapeutic resistance with autophagy inhibition |
| Funding Source: | Conquer Cancer Foundation of America |
| Role: | Co-I |
| ID: | COEUS #2611 |
| Date: | 2012 - 2014 |
| Title: | Phase I Study of BRAF Inhibitor GSK2118436 and VEGFR/PDGFR/KIT Inhibitor Pazopanib in Patients with Advanced Refractory Malignancies |
| Funding Source: | NCCN |
| Role: | Co-I |
| Date: | 2012 - 2013 |
| Title: | CTR1 Transporter Dysregulation in Platinum Resistance in NSCLC |
| Funding Source: | Conquer Cancer Foundation of America |
| Role: | Co-I |
| ID: | COEUS #2744 |
| Date: | 2012 - 2015 |
| Title: | Clinically Actionable Mutation Profiling for Cancer Personalized Medicine Using Scalable Ultra Deep NGS |
| Funding Source: | Latham, Asuragen Inc. CPRIT (prime) |
| Role: | Co-I |
| ID: | CP120017 |
| Date: | 2012 - 2013 |
| Title: | Multi-Modal Optical Imaging Systems for Early Detection of Oral Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) Subcontract with Rice University |
| Role: | Co-I |
| ID: | RP100932 03 |
| Date: | 2012 - 2014 |
| Title: | Novel High-Throughput Assays for NSCLC Therapy Prognosis and Prediction |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R21CA167376-01 |
| Date: | 2011 - 2013 |
| Title: | A measurement protocol for head & neck lymphedema |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R21DE022447-01 |
| Date: | 2011 - 2012 |
| Title: | Multiplex MRM Assay for Improved Lung Cancer Diagnosis and Treatment |
| Funding Source: | Expression Pathology, Inc |
| Role: | Co-I |
| ID: | LS2011-11121345RG |
| Date: | 2011 - 2016 |
| Title: | Personalizing NSCLC Therapy: Exploiting KRAS Activated Pathways |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 5 R01-CA155196 05 |
| Date: | 2011 - 2016 |
| Title: | Optical Systems for In Vivo Molecular Imaging of Cancer |
| Funding Source: | NIH/NCI Subcontract from Rice University |
| Role: | Co-I |
| ID: | 5R01 CA103830 09 |
| Date: | 2011 - 2016 |
| Title: | Early Therapeutics Development with Phase II Emphasis(PP-16) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | N01-CM-62202 |
| Date: | 2011 - 2016 |
| Title: | Cytokine-CREB Network in Lung Diseases |
| Funding Source: | NIH/NHLBI |
| Role: | Co-I |
| ID: | 1 R01 HL109828 01 |
| Date: | 2011 - 2012 |
| Title: | Prevalence and Prognostic Significance of Disruptive TP53 Mutations in Oral Cancer Around the World |
| Funding Source: | UTMDACC Sister Institution Network Fund (SINF) |
| Role: | Co-I |
| ID: | FReD #35702 |
| Date: | 2011 - 2016 |
| Title: | The Cancer Reclassification Project |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA163260 01 |
| Date: | 2011 - 2016 |
| Title: | Battle-2: Personalizing Non-Small Cell Lung Cancer Therapy (PC-B) |
| Funding Source: | NIH/NCI |
| Role: | Core Director |
| ID: | 1 P01 CA148133 01A1 |
| Date: | 2011 - 2013 |
| Title: | Notch and stem cells in lung cancer treated with erlotinib plus notch inhibitor |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| ID: | 1 R21 CA153017 01A1 |
| Date: | 2011 - 2015 |
| Title: | Phase I Studies of Targeted Anti-Cancer Therapies - (PC-A) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 U01 CA062461 19 |
| Date: | 2011 - 2013 |
| Title: | Profile-Related Evidence to Determine Individualized Cancer Therapy (PREDICT) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Investigator |
| ID: | N/A |
| Date: | 2010 - 2017 |
| Title: | A biomarker-Integrated Study in Previously Treated Patients with Non-Small Cell Lung Cancer. BATTLE II |
| Funding Source: | Merck and Company |
| Role: | Co-I |
| ID: | CS2011-00033943LG 01 |
| Date: | 2010 - 2015 |
| Title: | Novel Strategy for Chemoprevention and Treatment for 1GF-induced Lung Carcinogenesis |
| Funding Source: | NIH/NCI |
| Role: | Significant contributor |
| ID: | 2 R01CA109520 06A1 |
| Date: | 2010 - 2015 |
| Title: | Molecular Theranostics of Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | Advisor |
| ID: | 1 P01 CA 136397 01A2 |
| Date: | 2010 - 2013 |
| Title: | Personalizing Medicine: The Identification of Biomarkers for Predicting Response to Treatment in Advanced Non-Small Cell Lung Cancer |
| Funding Source: | V Foundation |
| Role: | Biostatistician |
| ID: | n/a |
| Date: | 2010 - 2013 |
| Title: | Genomic Profiling in a Personalized Biopsy-based Advanced NSCLC Clinical Trial |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 1 RC4 CA156578 01 |
| Date: | 2010 - 2014 |
| Title: | Semiparametric inference and model selection for correlated biomedical data |
| Funding Source: | NIH/NCI Subcontract with University of Illinois |
| Role: | Co-I |
| ID: | Fred 30863 |
| Date: | 2010 - 2013 |
| Title: | Prevention and Early Detection of Oral Cancer (PREDOC) Program |
| Funding Source: | MDACC MRP |
| Role: | Investigator |
| ID: | n/a |
| Date: | 2010 - 2014 |
| Title: | Blood-based biomarkers for predicting response and identifying resistance mechanisms to first-line treatment in advanced non-small cell lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | N/A |
| Date: | 2009 - 2012 |
| Title: | Stand Up to Cancer Dream Team Translational Research Grant |
| Funding Source: | American Association for Cancer Research (AACR) Subcontract from Massachusetts General Hospital |
| Role: | Biostatistician |
| ID: | SU2C-AACR-DT0309 01 |
| Date: | 2009 - 2011 |
| Title: | Biomarker validation via patient level meta-analysis in lung cancer targeted therapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 RC1 CA147597 01 |
| Date: | 2009 - 2011 |
| Title: | Trace Metals and Risk of Prostate Cancer: A Case-Control Analysis |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 RC1 CA145775 01 |
| Date: | 2009 - 2017 |
| Title: | Salivary Gland Tumor Biorepository |
| Funding Source: | NIH/NIDCR |
| Role: | Biostatistician |
| ID: | HHSN268200900039C 02 |
| Date: | 2009 - 2011 |
| Title: | Biomarker's for Personalized Cancer Therapy PC- B |
| Funding Source: | NIH/NCI |
| Role: | Core Director |
| ID: | 1 RC2 CA148020 01 |
| Date: | 2008 - 2014 |
| Title: | Reducing Uncertainties in Proton Radiation Therapy - Optimizing Proton Radiation Therapy - (PC-C) |
| Funding Source: | NIH/NCI Subcontract from Massachusetts General Hospital |
| Role: | Co-I |
| ID: | 5 P01 CA021239 34 |
| Date: | 2008 - 2014 |
| Title: | MD Anderson Cancer Center Head and Neck SPORE, (PC-B) |
| Funding Source: | NIH/NCI |
| Role: | Core Director |
| ID: | 5 P50 CA097007 10 |
| Date: | 2008 - 2010 |
| Title: | Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination AKA Battle II (PC-B) |
| Funding Source: | Cohen-Reinach Foundation |
| Role: | Co-I |
| ID: | BATTLE 02 |
| Date: | 2007 - 2012 |
| Title: | PROSPECT, Profiling of resistance patterns & oncogenic signaling pathways in evaluation of cancers of the thorax and therapeutic target identification (PC-B) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Core Director |
| ID: | W81XWH-07-1-0306 04 |
| Date: | 2006 - 2007 |
| Title: | U.T. M.D. Anderson Community Clinical Oncology Program (CCOP) Research Base |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 5 U10CA045809 18 |
| Date: | 2006 - 2010 |
| Title: | BATTLE (Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Core Director |
| ID: | W81XWH-06-1-0303-04 |
| Date: | 2005 - 2016 |
| Title: | IMPACT: Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets, Complementary/Innovative Treatments, and Therapeutic Modalities (PC-B) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Core Director |
| ID: | W81XWH-05-2-0027-04 |
| Date: | 2004 - 2012 |
| Title: | Molecular-Based Therapy for Oral Cancer Prevention, (PC-B) |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | 5 P01 CA106451 06 |
| Date: | 2003 - 2009 |
| Title: | VITAL (Vanguard Trial Investigations of Therapeutic Approaches to Lung Cancer) - (PC-B) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Core Director |
| ID: | W81XWH-04-1-0142-05 |
| Date: | 2003 - 2012 |
| Title: | Phase I & II Clinical Trials of Chemopreventive Agents (PP-1) |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | N01 CN035159 07 |
| Date: | 2002 - 2013 |
| Title: | HIV Supplement of the Head and Neck SPORE |
| Funding Source: | NIH/NCI |
| Role: | Project Director |
| ID: | 3 P50 CA097007 08S2 |
| Date: | 2002 - 2006 |
| Title: | TARGET (Translational Approaches for the Reversal, Genetic Evaluation and Treatment) of Lung Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Core Director |
| ID: | DAMD17-02-1-0706 03 |
| Date: | 2002 - 2015 |
| Title: | Fluorescence Spectroscopy to Detect Oral Neoplasia |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 5 R01 CA095604 09 |
| Date: | 2002 - 2002 |
| Title: | Phase III Double-Blind Randomized Trial of 13-cis-Retinoic Acid (13-cRA) to Prevent Secondary Primary Tumors (SPTs) in Stage I Non-Small Cell Lung Cancer |
| Funding Source: | Hoffman-LaRoche, Inc |
| Role: | Biostatistician |
| ID: | CS2002-00006792RM 01 |
| Date: | 2001 - 2008 |
| Title: | The Impact of Smoking on Lung Cancer Chemoprevention, (PC-B) |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | 5 P01 CA091844 05 |
| Date: | 2001 - 2008 |
| Title: | The Impact of Smoking on Lung Cancer Chemoprevention (PP-1), (PC-B) |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator, Core Leader |
| ID: | 5 P01 CA091844 05 |
| Date: | 2000 - 2003 |
| Title: | University of Texas SPORE in Lung Cancer, LCBCC Supplement, Biostatistics |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 P50 CA70907 05S4 |
| Date: | 1999 - 2001 |
| Title: | Project 10 - Biostatistics for Translational Research. Novel Targeted Approaches to Lung and Oral Cancer |
| Funding Source: | Tobacco Research Fund, Texas State Legislature |
| Role: | Project Leader |
| Date: | 1998 - 2005 |
| Title: | Biochemoprevention in Advanced Laryngeal Dysplasia |
| Funding Source: | NIH/NHLBI |
| Role: | Biostatistician |
| ID: | 5 U01 CA079437 05 |
| Date: | 1996 - 2002 |
| Title: | Novel Diagnosis and Therapy of Early Oral Cancers |
| Funding Source: | NIH/NIDCR |
| Role: | Core Director |
| ID: | 5 P50 DE11906 03 |
| Date: | 1995 - 2001 |
| Title: | Lung Cancer Chemoprevention Research Program |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 5 U19 CA068437 05 |
| Date: | 1995 - 2000 |
| Title: | Training of Academic Head and Neck Surgical Oncologist |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 5 T32 CA060374 07 |
| Date: | 1991 - 2004 |
| Title: | Biology and Chemoprevention of Head and Neck Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 P01 CA52051 10 |
Selected Publications
Peer-Reviewed Articles
- Saad, M, Al Tashi, Q, Hong, L, Verma, V, Li, W, Boiarsky, D, Li, S, Petranovic, M, Wu, CC, Carter, B, Shroff, G, Cascone, T, Le, X, Elamin, YY, Altan, M, Heeke, S, Sheshadri, A, Chang, JY, Lee, PP, Liao, Z, Gibbons, DL, Vaporciyan, AA, Lee, JJ, Wistuba, II, Haymaker, CL, Mirjalili, S, Jaffray, D, Gainor, J, Lou, Y, Di Federico, A, Pecci, F, Awad, MM, Ricciuti, B, Heymach, JV, Vokes, N, Zhang, J, Wu, J. Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40707438.
- Kalluri, VS, Smaglo, BG, Mahadevan, KK, Kirtley, ML, McAndrews, KM, Mendt Vilchez, MC, Yang, S, Maldonado, AS, Sugimoto, H, Salvatierra De Aranguren, M, Solis Soto, LM, Haymaker, CL, Finch, RA, Gagea Iurascu, M, Fluty, AC, Ludtke, SJ, Lee, JJ, Jain, A, Varadhachary, GR, Shroff, R, Maitra, A, Shpall, E, Pant, S, Kalluri, R. Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer. Nature communications 16(1), 2025. e-Pub 2025. PMID: 41027940.
- Saad MB, Showkatian E, Verma V, Al-Tashi Q, Aminu M, Xu X, Qayati Mohamed M, Salehjahromi M, Sujit SJ, Kitsel Y, Lin SH MD,, Liao Z, Gandhi S, Qian D, Jaffray D, Chung C, Vokes NI, Zhang J, Lee JJ, Heymach JV, Wu J, Chang JY. Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial. J Immunother Cancer 13(10), 2025. e-Pub 2025. PMID: 41052882.
- Lu X, Lee JJ. Bayesian clustering prior with overlapping indices for effective use of multisource external data. Stat Methods Med Res:9622802251367439, 2025. e-Pub 2025. PMID: 40953124.
- Pecci F, Li H, Di Federico A, Wu J, Chen H, Gariazzo E, Mantuano F, Garbo E, Aldea M, Santo V, Gibbons D, Tran H, Paoloni F, Rossato de Almeida G, Metro G, De Giglio A, Gelsomino F, Wang X, Tiseo M, Rotow J, Ardizzoni A, Lee JJ, Awad MM, Addeo A, Hong L, Negrao MV, Janne PA, Heymach JV, Zhang J, Ricciuti B, Le X. First-line MET tyrosine kinase inhibitors versus immunotherapy +/- chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC. Clin Cancer Res, 2025. e-Pub 2025. PMID: 40864503.
- Jiang X, Rudqvist NP, Jiang B, Ye S, He S, Liang Q, Dou J, Williams MD, Dunn JD, Johnson JM, Akagi K, Xiao W, Liang S, Elayavalli S, Sun B, Parra ER, Ferrarotto R, Garden AS, Fuller CD, Reddy J, Gross ND, Lango MN, Leung CH, Liu S, Liu DD, Li M, Lee JJ, Curran MA, Phan J, Chen K, Gillison ML. Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade. Cancer Discov 15(8):1569-1592, 2025. e-Pub 2025. PMID: 40249124.
- Wong WK, Ryeznik Y, Sverdlov O, Chen PY, Fang X, Chen RB, Zhou S, Lee JJ. Nature-inspired metaheuristics for optimizing dose-finding and computationally challenging clinical trial designs. Clin Trials 22(4):422-429, 2025. e-Pub 2025. PMID: 40650489.
- Hong L, Di Federico A, Liu B, Cooper AJ, Alessi JV, Clark P, Rinsurongkawong W, Young C, Li H, Qin K, Aminu M, Santo V, Elamin Y, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Lee JJ, Le X, Wu J, Roy-Chowdhuri S, Routbort MJ, Futreal PA, Heymach JV, Awad MM, Schoenfeld AJ, Zhang J, Ricciuti B, Deng L, Vokes NI. Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40716572.
- Xu X, Yuan Y, Lee JJ. Assessing the role of correlation between efficacy and toxicity endpoints in the performance of Bayesian optimal phase II design. Contemp Clin Trials 154:107939, 2025. e-Pub 2025. PMID: 40324518.
- Patel SP, Fisher J, Chae YK, Soto LS, Kasi A, Konda B, Walshauser M, Parra E, Zhang J, Duault C, Gonzalez-Kozlova E, Manyam G, Zhang J, Chen H, Duose DY, Laberiano Fernandez C, Luthra R, Al-Atrash G, Kim-Schulze S, Maecker HT, Wistuba II, Gnjatic S, Lee JJ, Zhang J, Magner CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke C, Haymaker CL, Kurzrock R. Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort. J Immunother Cancer 13(6), 2025. e-Pub 2025. PMID: 40588371.
- Zhu B, Chen P, Aminu M, Li JR, Fujimoto J, Tian Y, Hong L, Chen H, Hu X, Li C, Vokes N, Moreira AL, Gibbons DL, Solis Soto LM, Parra Cuentas ER, Shi O, Diao S, Ye J, Rojas FR, Vilar E, Maitra A, Chen K, Navin N, Nilsson M, Huang B, Heeke S, Zhang J, Haymaker CL, Velcheti V, Sterman DH, Kochat V, Padron WI, Alexandrov LB, Wei Z, Le X, Wang L, Fukuoka J, Lee JJ, Wistuba II, Pass HI, Davis M, Hanash S, Cheng C, Dubinett S, Spira A, Rai K, Lippman SM, Futreal PA, Heymach JV, Reuben A, Wu J, Zhang J. Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer Cell 43(6):1125-1140.e10, 2025. e-Pub 2025. PMID: 40345189.
- Altan M, Sui D, Xu C, Simon GR, Sulihem ST, Malveaux D, Ponce D, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Santorelli ML, Burke T, Williams LA. PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017-2021. J Immunother Precis Oncol 8(2):161-171, 2025. e-Pub 2025. PMID: 40235643.
- Li H, Salehjahromi M, Godoy MCB, Qin K, Plummer CM, Zhang Z, Hong L, Heeke S, Le X, Vokes N, Zhang B, Araujo HA, Altan M, Wu CC, Antonoff MB, Ostrin EJ, Gibbons DL, Heymach JV, Lee JJ, Gerber DE, Wu J, Zhang J. Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model. Cancers (Basel) 17(9), 2025. e-Pub 2025. PMID: 40361426.
- LeBleu VS, Smaglo BG, Mahadevan KK, Kirtley ML, McAndrews KM, Mendt M, Yang S, Maldonado AS, Sugimoto H, Salvatierra ME, Solis Soto LM, Finch R, Gagea M, Fluty AC, Ludtke SJ, Lee JJ, Jain AK, Varadhachary G, Shroff RT, Maitra A, Shpall E, Kalluri R, Pant S. KRAS (G12D) -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients. medRxiv, 2025. e-Pub 2025. PMID: 40093249.
- Lee J, Fu, C, Zhou, S. Posterior Predictive Design for Phase I Clinical Trials. Journal of the American Statistical Association:1-12, 2025.
- Johnson FM, O'Hara MP, Yapindi L, Jiang P, Tran HT, Reuben A, Xiao W, Gillison M, Sun X, Khalaf A, Lee JJ, Sastry JK, Ghosh S. Phase 1/2 Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. Clin Cancer Res, 2024. e-Pub 2024. PMID: 39589337.
- Chen K, Zhou H, Lee JJ, Yuan Y. BOP2-TE: Bayesian optimal phase 2 design for jointly monitoring efficacy and toxicity with application to dose optimization. J Biopharm Stat:1-16, 2024. e-Pub 2024. PMID: 39582234.
- Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
- Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
- Lin TA, McCaw ZR, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Sherry AD, Noticewala SS, Fuller CD, Thomas CR Jr, Sun R, Lee JJ, Lin R, Yuan Y, Shyr Y, Meirson T, Ludmir EB. Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation. Clin Cancer Res 30(20):4791-4799, 2024. e-Pub 2024. PMID: 39133081.
- Rahal Z, Liu Y, Peng F, Yang S, Jamal MA, Sharma M, Moreno H, Damania AV, Wong MC, Ross MC, Sinjab A, Zhou T, Chen M, Tarifa Reischle I, Feng J, Chukwuocha C, Tang E, Abaya C, Lim JK, Leung CH, Lin HY, Deboever N, Lee JJ, Sepesi B, Gibbons DL, Wargo JA, Fujimoto J, Wang L, Petrosino JF, Ajami NJ, Jenq RR, Moghaddam SJ, Cascone T, Hoffman K, Kadara H. Inflammation mediated by gut microbiome alterations promotes lung cancer development and an immunosuppressed tumor microenvironment. Cancer Immunol Res, 2024. e-Pub 2024. PMID: 39269772.
- Wu WY, Luke B, Wu XC, Lee JJ, Yi Y, Okpechi SC, Gause B, Mehta P, Sherman SI, Ochoa A, Dmitrovsky E, Liu X. Glycemic control in diabetic patients improved overall lung cancer survival across diverse populations. JNCI Cancer Spectr 8(5), 2024. e-Pub 2024. PMID: 39270065.
- Yang CH, Kwiatkowski E, Lee JJ, Lin R. REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors. Stat Med 43(18):3484-3502, 2024. e-Pub 2024. PMID: 38857904.
- Hsu EJ, Lin TA, Dabush DR, McCaw Z, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Noticewala S, Yang Y, Sherry AD, Fuller CD, Thomas CR Jr, Tang C, Msaouel P, Das P, Huang B, Tian L, Sun R, Lee JJ, Meirson T, Ludmir EB. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials. J Natl Cancer Inst 116(6):990-994, 2024. e-Pub 2024. PMID: 38331394.
- Aminu M, Hong L, Vokes N, Schmidt ST, Saad M, Zhu B, Le X, Tina C, Sheshadri A, Wang B, Jaffray D, Futreal A, Lee JJ, Byers LA, Gibbons D, Heymach J, Chen K, Cheng C, Zhang J, Wu J. Joint multi-omics discriminant analysis with consistent representation learning using PANDA. Res Sq, 2024. e-Pub 2024. PMID: 38798352.
- Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez FR, Heeke S, Moreira AL, Solis LM, Haymaker C, Velcheti V, Sterman DH, Pass HI, Cheng C, Lee JJ, Zhang J, Wei Z, Wu J, Le X, Ostrin E, Toumazis I, Gibbons D, Su D, Fukuoka J, Antonoff MB, Gerber DE, Li C, Kadara H, Wang L, Davis M, Heymach JV, Hannash S, Wistuba I, Dubinett S, Alexandrov L, Lippman S, Spira A, Futreal AP, Reuben A, Zhang J. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion. Res Sq, 2024. e-Pub 2024. PMID: 38798564.
- Anderson BJ, Moreno AC, Qing Y, Lee JJ, Johnson FM, Lango MN, Barbon CEA, Tripuraneni L, Sahli A, Piper V, Gross N, Fuller CD, Lai SY, Myers JN, Hutcheson KA. Revisiting feeding tube utilization in oropharynx cancer: 6-year prospective registry analysis. Otolaryngol Head Neck Surg 170(5):1319-1330, 2024. e-Pub 2024. PMID: 38353360.
- Sujit SJ, Aminu M, Karpinets TV, Chen P, Saad MB, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, Antonoff MB, Hong L, Hu X, Heeke S, Tran HT, Le X, Elamin YY, Altan M, Vokes NI, Sheshadri A, Lin J, Zhang J, Lu Y, Behrens C, Godoy MCB, Wu CC, Chang JY, Chung C, Jaffray DA, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Heymach J, Zhang J, Cascone T, Wu J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun 15(1):3152, 2024. e-Pub 2024. PMID: 38605064.
- Feldman H, Sepesi B, Leung CH, Lin H, Weissferdt A, Pataer A, William WN Jr, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 167(4):1444-1453.e4, 2024. e-Pub 2024. PMID: 37816395.
- Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst RS, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. Multi-omics analysis reveals immune features associated with immunotherapy benefit in patients with squamous cell lung cancer from phase III Lung-MAP S1400I Trial. Clin Cancer Res 30(8):1655-1668, 2024. e-Pub 2024. PMID: 38277235.
- Salehjahromi M, Karpinets TV, Sujit SJ, Qayati M, Chen P, Aminu M, Saad MB, Bandyopadhyay R, Hong L, Sheshadri A, Lin J, Antonoff MB, Sepesi B, Ostrin EJ, Toumazis I, Huang P, Cheng C, Cascone T, Vokes NI, Behrens C, Siewerdsen JH, Hazle JD, Chang JY, Zhang J, Lu Y, Godoy MCB, Chung C, Jaffray D, Wistuba I, Lee JJ, Vaporciyan AA, Gibbons DL, Gladish G, Heymach JV, Wu CC, Zhang J, Wu J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept. Cell Rep Med 5(3):101463, 2024. e-Pub 2024. PMID: 38471502.
- Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol 19(3):500-506, 2024. e-Pub 2024. PMID: 38012986.
- Zhang, B, Lewis, WE, Stewart, C, Morris, BB, Solis Soto, LM, Serrano, A, Xi, Y, Wang, Q, Lopez, ER, Concannon, K, Heeke, S, Tang, X, Raso, G, Cardnell, R, Vokes, N, Blumenschein, GR, Elamin, YY, Fosella, F, Tsao, A, Skoulidis, F, Hume, CB, Sasak, K, Lewis, J, Rinsurongkawong, W, Rinsurongkawong, V, Lee, JJ, Tran, HT, Zhang, J, Gibbons, DL, Vaporciyan, AA, Wang, J, Park, K, Heymach, JV, Byers, LA, Gay, CM, Le, X. Brief Report. JTO Clinical and Research Reports 5(2), 2024. e-Pub 2024. PMID: 38357092.
- Qin K, Wang K, Li S, Hong L, Padmakumar P, Waree R, Hubert SM, Le X, Vokes N, Rai K, Vaporciyan A, Gibbons DL, Heymach JV, Lee JJ, Woodman SE, Chung C, Jaffray DA, Altan M, Lou Y, Zhang J. Clinical benefit from docetaxel +/- ramucirumab is not associated with mutation status in metastatic non-small-cell lung cancer patients who progressed on platinum doublets and immunotherapy. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473297.
- Li H, Hu X, Ning MS, Fuller GN, Stewart JM, Gilliam JC, Wu J, Le X, Vaporciyan AA, Lee JJ, Gibbons DL, Heymach JV, Futreal A, Zhang J. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features. Front Oncol 14:1324057, 2024. e-Pub 2024. PMID: 38590653.
- Vokes NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, Trevino S 3rd, Druker V, Qian Y, Patel S, Schmidt S, Hong L, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Negrao MV, Gibbons DL, Vaporciyan A, Le X, Wu J, Zhang J, Rigney U, Iyer S, Dean E, Heymach JV. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Clin Cancer Res 29(23):4958-4972, 2023. e-Pub 2023. PMID: 37733794.
- Hong, L, Aminu, M, Li, S, Lu, X, Petranovic, M, Saad, MB, Chen, P, Qin, K, Varghese, S, Rinsurongkawong, W, Rinsurongkawong, V, Spelman, AR, Elamin, YY, Vailati Negrao, M, Skoulidis, F, Gay, CM, Cascone, T, Gandhi, S, Lin, SH, Lee, PP, Carter, B, Wu, CC, Antonoff, MB, Sepesi, B, Lewis, J, Gibbons, DL, Vaporciyan, AA, Le, X, Lee, JJ, Roy Chowdhuri, S, Routbort, MJ, Gainor, J, Heymach, JV, Lou, Y, Wu, J, Zhang, J, Vokes, N. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nature communications 14(1), 2023. e-Pub 2023. PMID: 36755027.
- Chen P, Rojas FR, Hu X, Serrano A, Zhu B, Chen H, Hong L, Bandyoyadhyay R, Aminu M, Kalhor N, Lee JJ, El Hussein S, Khoury JD, Pass HI, Moreira AL, Velcheti V, Sterman DH, Fukuoka J, Tabata K, Su D, Ying L, Gibbons DL, Heymach JV, Wistuba II, Fujimoto J, Solis Soto LM, Zhang J, Wu J. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Mod Pathol 36(12):100326, 2023. e-Pub 2023. PMID: 37678674.
- Altan M, Soto F, Zhong LL, Akhmedzhanov FO, Wilson NR, Zarifa A, Albittar AA, Yang V, Lewis J, Rinsurongkawong W, Jack Lee J, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Jennings K, Khawaja F, Faiz SA, Shannon VR, Shroff G, Godoy MCB, Daver NG, Gandhi S, Mendoza TR, Naing A, Daniel-MacDougall C, Heymach JV, Sheshadri A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist 28(11):e1065-e1074, 2023. e-Pub 2023. PMID: 37156009.
- Yang P, Hubert SM, Futreal PA, Song X, Zhang J, Lee JJ, Wistuba I, Yuan Y, Zhang J, Li Z. A novel Bayesian model for assessing intratumor heterogeneity of tumor infiltrating leukocytes with multi-region gene expression sequencing. bioRxiv, 2023. e-Pub 2023. PMID: 37961165.
- Weissferdt A, Leung CH, Lin H, Sepesi B, William WN, Swisher SG, Cascone T, Lee JJ, Pataer A. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Mod Pathol 37(1):100353. e-Pub 2023. PMID: 37844869.
- Dacic S, Travis W, Redman M, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, Wijeratne MT, Connolly C, Wynes M, Bota-Rabassedas N, Sanchez-Espiridion B, Lee JJ, Berezowska S, Chou TY, Kerr K, Nicholson A, Poleri C, Schalper KA, Tsao MS, Carbone DP, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn PA, Kris MG, Belani CP, Kelly K, Wistuba I, Committee IP. International association for the study of lung cancer study of reproducibility in assessment of pathologic response in resected lung cancers after neoadjuvant therapy. J Thorac Oncol 18(10):1290-1302, 2023. e-Pub 2023. PMID: 37702631.
- Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
- Noh, S, Bertini, CD, Mira-Avendano, I, Kaous, M, Patel, B, Faiz, S, Shannon, VR, Balachandran, D, Bashoura, L, Adachi, R, Evans, S, Dickey, BF, Wu, CC, Shroff, G, Manzano, JM, Granwehr, BP, Holloway, S, Dickson, KB, Mohammed, AD, Muthu, M, Song, H, Aroe, A, Aloia, TA, Lee Andrews, II, Badami, KK, Beird, H, Brock, K, Cata, JP, Dabaja, BS, Draetta, G, French, KE, Godoy, M, Hutcheson, KA, Jaffray, D, John, TM, Lee, JJ, Litton, J, McEnery, KW, Musunuru, TN, Nates, JL, Palaskas, NL, Ravi, V, Scheet, PA, Shete, S, Subbiah, IM, Tawbi, H, Woodman, SE, Chung, C, Khawaja, F, Sheshadri, A. Interstitial lung abnormalities after hospitalization for COVID-19 in patients with cancer. Cancer medicine 12(17):17753-17765, 2023. e-Pub 2023. PMID: 37592894.
- Al-Tashi Q, Saad MB, Sheshadri A, Wu CC, Chang JY, Al-Lazikani B, Gibbons C, Vokes NI, Zhang J, Lee JJ, Heymach JV, Jaffray D, Mirjalili S, Wu J. SwarmDeepSurv: swarm intelligence advances deep survival network for prognostic radiomics signatures in four solid cancers. Patterns (N Y) 4(8):100777, 2023. e-Pub 2023. PMID: 37602223.
- Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep 4(8):100533, 2023. e-Pub 2023. PMID: 37649681.
- Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov 13(7):1556-1571, 2023. e-Pub 2023. PMID: 37068173.
- Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
- O'Shea AE, Clifton GT, Qiao N, Heckman-Stoddard BM, Wojtowicz M, Dimond E, Bedrosian I, Weber D, Garber JE, Husband A, Pastorello R, Lee JJ, Hernandez M, Liu DD, Vornik LA, Brown PH, Alatrash G, Peoples GE, Mittendorf EA. Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ. Cancer Prev Res (Phila) 16(6):333-341, 2023. e-Pub 2023. PMID: 37259799.
- Singhi EK, Mott F, Worst M, Leung CH, Lee JJ, Carter B, Presley CJ, Heymach JV, Altan M. Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non-small cell lung cancer. Oncol Lett 25(6):262, 2023. e-Pub 2023. PMID: 37216156.
- Walsh LC, Sui D, Higgins RSD, Moon MR, Lee JJ, Antonoff MB. Surgeons of the Future: A Novel Screening Tool for High-School Students. J Surg Res 290:61-70. e-Pub 2023. PMID: 37209525.
- Florez MA, Jaoude JA, Patel RR, Kouzy R, Lin TA, De B, Beck EJ, Taniguchi CM, Minsky BD, Fuller CD, Lee JJ, Kupferman M, Raghav KP, Overman MJ, Thomas CR, Ludmir EB. Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials. JAMA Netw Open 6(5):e2313819, 2023. e-Pub 2023. PMID: 37195664.
- Serrano D, Gandini S, Thomas P, Crew KD, Kumar NB, Vornik LA, Lee JJ, Veronesi P, Viale G, Guerrieri-Gonzaga A, Lazzeroni M, Johansson H, D'Amico M, Guasone F, Spinaci S, Bertelsen BE, Mellgren G, Bedrosian I, Weber D, Castile T, Dimond E, Heckman-Stoddard BM, Szabo E, Brown PH, DeCensi A, Bonanni B. Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial. JAMA Oncol 9(5):664-672, 2023. e-Pub 2023. PMID: 36951827.
- Song J, Morita S, Kuo YW, Lee JJ. BayesESS: A tool for quantifying the impact of parametric priors in Bayesian analysis. SoftwareX 22, 2023. e-Pub 2023. PMID: 37377886.
- Parra ER, Zhang J, Jiang M, Tamegnon A, Pandurengan RK, Behrens C, Solis L, Haymaker C, Heymach JV, Moran C, Lee JJ, Gibbons D, Wistuba II. Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. Nat Commun 14(1):2364, 2023. e-Pub 2023. PMID: 37185575.
- Reddy, DS, Cuenca, JA, Botdorf, JS, Muthu, M, Hanmandlu, A, Wegner, RC, Crommett, JW, Gutierrez, C, Rathi, N, Sajith, B, Knafl, M, Abbas, HA, Woodman, SE, Nates, JL, Aaroe, AE, Aloia, TA, Andrews, L, Badami, KK, Baganz, JA, Bajwa, P, Baker, LR, Barbosa, GR, Beird, H, Bourgeois, M, Brock, K, Burton, EM, Cata, JP, Chung, C, Cutherell, M, Dabaja, BS, Draetta, G, French, KE, Futreal, A, Gibbons, C, Godoy, M, Gunther, J, Hutcheson, KA, Jaffray, D, John, TM, Lee, JJ, Litton, J, McEnery, KW, Palaskas, NL, Ravi, V, Scheet, PA, Schmidt, S, Subbiah, IM, Tawbi, H, Wu, J, Yao, JC. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19. Mayo Clinic Proceedings 98(3):451-457, 2023. e-Pub 2023. PMID: 36868753.
- William WN, Zhang J, Zhao X, Parra ER, Uraoka N, Lin HY, Peng SA, El-Naggar AK, Rodriguez-Canales J, Song J, Gillenwater AM, Wistuba II, Myers JN, Gold KA, Ferrarotto R, Hwu P, Davoli T, Lee JJ, Heymach JV, Papadimitrakopoulou VA, Lippman SM. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer 129(5):714-727, 2023. e-Pub 2023. PMID: 36597662.
- Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
- Mlecnik B, Lugli A, Bindea G, Marliot F, Bifulco C, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert CI, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang J, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Lafontaine L, Maby P, Majdi A, Hijazi A, El Sissy C, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, van de Water C, Vliet SVL, Knijn N, Mu?ina AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Patel P, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Fox BA, Pagès F, Galon J. Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer. Cancers (Basel) 15(2), 2023. e-Pub 2023. PMID: 36672367.
- Thomas PS, Patel AB, Lee JJ, Liu DD, Hernandez M, Muzzio M, Contreras A, Sepeda V, Mays C, Weber D, Vornik LA, Khan SA, Dimond E, Heckman-Stoddard BM, Perloff M, Brown PH. Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. Cancer Prev Res (Phila) 16(1):47-55, 2023. e-Pub 2023. PMID: 36228112.
- De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol 7:e2200540, 2023. e-Pub 2023. PMID: 36716413.
- Francisco-Cruz A, Rocha P, Reuben A, Krishnan SN, Das P, Chen R, Quek K, Li J, Parra ER, Solis LM, Barua S, Jiang M, Lazcano R, Chow CW, Behrens C, Gumb C, Little L, Fukuoka J, Kalhor N, Weissferdt A, Kadara H, Heymach JV, Swisher S, Sepesi B, Rao A, Moran C, Zhang J, Lee JJ, Fujimoto J, Futreal PA, Wistuba II, Peterson CB, Zhang J. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol 36(1):100028, 2023. e-Pub 2023. PMID: 36788067.
- Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol 14:1322818, 2023. e-Pub 2023. PMID: 38152395.
- Fang X, Liu X, Chinchilli VM, Wang M, Wang HG, Dokholyan NV, Shen C, Lee JJ, Zhou S. REAP-2: An interactive quantitative tool for robust and efficient dose-response curve estimation. J Clin Transl Sci 7(1):e219, 2023. e-Pub 2023. PMID: 38028338.
- Aminu M, Yadav D, Hong L, Young E, Edelkamp P, Saad M, Salehjahromi M, Chen P, Sujit SJ, Chen MM, Sabloff B, Gladish G, de Groot PM, Godoy MCB, Cascone T, Vokes NI, Zhang J, Brock KK, Daver N, Woodman SE, Tawbi HA, Sheshadri A, Lee JJ, Jaffray D, Team D, Wu CC, Chung C, Wu J. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Cancers (Basel) 15(1), 2022. e-Pub 2022. PMID: 36612278.
- Johnson FM, Janku F, Gouda MA, Tran HT, Kawedia JD, Schmitz D, Streefkerk H, Lee JJ, Andersen CR, Deng D, Rawal S, Shah PA, El-Naggar AK, Johnson JM, Frederick MJ. Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer. Oncologist 27(12):1004-e926, 2022. e-Pub 2022. PMID: 36124629.
- Trivedi MS, Arber N, Friedman E, Garber JE, Holcomb K, Horowitz NS, Wright JD, Lee JJ, Vornik LA, Abutaseh S, Castile T, Sauter ER, Dimond E, Heckman-Stoddard BM, House M, Samimi G, Brown PH, Crew KD. Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy. Cancer Prev Res (Phila) 15(11):721-726, 2022. e-Pub 2022. PMID: 36001346.
- Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 164(5):1327-1337, 2022. e-Pub 2022. PMID: 35190177.
- Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Andrew Futreal P, Zhang J, Fujimoto J, Reuben A. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer 172:19-28, 2022. e-Pub 2022. PMID: 35973335.
- Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Hirohashi Y, Furuhata T, Takemasa I, Patel P, Vora H, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Yoshino T, Taniguchi H, Bifulco C, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert CI, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang J, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson E, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Marliot F, Fredriksen T, Buttard B, Lafontaine L, Maby P, Majdi A, Hijazi A, El Sissy C, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, Van de Water C, van Lent-van Vliet S, Knijn N, Mu?ina AM, Scripcariu DV, Marincola FM, Ascierto PA, Fox BA, Pagès F, Kawakami Y, Galon J. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. Cancers (Basel) 14(18), 2022. e-Pub 2022. PMID: 36139506.
- Bayley EM, Ivy ML, Shewale JB, Ge PS, Antonoff MB, Francis AM, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Vaporciyan AA, Walsh GL, Lee JJ, Louie BE, Swisher SG. High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for whom Surgery Should Not Be Delayed. Ann Surg. e-Pub 2022. PMID: 36052678.
- Zhou S, Liu X, Fang X, Chinchilli VM, Wang M, Wang HG, Dokholyan NV, Shen C, Lee JJ. Robust and Efficient Assessment of Potency (REAP) as a quantitative tool for dose-response curve estimation. Elife 11, 2022. e-Pub 2022. PMID: 35921131.
- Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, Gibbons DL, Lee JJ, Wu J, Vokes NI, Heymach JV, Zhang J, Le X. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884533.
- Hassane M, Rahal Z, Karaoghlanian N, Zhang J, Sinjab A, Wong JW, Lu W, Scheet P, Lee JJ, Raso MG, Solis LM, Fujimoto J, Chami H, Shihadeh AL, Kadara H. Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung. Cancer Prev Res (Phila) 15(7):423-434, 2022. e-Pub 2022. PMID: 35468191.
- Roszik J, Lee JJ, Wu YH, Liu X, Kawakami M, Kurie JM, Belouali A, Boca SM, Gupta S, Beckman RA, Madhavan S, Dmitrovsky E. Real-World Studies Link Nonsteroidal Anti-inflammatory Drug Use to Improved Overall Lung Cancer Survival. Cancer Res Commun 2(7):590-601, 2022. e-Pub 2022. PMID: 35832288.
- Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridon B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, Provencio M, Wistuba II, Kadara H. Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC. Clin Cancer Res 28(11):2461-2473, 2022. e-Pub 2022. PMID: 35394499.
- Liu Y, Zhang Z, Rinsurongkawong W, Gay CM, Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, Swisher S, Gandhi S, Lee PP, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, Lin SH. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Netw Open 5(6):e2215589, 2022. e-Pub 2022. PMID: 35666500.
- Sun B, Laberiano-Fernández C, Salazar-Alejo R, Zhang J, Solorzano Rendon JL, Lee J, Solis Soto LM, Wistuba II, Parra ER. Impact of Region-of-Interest Size on Immune Profiling Using Multiplex Immunofluorescence Tyramide Signal Amplification for Paraffin-Embedded Tumor Tissues. Pathobiology:1-12. e-Pub 2022. PMID: 35609532.
- Tang RS, Zhu J, Chen TT, Liu F, Jiang X, Huang B, Lee JJ, Beckman RA. Impact of COVID-19 pandemic on oncology clinical trial design, data collection and analysis. Contemp Clin Trials 116:106736, 2022. e-Pub 2022. PMID: 35331946.
- Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, Blumenschein G, Lu C, Johnson FM, Bell D, Lewis J, Zhang J, Feng L, Wilson K, Marcelo-Lewis K, Wang J, Ginsberg L, Gillison M, Lee JJ, Meric-Bernstam F, Mills GB, William WN, Myers JN, Pickering CR. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res. e-Pub 2022. PMID: 35443062.
- Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
- Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, Tang A, Mark J, Zender C, Gillenwater AM, Bell D, Kurtzweil N, Mathews M, Allen CL, Mierzwa ML, Casper K, Jandarov R, Medvedovic M, Lee JJ, Harun N, Takiar V, Gillison M. Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 28(7):1345-1352, 2022. e-Pub 2022. PMID: 35338369.
- Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. e-Pub 2022. PMID: 35307972.
- Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, Barrese TZ, Massarelli E, William W, Johnson FM, Ferrarotto R, Wistuba I, Coarfa C, Lee J, Wang J, Melief CJM, Curran MA, Glisson BS. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35193933.
- Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med. e-Pub 2022. PMID: 35098585.
- Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Mott FE. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. e-Pub 2022. PMID: 35216923.
- Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer. Ann Oncol 33(1):42-56, 2022. e-Pub 2022. PMID: 34653632.
- Zhao, Yujie, Yang, Bo, Lee, al J. Bayesian Optimal Phase II Design for Randomized Clinical Trials. In: Statistics in Biopharmaceutical Research 14(4):423-432, 2022. e-Pub 2022.
- Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):7081, 2021. e-Pub 2021. PMID: 34873156.
- Kothari AN, DiBrito SR, Lee JJ, Caudle AS, Clemens MW, Gottumukkala VN, Katz MHG, Offodile AC, Uppal A, Team D, Chang GJ. Surgical Outcomes in Cancer Patients Undergoing Elective Surgery After Recovering from Mild-to-Moderate SARS-CoV-2 Infection. Ann Surg Oncol 28(13):8046-8053, 2021. e-Pub 2021. PMID: 34176060.
- Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, Yin X, Saito Y, Fan H, Li P, Kuo WL, Halpin A, Gibbons DL, Yagita H, Zhao Z, Pang D, Ren G, Yee C, Lee JJ, Yu D. The allergy mediator histamine confers resistanceto immunotherapy in cancer patients via activationof the macrophage histamine receptor H1. Cancer Cell. e-Pub 2021. PMID: 34822775.
- Lewis WE, Hong L, Mott FE, Simon G, Wu CC, Rinsurongkawong W, Lee JJ, Lam VK, Heymach JV, Zhang J, Le X. Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clin Res Rep 2(11):100237, 2021. e-Pub 2021. PMID: 34820641.
- Zhou Y, Lin R, Lee JJ. The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials. Pharm Stat 20(6):1183-1199, 2021. e-Pub 2021. PMID: 34008317.
- Zhou Y, Lee JJ, Wang S, Bailey S, Yuan Y. Incorporating historical information to improve phase I clinical trials. Pharm Stat 20(6):1017-1034, 2021. e-Pub 2021. PMID: 33793044.
- Bhamidipati D, Verma A, Sui D, Maru D, Mathew G, Lang W, Posadas J, Hein J, Kopetz S, Futreal A, Wistuba II, Gupta S, Lee JJ, Overman MJ, Tam AL. An analysis of research biopsy core variability from over 5000 prospectively collected core samples. NPJ Precis Oncol 5(1):94, 2021. e-Pub 2021. PMID: 34707215.
- Sousa LG, Wang K, Torman D, Binks BJ, Rubin ML, Andersen CR, Lewis WE, Rivera MJ, Kaya D, El-Naggar AK, Hanna EY, Esmaeli B, Frank SJ, Bell D, Glisson BS, Rodon J, Meric-Bernstam F, Lee JJ, Ferrarotto R. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer. e-Pub 2021. PMID: 34661906.
- Sicklick JK, Kato S, Okamura R, Patel H, Nikanjam M, Fanta PT, Hahn ME, De P, Williams C, Guido J, Solomon BM, McKay RR, Krie A, Boles SG, Ross JS, Lee JJ, Leyland-Jones B, Lippman SM, Kurzrock R. Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome Med 13(1):155, 2021. e-Pub 2021. PMID: 34607609.
- Akturk G, Parra ER, Gjini E, Lako A, Lee JJ, Neuberg D, Zhang J, Yao S, Laface I, Rogic A, Chen PH, Sanchez-Espiridion B, Del Valle DM, Moravec R, Kinders R, Hudgens C, Wu C, Wistuba II, Thurin M, Hewitt SM, Rodig S, Gnjatic S, Tetzlaff MT. Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. Clin Cancer Res 27(18):5072-5083, 2021. e-Pub 2021. PMID: 34253580.
- Sahaf B, Pichavant M, Lee BH, Duault C, Thrash EM, Davila M, Fernandez N, Millerchip K, Bentebibel SE, Haymaker C, Sigal N, Del Valle DM, Ranasinghe S, Fayle S, Sanchez-Espiridion B, Zhang J, Bernatchez C, Wu CJ, Wistuba II, Kim-Schulze S, Gnjatic S, Bendall SC, Song M, Thurin M, Lee JJ, Maecker HT, Rahman A. Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clin Cancer Res 27(18):5062-5071, 2021. e-Pub 2021. PMID: 34266889.
- Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12(1):5045, 2021. e-Pub 2021. PMID: 34413300.
- Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
- Guo TW, Saiyed F, CMKL Y, Kiong KL, Martinez J, Sacks R, Lee JJ, Moreno AC, Frank SJ, Rosenthal DI, Glisson BS, Ferrarotto R, Mott FE, Johnson FM, Myers JN. Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer 127(16):2916-2925, 2021. e-Pub 2021. PMID: 33873251.
- Guerrieri-Gonzaga A, Serrano D, Thomas P, Crew KD, Kumar NB, Gandini S, Vornik LA, Lee J, Cagnacci S, Vicini E, Accornero CA, D'Amico M, Guasone F, Spinaci S, Webber TB, Brown PH, Szabo E, Heckman-Stoddard B, Bonanni B. Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial. Contemp Clin Trials 107:106498, 2021. e-Pub 2021. PMID: 34216815.
- Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Adv Ther. e-Pub 2021. PMID: 34241781.
- Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 21(1):111, 2021. e-Pub 2021. PMID: 34074267.
- Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J. Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun 12(1):2888, 2021. e-Pub 2021. PMID: 33980839.
- Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, Su D, Fukuoka J, Tabata K, Pham HHN, Mcgranahan N, Zhang B, Ye J, Ying L, Little L, Gumbs C, Chow CW, Estecio MR, Godoy MCB, Antonoff MB, Sepesi B, Pass HI, Behrens C, Zhang J, Vaporciyan AA, Heymach JV, Scheet P, Lee JJ, Wu J, Futreal PA, Reuben A, Kadara H, Wistuba II, Zhang J. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun 12(1):2722, 2021. e-Pub 2021. PMID: 33976164.
- William WN, Zhao X, Bianchi JJ, Lin HY, Cheng P, Lee JJ, Carter H, Alexandrov LB, Abraham JP, Spetzler DB, Dubinett SM, Cleveland DW, Cavenee W, Davoli T, Lippman SM. Immune evasion in HPV- head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss. Proc Natl Acad Sci U S A 118(19), 2021. e-Pub 2021. PMID: 33952700.
- Parra ER, Ferrufino-Schmidt MC, Tamegnon A, Zhang J, Solis L, Jiang M, Ibarguen H, Haymaker C, Lee JJ, Bernatchez C, Wistuba II. Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. Sci Rep 11(1):8511, 2021. e-Pub 2021. PMID: 33875760.
- Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. e-Pub 2021. PMID: 33686493.
- Schwalk AJ, Ost DE, Saltijeral SN, De La Garza H, Casal RF, Jimenez CA, Eapen GA, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Elamin Y, Zhang J, Roth JA, Swisher S, Heymach JV, Grosu HB. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest 159(3):1256-1264, 2021. e-Pub 2021. PMID: 33217413.
- Lee MK, Lee JJ. Evaluating Bayesian adaptive randomization procedures with adaptive clip methods for multi-arm trials. Stat Methods Med Res:962280221995961. e-Pub 2021. PMID: 33689524.
- Sitthideatphaiboon P, Galan-Cobo A, Negrao MV, Qu X, Poteete A, Zhang F, Liu DD, Lewis WE, Kemp HN, Lewis J, Rinsurongkawong W, Giri U, Lee JJ, Zhang J, Roth JA, Swisher S, Heymach JV. STK1/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clin Cancer Res 27(6):1720-1733, 2021. e-Pub 2021. PMID: 33323404.
- Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. e-Pub 2021. PMID: 33603241.
- Schvartsman G, Bell D, Rubin ML, Tetzlaff M, Hanna E, Lee JJ, Weber R, Phan J, Glisson BS, Ferrarotto R. The tumor immune contexture of salivary duct carcinoma. Head Neck. e-Pub 2021. PMID: 33576119.
- Tam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta S. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clin Radiol 76(2):155.e25-155.e34, 2021. e-Pub 2021. PMID: 33268083.
- Hu X, Estecio MR, Chen R, Reuben A, Wang L, Fujimoto J, Carrot-Zhang J, McGranahan N, Ying L, Fukuoka J, Chow CW, Pham HHN, Godoy MCB, Carter BW, Behrens C, Zhang J, Antonoff MB, Sepesi B, Lu Y, Pass HI, Kadara H, Scheet P, Vaporciyan AA, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Su D, Issa JJ, Zhang J. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun 12(1):687, 2021. e-Pub 2021. PMID: 33514726.
- Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. e-Pub 2021. PMID: 33416944.
- Lee JJ, Yin G. Principles and Reporting of Bayesian Trials. J Thorac Oncol 16(1):30-36, 2021. e-Pub 2021. PMID: 33229069.
- Zhou Y, Lin R, Kuo YW, Lee JJ, Yuan Y. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. JCO Clin Cancer Inform 5:91-101, 2021. e-Pub 2021. PMID: 33439726.
- Chen HX, Song M, Maecker HT, Gnjatic S, Patton D, Lee JJ, Adam SJ, Moravec R, Liu XS, Cerami E, Lindsay J, Hodi FS, Wu C, Wistuba II, Al-Atrash G, Bernatchez C, Bendall SC, Hewitt SM, Sharon E, Streicher H, Enos RA, Bowman MD, Tatard-Leitman VM, Sanchez-Espiridion B, Ranasinghe S, Pichavant M, Del Valle DM, Yu J, Janssens S, Peterson-Klaus J, Rowe C, Bongers G, Jenq RR, Chang CC, Abrams JS, Mooney M, Doroshow JH, Harris LN, Thurin M. Network for biomarker immunoprofiling for cancer immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clin Cancer Res 27(18):5038-5048, 2021. e-Pub 2021. PMID: 33419780.
- Zhou Y, Li R, Yan F, Lee JJ, Yuan Y. A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3 + 3 (i3 + 3) Design for Phase I Oncology Dose-Finding Trials. Statistics in Biopharmaceutical Research 13(2):147-155, 2021. e-Pub 2021. PMID: 34249223.
- Behrens C, Rocha P, Parra ER, Feng L, Rodriguez-Canales J, Solis LM, Mino B, Zhang J, Gibbons DL, Sepesi B, Rice D, Heymach JV, Moran C, Creighton CJ, Lee JJ, Kadara H, Wistuba II. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer. May;22(3):e415-e424, 2021. e-Pub 2021. PMID: 32763065.
- Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Wang J, Rinsurongkawong W, Raymond VM, Lanman RB, Lewis J, Roarty EB, Roth J, Swisher S, Lee JJ, Gibbons DL, Papadimitrakopoulou VA, Heymach JV. Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. J Thorac Oncol. e-Pub 2020. PMID: 33388476.
- Ferrarotto R, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D, Frank SJ, Song X, Kupferman ME, Liu B, Lee JJ, Glisson BS, Zhang J, Aster JC, Lin SY, Futreal PA, Heymach JV, El-Naggar AK. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. e-Pub 2020. PMID: 33172898.
- Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol 21(1):271, 2020. e-Pub 2020. PMID: 33148332.
- Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Lafontaine L, Bruni D, Lanzi A, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Musina AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Fox BA, Pagès F, Galon J. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. J Clin Oncol:JCO1903205. e-Pub 2020. PMID: 32897827.
- Chen N, Lee JJ. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints. Stat Methods Med Res 29(9):2717-2732, 2020. e-Pub 2020. PMID: 32178585.
- McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, Leveille JM, Brunner MR, Holden K, Hopkins NS, Harris A, Kumpati JJ, Whitt MA, Lee JJ, Ostrosky-Zeichner L, Papanna R, LeBleu V, Allison J, Kalluri R. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19 immunity. JCI Insight. e-Pub 2020. PMID: 32796155.
- Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, Rice D, Swisher SG, Sepesi B, Tran HT, Chow CW, Little LD, Gumbs C, Haymaker C, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Zhang J, Reuben A, Tsao AS, Zhang J. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res. e-Pub 2020. PMID: 32816946.
- Reyes-Uribe L, Wu W, Gelincik O, Bommi PV, Francisco-Cruz A, Solis LM, Lynch PM, Lim R, Stoffel EM, Kanth P, Samadder NJ, Mork ME, Taggart MW, Milne GL, Marnett LJ, Vornik L, Liu DD, Revuelta M, Chang K, You YN, Kopelovich L, Wistuba II, Lee JJ, Sei S, Shoemaker RH, Szabo E, Richmond E, Umar A, Perloff M, Brown PH, Lipkin SM, Vilar E. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut. e-Pub 2020. PMID: 32641470.
- Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. e-Pub 2020. PMID: 32608142.
- Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. J Thorac Oncol. e-Pub 2020. PMID: 32389639.
- Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. e-Pub 2020. PMID: 32300858.
- Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman Karagiannis DT, Warneke CL, Hessel AC, Garden AS, Myers JN, Johnson FM, Lee JJ, Sikora A, Gillison ML, Glisson BS, Gross ND. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial. Clin Cancer Res. e-Pub 2020. PMID: 32269052.
- Xu G, Zhu H, Lee JJ. Borrowing Strength and Borrowing Index for Bayesian Hierarchical Models. Comput Stat Data Anal 144, 2020. e-Pub 2020. PMID: 32341613.
- Cascone T, Sepesi B, Lin H, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella F, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Reza MJ, Rice D, Behren C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. e-Pub 2020. PMID: 32193228.
- Gaudreau PO, Lee JJ, Heymach JV, Gibbons DL. Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Clin Lung Cancer. e-Pub 2020. PMID: 32299768.
- Weissferdt A, Pataer A, Vaporciyan AA, Correa AM, Sepesi B, Moran CA, Wistuba II, Roth JA, Shewale JB, Heymach JV, Kalhor N, Cascone T, Hofstetter WL, Lee JJ, Swisher SG. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer. e-Pub 2020. PMID: 32279936.
- Yang RK, Qing Y, Jelloul FZ, Routbort MJ, Wang P, Shaw K, Zhang J, Lee J, Medeiros LJ, Kopetz S, Tetzlaff MT, Broaddus RR. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. Oncotarget 11(6):600-618, 2020. e-Pub 2020. PMID: 32110280.
- Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
- Wang Y, Zhu H, Lee JJ. Evaluation of bias for outcome adaptive randomization designs with binary endpoints. Statistics and Its Interface 13:287-315, 2020. e-Pub 2020.
- Liu X, Hong L, Nilsson M, Hubert SM, Wu S, Rinsurongkawong W, Lewis J, Spelman A, Roth J, Swisher S, He Y, Lee JJ, Fang B, Heymach JV, Zhang J, Le X. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer(149):33-40, 2020. e-Pub 2020.
- Zeng Z, Fu J, Cibulskis C, Jhaveri A, Gumbs C, Das B, Sanchez-Espiridion B, Janssens S, Taing L, Wang J, Lindsay J, Vilimas T, Zhang J, Tokheim C, Das Sahu A, Jiang P, Yan C, Duose DY, Cerami E, Chen L, Cohen D, Chen QR, Enos RA, Huang X, Lee JJ, Liu Y, Neuberg DS, Nguyen C, Patterson C, Sarkar S, Shukla SA, Tang M, Tsuji J, Uduman M, Wang X, Weirather JL, Yu J, Yu J, Zhang J, Zhang J, Meerzaman D, Thurin M, Futreal PA, Karlovich C, Gabriel SB, Wistuba II, Liu XS, Wu C. Cross-site concordance evaluation of tumor DNA and RNA sequencing platforms for the CIMAC-CIDC network. Clin Cancer Res 27(18):5049-5061, 2020. e-Pub 2020. PMID: 33323402.
- Pestana RC, Becnel M, Rubin ML, Torman DK, Crespo J, Phan J, Hanna E, Bell D, Glisson BS, Johnson JM, Lee JJ, Ferrarotto R. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol 101:104523. e-Pub 2019. PMID: 31864957.
- Zhou Y, Lee JJ, Yuan Y. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med 38(28):5299-5316, 2019. e-Pub 2019. PMID: 31621952.
- Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol:doi: 10.1001/jamaoncol.2019.5367. e-Pub 2019. PMID: 31876895.
- Lu Y, Lee JJ. A Collection of Statistical Methods for Precision Oncology. JCO Precis Oncol 3:1-3, 2019. e-Pub 2019. PMID: 35100724.
- Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas H, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. Clin Cancer Res. e-Pub 2019. PMID: 31694833.
- Shi B, Behrens C, Vaghani V, Riquelme EM, Rodriguez-Canales J, Kadara H, Lin H, Lee J, Liu H, Wistuba I, Simon G. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer. Cancer Med 8(14):6383-6392, 2019. e-Pub 2019. PMID: 31456359.
- Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol 30(9):1521-1530, 2019. e-Pub 2019. PMID: 31282941.
- Mitchell KG, Parra ER, Nelson DB, Zhang J, Wistuba II, Fujimoto J, Roth JA, Antonoff MB, Group MD. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 158(3):911-919.e6, 2019. e-Pub 2019. PMID: 31235357.
- Zhu H, Piao J, Lee JJ, Hu F, Zhang L. Response adaptive randomization procedures in seamless phase II/III clinical trials. J Biopharm Stat 30(1):3-17. e-Pub 2019. PMID: 31454295.
- Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun 10(1):2978, 2019. e-Pub 2019. PMID: 31278276.
- Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 37(18):1558-1565, 2019. e-Pub 2019. PMID: 31067138.
- Davis JS, Prophet E, Peng HL, Lee HY, Tidwell RSS, Lee JJ, Thomas A, Szabo E, Chang S. Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer. JNCI Cancer Spectr 3(2):pkz010, 2019. e-Pub 2019. PMID: 31218274.
- Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 25(5):744-750, 2019. e-Pub 2019. PMID: 31011206.
- Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med 25(5):751-758, 2019. e-Pub 2019. PMID: 31011205.
- Ibrahim MY, Nunez MI, Harun N, Lee JJ, El-Naggar AK, Ferrarotto R, Wistuba I, Myers J, Glisson BS, William WN. PI3-kinase pathway biomarkers in oral cancer and tumor immune cells. Head Neck 41(3):615-622, 2019. e-Pub 2019. PMID: 30556200.
- Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas 48(3):381-386. e-Pub 2019. PMID: 30768575.
- Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun 10(1):552, 2019. e-Pub 2019. PMID: 30696827.
- Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L, Wang J, van der Burg SH, Melief CJ, Glisson B. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol 5(1):67-73, 2019. e-Pub 2019. PMID: 30267032.
- Lam VK, Tran HT, Banks KC, Lanman RB, Rinsurongkawong W, Peled N, Lewis J, Lee JJ, Roth J, Roarty EB, Swisher S, Talasaz A, Futreal PA, Papadimitrakopoulou V, Heymach JV, Zhang J. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. Clin Lung Cancer 20(1):30-36.e3, 2019. e-Pub 2019. PMID: 30279110.
- Kopetz S, Mills Shaw KR, Lee JJ, Zhang J, Litzenburger B, Holla V, Kinyua W, Broaddus E, Daniels MS, Meric-Bernstam F, Broaddus RR. Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32914008.
- Ruberg, SJ, Harrell, FE, Jr, Gamalo-Siebers, M, LaVange, L, Lee, Jack J, Price, K, Peck, C. Inference and Decision Making for 21st-Century Drug Development and Approval (2019) American Statistician 73(sup1):319-327, 2019. e-Pub 2019.
- Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Jr BG, Jr WW, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol 30(3):471-477, 2019. e-Pub 2019. PMID: 30596812.
- Yuan Y, Lee JJ, Hilsenbeck SG. Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. JCO Precision Oncology 3:1-12, 2019. e-Pub 2019.
- Tidwell RSS, Peng SA, Chen M, Liu DD, Yuan Y, Lee JJ. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clin Trials 16:645-656, 2019. e-Pub 2019. PMID: 31450957.
- Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J. PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer. J Thorac Oncol 14(6):1021-1031, 2019. e-Pub 2019. PMID: 30780001.
- Chen N, Lee JJ. Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes. Biom J 61(5):1219-1231, 2019. e-Pub 2019. PMID: 30506747.
- Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV. Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC. Clin Cancer Res 24(24):6195-6203, 2018. e-Pub 2018. PMID: 30228210.
- Lippman SM, Abate-Shen C, Colbert Maresso KL, Colditz GA, Dannenberg AJ, Davidson NE, Disis ML, DuBois RN, Szabo E, Giuliano AR, Hait WN, Lee JJ, Kensler TW, Kramer BS, Limburg P, Maitra A, Martinez ME, Rebbeck TR, Schmitz KH, Vilar E, Hawk ET. AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. Cancer Prev Res (Phila) 11(12):735-778, 2018. e-Pub 2018. PMID: 30530635.
- Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget 9(74):33995-34008, 2018. e-Pub 2018. PMID: 30338041.
- Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun 9(1):3114, 2018. e-Pub 2018. PMID: 30082701.
- Yin G, Chen N, Lee JJ. Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint. Stat Biosci 10(2):420-438, 2018. e-Pub 2018. PMID: 30559900.
- Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8(7):822-835, 2018. e-Pub 2018. PMID: 29773717.
- Ferrarotto R, William WN, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Lee JJ, Wistuba IW, Haddad RI, Glisson BS. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol 82:83-90, 2018. e-Pub 2018. PMID: 29909907.
- Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6(1):48, 2018. e-Pub 2018. PMID: 29871672.
- Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, Wistuba II. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol 13(6):779-791, 2018. e-Pub 2018. PMID: 29526824.
- Gold KA, Kies MS, William WN, Johnson FM, Lee JJ, Glisson BS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer 124(10):2169-2173, 2018. e-Pub 2018. PMID: 29579331.
- William WN, Tsao AS, Feng L, Ginsberg LE, Lee JJ, Kies MS, Glisson BS, Kim ES. Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. Oncologist 23(5):526-e49, 2018. e-Pub 2018. PMID: 29371473.
- Saintigny P, William WN, Foy JP, Papadimitrakopoulou V, Lang W, Zhang L, Fan YH, Feng L, Kim ES, El-Naggar AK, Lee JJ, Mao L, Hong WK, Lingen MW, Lippman SM. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst 110(3), 2018. e-Pub 2018. PMID: 29617836.
- Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, Sepeda V, O'Kane H, Krasne M, Williams S, Morris PG, Heckman-Stoddard BM, Dunn BK, Hudis CA, Brown PH, Dannenberg AJ. A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions or Benign Breast Disease. Cancer Prev Res (Phila). e-Pub 2018. PMID: 29453232.
- Tsao AS, Lin H, Carter BW, Lee JJ, Rice D, Vaporcyan A, Swisher S, Mehran R, Heymach J, Nilsson M, Fan Y, Nunez M, Diao L, Wang J, Fujimoto J, Wistuba II, Hong WK. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. J Thorac Oncol 13(2):246-257, 2018. e-Pub 2018. PMID: 29313814.
- Pai SI, Lee JJ, Carey TE, Westra WH, Ferrone S, Moore C, Mosunjac MB, Shin DM, Ferris RL, consortium HNC. HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97, 2018. e-Pub 2018. PMID: 29362132.
- Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol:JCO2017740720. e-Pub 2018. PMID: 29293386.
- Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol 31(6):947-955, 2018. e-Pub 2018. PMID: 29410488.
- Du Y, Cook JD, Lee JJ. Comparing three regularization methods to avoid extreme allocation probability in response-adaptive randomization. J Biopharm Stat 28(2):1-11, 2018. e-Pub 2018. PMID: 28323532.
- Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR, Head, Supplement Consortium NCSPOREHIV. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124(1):84-94, 2018. e-Pub 2018. PMID: 29053175.
- Hobbs BP, Chen N, Lee JJ. Controlled multi-arm platform design using predictive probability. Stat Methods Med Res 27(1):65-78, 2018. e-Pub 2018. PMID: 26763586.
- Yin G, Chen N, Lee JJ. Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint. Statistics in Biosciences 10(2):420-438, 2018. e-Pub 2018.
- Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med 9(415), 2017. e-Pub 2017. PMID: 29118262.
- Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MFK, Zhang J, Roarty EB, Lacerda L, Swisher S, Heymach JV, Fossella FV, William WN. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 112:90-95, 2017. e-Pub 2017. PMID: 29191606.
- Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J, Pai SI, Sidransky D, Westra WH, William WN, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM, Head, supplement consortium NCSH. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck. e-Pub 2017. PMID: 28945296.
- Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Lee JJ, Srivastava S, Sen S, McNeill Killary A. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. J Natl Cancer Inst 109(8), 2017. e-Pub 2017. PMID: 28376184.
- Reuben A, Gittelman RM, Gao J, Zhang J, Yusko E, Wu CJ, Emerson R, Zhang J, Tipton CM, Li J, Quek K, Gopalakrishnan V, Chen R, Vence L, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher SG, Heymach J, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. e-Pub 2017. PMID: 28733428.
- Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG. JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol Cancer Ther. e-Pub 2017. PMID: 28729401.
- Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546(7659):498-503, 2017. e-Pub 2017. PMID: 28607485.
- Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, Johnson FM, Hong S, Zheng L, Hu S, Villalobos PA, Behrens C, Wistuba I, Freemantle S, Liu X, Dmitrovsky E. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst 109(6), 2017. e-Pub 2017. PMID: 28376145.
- Kim S, Baladandayuthapani V, Lee JJ. Prediction-Oriented Marker Selection (PROMISE): With Application to High-Dimensional Regression. Stat Biosci 9(1):217-245, 2017. e-Pub 2017. PMID: 28785367.
- Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells KJ, Haddad V, Hanrahan EO, Nilsson M, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Juergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach J. The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer. Clin Cancer Res. e-Pub 2017. PMID: 28559461.
- Wan R, Wang Z, Lee JJ, Wang S, Li Q, Tang F, Wang J, Sun Y, Bai H, Wang D, Zhao J, Duan J, Zhuo M, An T, Wu M, Chen Z, Yang Z, Wang J. Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small-cell lung cancer. J Thorac Oncol. e-Pub 2017. PMID: 28552765.
- Berkman AM, Brewster AM, Jones LW, Yu J, Lee JJ, Peng SA, Crocker A, Ater JL, Gilchrist SC. Racial Differences in 20-Year Cardiovascular Mortality Risk Among Childhood and Young Adult Cancer Survivors. J Adolesc Young Adult Oncol. e-Pub 2017. PMID: 28530506.
- Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the clinical research infrastructure at a dedicated clinical trials unit: assessment of trial development, activation, and participant accrual. Clin Cancer Res 23(6):1407-1413, 2017. e-Pub 2017. PMID: 27852698.
- Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res 23(6):1414-1421, 2017. e-Pub 2017. PMID: 28275168.
- Logan JK, Tang C, Liao Z, Lee JJ, Heymach JV, Swisher SG, Welsh JW, Zhang J, Lin SH, Gomez DR. Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. Int J Radiat Oncol Biol Phys 97(4):770-777, 2017. e-Pub 2017. PMID: 28244413.
- Wan Y, Datta S, Lee JJ, Kong M. Monotonic single-index models to assess drug interactions. Stat Med 36(4):655-670, 2017. e-Pub 2017. PMID: 27804146.
- Walline HM, Carey TE, Goudsmit CM, Bellile EL, D'Souza G, Peterson LA, McHugh JB, Pai SI, Lee JJ, Shin DM, Ferris RL, consortium HNC. High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15(2):179-188, 2017. e-Pub 2017. PMID: 27899422.
- Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol 35(3):JCO2016675264, 2017. e-Pub 2017. PMID: 27870570.
- Zang Y, Lee JJ. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials. Stat Med 36(1):27-42, 2017. e-Pub 2017. PMID: 27538818.
- Mustachio LM, Kawakami M, Lu Y, Rodriguez-Canales J, Mino B, Behrens C, Wistuba I, Bota-Rabassedas N, Yu J, Lee JJ, Roszik J, Zheng L, Liu X, Freemantle SJ, Dmitrovsky E. The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget 8(1):3-14, 2017. e-Pub 2017. PMID: 27980214.
- Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol 28(1):75-82, 2017. e-Pub 2017. PMID: 27687306.
- Choi M, Kadara H, Zhang J, Cuentas EP, Canales JR, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee JJ, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol 28(1):83-89, 2017. e-Pub 2017. PMID: 27687303.
- Zhou H, Lee JJ, Yuan Y. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Stat Med 36(21):3302-3314, 2017. e-Pub 2017. PMID: 28589563.
- Jiang F, Ma Y, Lee, JJ. A second-order semiparametric method for survival analysis, with application to an acquired immune deficiency syndrome clinical trial study. Journal of the Royal Statistical Society Series C, Applied Statistics 66(4):833-846, 2017. e-Pub 2017.
- Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II. Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients. Clin Cancer Res 22(24):6278-6289, 2016. e-Pub 2016. PMID: 27252415.
- Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672-1682, 2016. e-Pub 2016. PMID: 27789196.
- Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol 2(11):1452-1459, 2016. e-Pub 2016. PMID: 27273579.
- Liu Y, Zhang J, Li L, Yin G, Zhang J, Zheng S, Cheung H, Wu N, Lu N, Mao X, Yang L, Zhang J, Zhang L, Seth S, Chen H, Song X, Liu K, Xie Y, Zhou L, Zhao C, Han N, Chen W, Zhang S, Chen L, Cai W, Li L, Shen M, Xu N, Cheng S, Yang H, Lee JJ, Correa A, Fujimoto J, Behrens C, Chow CW, William WN, Heymach JV, Hong WK, Swisher S, Wistuba II, Wang J, Lin D, Liu X, Futreal PA, Gao Y. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun 7:13200, 2016. e-Pub 2016. PMID: 27767028.
- Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors:Implications for Targeted Therapeutics. Mol Cancer Ther 15(10):2475-2485, 2016. e-Pub 2016. PMID: 27466356.
- Boo HJ, Min HY, Jang HJ, Yun HJ, Smith JK, Jin Q, Lee HJ, Liu D, Kweon HS, Behrens C, Lee JJ, Wistuba II, Lee E, Hong WK, Lee HY. The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. Nat Commun 7:12961, 2016. e-Pub 2016. PMID: 27666821.
- Cardó-Vila M, Marchiò S, Sato M, Staquicini FI, Smith TL, Bronk JK, Yin G, Zurita AJ, Sun M, Behrens C, Sidman RL, Lee JJ, Hong WK, Wistuba II, Arap W, Pasqualini R. Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity. Am J Pathol 186(8):2162-70, 2016. e-Pub 2016. PMID: 27317903.
- Papadimitrakopoulou V, Lee JJ, et al. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 34(30):3638-3647. e-Pub 2016. PMID: 27480147.
- Sio TT, Lin HK, Shi Q, Gunn GB, Cleeland CS, Lee JJ, Hernandez M, Blanchard P, Thaker NG, Phan J, Rosenthal DI, Garden AS, Morrison WH, Fuller CD, Mendoza TR, Mohan R, Wang XS, Frank SJ. Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys 95(4):1107-14, 2016. e-Pub 2016. PMID: 27354125.
- Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res 76(13):3690-701, 2016. e-Pub 2016. PMID: 27197177.
- Blanchard P, Garden AS, Gunn GB, Rosenthal DI, Morrison WH, Hernandez M, Crutison J, Lee JJ, Ye R, Fuller CD, Mohamed AS, Hutcheson KA, Holliday EB, Thaker NG, Sturgis EM, Kies MS, Zhu XR, Mohan R, Frank SJ. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. Radiother Oncol 120(1):48-55, 2016. e-Pub 2016. PMID: 27342249.
- Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Lee JJ, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat 158(1):67-77, 2016. e-Pub 2016. PMID: 27287781.
- Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ. Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development. Stat Biosci 8((1)):99-128, 2016. e-Pub 2016. PMID: 27617040.
- Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine 7:85-93, 2016. e-Pub 2016. PMID: 27322462.
- Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD, Wistuba II. Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. Cancer Res 76(3):675-85, 2016. e-Pub 2016. PMID: 26676756.
- William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol 2(2):1-8, 2016. e-Pub 2016. PMID: 26540028.
- Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman SM. Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila) 9(1):2-10, 2016. e-Pub 2016. PMID: 26744449.
- Tsao AS, Papadimitrakopoulou V, Lin H, Guo M, Lee JJ, Holsinger FC, Hong WK, Sturgis EM. Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infect Agent Cancer 11:21, 2016. e-Pub 2016. PMID: 27123042.
- Zang Y, Lee JJ, Yuan Y. Two-stage marker-stratified clinical trial design in the presence of biomarker misclassification. Journal of the Royal Statistical Society. Series C: Applied Statistics 65(4):585-601, 2016. e-Pub 2016.
- Xing Y, Zhang J, Lin H, Gold KA, Sturgis EM, Garden AS, Lee JJ, William WN. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer 122(4):534-545, 2016. e-Pub 2016. PMID: 26554754.
- Joe AK, Schnoll-Sussman F, Bresalier RS, Abrams JA, Hibshoosh H, Cheung K, Friedman RA, Yang CS, Milne GL, Liu DD, Lee JJ, Abdul K, Bigg M, Foreman J, Su T, Wang X, Ahmed A, Neugut AI, Akpa E, Lippman SM, Perloff M, Brown PH, Lightdale CJ. Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus. Cancer Prev Res (Phila) 8(12):1131-7, 2015. e-Pub 2015. PMID: 26471236.
- Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P. Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus. Cancer Prev Res (Phila) 8(11):1027-35, 2015. e-Pub 2015. PMID: 26342026.
- Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst 107(11), 2015. e-Pub 2015. PMID: 26378224.
- Halperin DM, Lee JJ, Dagohoy CG, Yao JC. Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. J Clin Oncol 33(26):2914-9, 2015. e-Pub 2015. PMID: 26261263.
- Liu S, Lee JJ. An overview of the design and conduct of the BATTLE trials. Chin Clin Oncol 4(3):33, 2015. e-Pub 2015. PMID: 26408300.
- Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol 26(8):1791-8, 2015. e-Pub 2015. PMID: 25908602.
- Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Hong CS, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Yin QM, Wang LZ, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Zhuang Z, Lee JJ, Myers JN, Zhang ZY. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Oncotarget 6(21):18707-14, 2015. e-Pub 2015. PMID: 26124084.
- Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 26(7):1476-80, 2015. e-Pub 2015. PMID: 26025965.
- Kim JS, Kim ES, Liu D, Lee JJ, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee E, Lee HY. Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget 6(18):16746-56, 2015. e-Pub 2015. PMID: 25944691.
- Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget 6(16):14139-52, 2015. e-Pub 2015. PMID: 25944621.
- Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 92(2):317-24, 2015. e-Pub 2015. PMID: 25968826.
- Tong P, Coombes KR, Johnson FM, Byers LA, Diao L, Liu DD, Lee JJ, Heymach JV, Wang J. drexplorer: A tool to explore dose-response relationships and drug-drug interactions. Bioinformatics 31(10):1692-4, 2015. e-Pub 2015. PMID: 25600946.
- Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR. A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers. Head Neck 37(5):644-9, 2015. e-Pub 2015. PMID: 24585506.
- Yu YH, Morales J, Feng L, Lee JJ, El-Naggar AK, Vigneswaran N. CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: A tissue microarray study. Oral Surg Oral Med Oral Pathol Oral Radiol 119(5):553-65, 2015. e-Pub 2015. PMID: 25747176.
- Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William WN. Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry. J Thorac Oncol 10(4):682-90, 2015. e-Pub 2015. PMID: 25590605.
- Staquicini FI, Qian MD, Salameh A, Dobroff AS, Edwards JK, Cimino DF, Moeller BJ, Kelly P, Nunez MI, Tang X, Liu DD, Lee JJ, Hong WK, Ferrara F, Bradbury AR, Lobb RR, Edelman MJ, Sidman RL, Wistuba II, Arap W, Pasqualini R. Receptor Tyrosine Kinase EphA5 Is a Functional Molecular Target in Human Lung Cancer. J Biol Chem 290(12):7345-59, 2015. e-Pub 2015. PMID: 25623065.
- Atlas Network CG. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536):576-82, 2015. e-Pub 2015. PMID: 25631445.
- Du Y, Wang X, Lee JJ. Simulation study for evaluating the performance of response-adaptive randomization. Contemp Clin Trials 40:15-25, 2015. e-Pub 2015. PMID: 25460340.
- Timsah Z, Berrout J, Suraokar M, Behrens C, Song J, Lee JJ, Ivan C, Gagea M, Shires M, Hu X, Vallien C, Kingsley CV, Wistuba I, Ladbury JE. Expression pattern of FGFR2, Grb2 and Plcγ1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. Am J Cancer Res 5(10):3135-48, 2015. e-Pub 2015. PMID: 26693065.
- Min HY, Yun HJ, Lee JS, Lee HJ, Cho J, Jang HJ, Park SH, Liu D, Oh SH, Lee JJ, Wistuba II, Lee HY. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer 14:113, 2015. e-Pub 2015. PMID: 26041671.
- Alber, S A, Lee, J J. Calibrating the prior distribution for a normal model with conjugate prior. Journal of Statistical Computation and Simulation 85(15):3108-3128, 2015. e-Pub 2015.
- Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, Yu J, Muzny DM, Doddapaneni H, Shinbrot E, Covington KR, Zhang J, Seth S, Caulin C, Clayman GL, El-Naggar AK, Gibbs RA, Weber RS, Myers JN, Wheeler DA, Frederick MJ. Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. Clin Cancer Res 20(24):6582-92, 2014. e-Pub 2014. PMID: 25303977.
- Wheler J, Lee JJ, Kurzrock R. Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations. Cancer Res 74(24):7181-4, 2014. e-Pub 2014. PMID: 25326492.
- Zang Y, Lee JJ. Adaptive clinical trial designs in oncology. Chin Clin Oncol 3(4):49, 2014. e-Pub 2014. PMID: 25841530.
- Kim MO, Liu C, Hu F, Lee JJ. Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs. Stat Med 33(23):4029-42, 2014. e-Pub 2014. PMID: 24889540.
- Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346(6206):256-9, 2014. e-Pub 2014. PMID: 25301631.
- Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Mol Cancer Ther. e-Pub 2014. PMID: 25253784.
- Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Lee JJ, Hong WK, Herbst RS, Jimenez CA. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. Clin Lung Cancer 15(5):379-86, 2014. e-Pub 2014. PMID: 24913066.
- He Y, Gong Y, Gu J, Lee JJ, Lippman SM, Wu X. Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology study. Carcinogenesis 35(8):1760-4, 2014. e-Pub 2014. PMID: 24743515.
- Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson MB, Simon G, Wang J, Coombes KR, Lee JJ, Hong WK, Heymach J, Minna JD, Wistuba II. VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2-Targeted Therapy. Clin Cancer Res 20(14):3849-61, 2014. e-Pub 2014. PMID: 24850841.
- Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba I. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol 18(3):140-5, 2014. e-Pub 2014. PMID: 24747001.
- Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba II. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol 25(6):1184-92, 2014. e-Pub 2014. PMID: 24669013.
- Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget 5(9):2349-54, 2014. e-Pub 2014. PMID: 24811890.
- Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic Implications of Tumoral Expression of Insulin Like Growth Factors 1 and 2 in Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer 15(3):213-21, 2014. e-Pub 2014. PMID: 24485233.
- Zang Y, Lee JJ, Yuan Y. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clin Trials 11(3):319-327. e-Pub 2014. PMID: 24844841.
- Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I. Phase I trial of Cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer 15(3):197-201, 2014. e-Pub 2014. PMID: 24492162.
- Stewart DJ, Nunez MI, Behrens C, Liu D, Lin YH, Lee JJ, Roth J, Heymach J, Swisher SG, Hong WK, Wistuba II. Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I-II Non-Small-Cell Lung Cancer. J Thorac Oncol 9(5):675-84, 2014. e-Pub 2014. PMID: 24662455.
- D'souza G, Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL. Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients. J Acquir Immune Defic Syndr 65(5):603-10, 2014. e-Pub 2014. PMID: 24326607.
- Gold KA, Kim ES, Liu DD, Yuan P, Behrens C, Solis LM, Kadara H, Rice DC, Wistuba II, Swisher SG, Hofstetter WL, Lee JJ, Hong WK. Prediction of survival in resected non-small cell lung cancer using a protein-expression based risk model: Implications for personalized chemoprevention and therapy. Clin Cancer Res 20(7):1946-54, 2014. e-Pub 2014. PMID: 24366692.
- Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Rep 6(2):377-87, 2014. e-Pub 2014. PMID: 24440717.
- Marchenko O, Fedorov V, Lee JJ, Nolan C, Pinheiro J. Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges. Ther Innov Regul Sci 48(1):20-30, 2014. e-Pub 2014. PMID: 28670507.
- Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer. Oncologist 19(10):1040-1041, 2014. e-Pub 2014. PMID: 25170013.
- Marchenko, O, Fedorov, V, Lee, JJ, Nolan, C, Pinheiro, J. Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges. Therapeutic Innovation and Regulatory Science 48(1):20-30, 2014. e-Pub 2014.
- Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial. Clin Cancer Res 19(24):6967-75, 2013. e-Pub 2013. PMID: 24166906.
- Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, Swisher SG, Simon GR, Stewart DJ, Lee JJ, Wistuba II. EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non-Small Cell Lung Carcinoma. Clin Cancer Res 19(23):6556-65, 2013. e-Pub 2013. PMID: 24097870.
- Bau DT, Lippman SM, Xu E, Gong Y, Lee JJ, Wu X, Gu J. Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. Cancer 119(24):4277-83, 2013. e-Pub 2013. PMID: 24105340.
- Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations. Mol Cancer Ther 12(12):2857-63, 2013. e-Pub 2013. PMID: 24092809.
- Gu X, Yin G, Lee JJ. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Contemp Clin Trials 36(2):642-50, 2013. e-Pub 2013. PMID: 24075829.
- Yao JC, Meric-Bernstam F, Lee JJ, Eckhardt SG. Accelerated approval and breakthrough therapy designation: oncology drug development on speed?. Clin Cancer Res 19(16):4305-4308, 2013. e-Pub 2013. PMID: 23833307.
- Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow CW, Mendoza G, Momin AA, James BP, Solis L, Behrens C, Lee JJ, Wistuba II, Kadara H. ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non-Small Cell Lung Cancer. Clin Cancer Res 19(13):3383-3395, 2013. e-Pub 2013. PMID: 23659968.
- Zhong LP, Zhu DW, William WN, Liu Y, Ma J, Yang CZ, Yang X, Wang LZ, Li J, Myers JN, Lee JJ, Zhang CP, Zhang ZY. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther 12(6):1112-1121, 2013. e-Pub 2013. PMID: 23515614.
- Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol 8(5):658-651, 2013. e-Pub 2013. PMID: 829271.
- Jiang F, Lee JJ, Müller P. A Bayesian decision-theoretic sequential response-adaptive randomization design. Stat Med 32(12):1975-1994, 2013. e-Pub 2013. PMID: 23315678.
- Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. Oncotarget 4(5):705-714, 2013. e-Pub 2013. PMID: 23670029.
- Chen N, Lee JJ. Optimal continuous-monitoring design of single-arm phase ii trial based on the simulated annealing method. Contemp Clin Trials 35(1):170-178, 2013. e-Pub 2013. PMID: 23545075.
- Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol 8(4):436-442, 2013. e-Pub 2013. PMID: 23442309.
- Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY. Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma. J Clin Oncol 31(6):744-751, 2013. e-Pub 2013. PMID: 23129742.
- William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, Research Group UOTMALCC. Computed tomography recist assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 8(2):222-228, 2013. e-Pub 2013. PMID: 23287849.
- Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571-582, 2013. e-Pub 2013. PMID: 23204236.
- Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials. Cancer Res 73(1):276-284, 2013. e-Pub 2013. PMID: 23066039.
- Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II. Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila) 6(1):8-17, 2013. e-Pub 2013. PMID: 23087048.
- Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19(1):279-290, 2013. e-Pub 2013. PMID: 23091115.
- Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, Sharafkhaneh A, Lotan R, Wistuba II. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol 7(12):1747-1754, 2012. e-Pub 2012. PMID: 23154545.
- Xue Y, Ren H, Xiao W, Chu Z, Lee JJ, Mao L. Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer. Int J Oncol 41(5):1798-808, 2012. e-Pub 2012. PMID: 22948297.
- Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial. J Thorac Oncol 7(11):1645-52, 2012. e-Pub 2012. PMID: 23059780.
- Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med 31(25):2955-72, 2012. e-Pub 2012. PMID: 22711340.
- Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30(27):3345-52, 2012. e-Pub 2012. PMID: 22891266.
- Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, Zhou Q, Zhuo M, Mao L, An T, Duan J, Yang L, Wu M, Liang Z, Wang Y, Kang X, Wang J. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 30(25):3077-3083, 2012. e-Pub 2012. PMID: 22826274.
- Lee JJ, Chen N, Yin G. Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clin Cancer Res 18(17):4498-507, 2012. e-Pub 2012. PMID: 22753588.
- Zhang L, Poh CF, Williams M, Laronde DM, Berean K, Gardner PJ, Jiang H, Wu L, Lee JJ, Rosin MP. Loss of heterozygosity (LOH) profiles-validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) 5(9):1081-1089, 2012. e-Pub 2012. PMID: 22911111.
- Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, Hong WK, Lee HY. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer 118(16):3993-4003, 2012. e-Pub 2012. PMID: 22359227.
- Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 30(21):2684-2690, 2012. e-Pub 2012. PMID: 22689801.
- Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ, Dignam J, Efstathiou JA, FitzGerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, Ten Haken RK, Timmerman R, Tunis S, Coleman CN, Purdy J. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys 83(3):782-90, 2012. e-Pub 2012. PMID: 22425219.
- Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X. Genetic variants in the PI3K/PTEN/AKT/MTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 18(13):3705-13, 2012. e-Pub 2012. PMID: 22577058.
- Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba II, Moran CA. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer 118(11):2889-99, 2012. e-Pub 2012. PMID: 22020674.
- Pierce MC, Schwarz RA, Bhattar VS, Mondrik S, Williams MD, Lee JJ, Richards-Kortum R, Gillenwater AM. Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia. Cancer Prev Res (Phila) 5(6):801-9, 2012. e-Pub 2012. PMID: 22551901.
- Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 118(9):2454-65, 2012. e-Pub 2012. PMID: 21952750.
- Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol 7(5):833-40, 2012. e-Pub 2012. PMID: 22729036.
- Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG, Research Group UOTMALCC. Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. J Thorac Oncol 7(5):825-32, 2012. e-Pub 2012. PMID: 22481232.
- Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82, 2012. e-Pub 2012. PMID: 22271473.
- Yin G, Chen N, Lee JJ. Phase II trial design with Bayesian adaptive randomization and predictive probability. J R Stat Soc Ser C Appl Stat 61(2):219-35, 2012. e-Pub 2012. PMID: 24259753.
- Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 104(3):228-39, 2012. e-Pub 2012. PMID: 22247021.
- William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HY. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol 23(1):78-85, 2012. e-Pub 2012. PMID: 21430184.
- Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA. Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans. PLoS One 7(4):e34833, 2012. e-Pub 2012. PMID: 22558101.
- Janku, F, Wheler, JJ, Naing, A, Stepanek, VM, Falchook, GS, Fu, S, Garrido-Laguna, I, Tsimberidou, AM, Piha-Paul, SA, Moulder, SL, Lee, JJ, Luthra, R, Hong, DS, Kurzrock, R. PIK3CA mutations in advanced cancers: Characteristics and outcomes. Oncotarget 3(12):8-17, 2012. e-Pub 2012. PMID: 23248156.
- Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma. J Thorac Oncol 6(12):2104-11, 2011. e-Pub 2011. PMID: 21892101.
- Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II. Immunohistochemical Overexpression of Platelet-Derived Growth Factor Receptor-Beta (PDGFR-ß) is Associated With PDGFRB Gene Copy Number Gain in Sarcomatoid Non-Small-Cell Lung Cancer. Clin Lung Cancer 12(6):369-74, 2011. e-Pub 2011. PMID: 21729646.
- Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, De la Cerda J, Eagle C, Viner JL, Palmer JL, Lerner SP. A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer. Cancer Prev Res (Phila) 4(10):1580-1589, 2011. e-Pub 2011. PMID: 21881030.
- Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res 71(16):5512-21, 2011. e-Pub 2011. PMID: 21724587.
- Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) 4(7):962-72, 2011. e-Pub 2011. PMID: 21733820.
- Kim WY, Kim MJ, Moon H, Yuan P, Kim JS, Woo JK, Zhang G, Suh YA, Feng L, Behrens C, Van Pelt CS, Kang H, Lee JJ, Hong WK, Wistuba II, Lee HY. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology 152(6):2164-73, 2011. e-Pub 2011. PMID: 21447628.
- Kim ES, Lee JJ, Wistuba II. Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila) 4(6):779-82, 2011. e-Pub 2011. PMID: 21636543.
- Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discov 1(1):44-53, 2011. e-Pub 2011. PMID: 22586319.
- Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II. Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis. Clin Cancer Res 17(8):2434-43, 2011. e-Pub 2011. PMID: 21257719.
- Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, Byers LA, Heymach JV, Story MD, Lee JJ, Sturgis EM, Weber RS, Garden AS, Ang KK, Schwartz DL. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res 17(7):2035-43, 2011. e-Pub 2011. PMID: 21349997.
- Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, Wistuba II, Lotan R. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res 17(6):1490-501, 2011. e-Pub 2011. PMID: 21163870.
- Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) 4(2):218-29, 2011. e-Pub 2011. PMID: 21292635.
- Lee JJ, Wu X, Hildebrandt MA, Yang H, Khuri FR, Kim E, Gu J, Ye Y, Lotan R, Spitz MR, Hong WK. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4(2):185-93, 2011. e-Pub 2011. PMID: 21292633.
- Bhutani M, Pathak AK, Tang H, Fan YH, Liu DD, Lee JJ, Kurie J, Morice RC, Hong WK, Mao L. Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer. Exp Ther Med 2(1):137-142, 2011. e-Pub 2011. PMID: 22977481.
- Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. PLoS One 6(7):e22769, 2011. e-Pub 2011. PMID: 21829508.
- Poh CF, Durham JS, Brasher PM, Anderson DW, Berean KW, MacAulay CE, Lee JJ, Rosin MP. Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial. BMC Cancer 11(1):462, 2011. e-Pub 2011. PMID: 22026481.
- Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, Lin HY, Wistuba II, Lee JJ, Yen CJ, Su WC, Chang KY, Chang WC, Chou TC, Chou CK, Tsai CH, Hung MC. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One 6(6):e21428, 2011. e-Pub 2011. PMID: 21731744.
- Zhang X, Yang H, Lee JJ, Kim E, Lippman SM, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 31(12):2118-23, 2010. e-Pub 2010. PMID: 20819778.
- Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. Int J Radiat Oncol Biol Phys 78(3):667-74, 2010. e-Pub 2010. PMID: 20171802.
- Roblyer D, Kurachi C, Stepanek V, Schwarz RA, Williams MD, El-Naggar AK, Lee JJ, Gillenwater AM, Richards-Kortum R. Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objective discrimination of oral neoplasia. J Biomed Opt 15(6):066017, 2010. e-Pub 2010. PMID: 21198191.
- Wang J, Lippman SM, Lee JJ, Yang H, Khuri FR, Kim E, Lin J, Chang DW, Lotan R, Hong WK, Wu X. Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis 31(10):1755-61, 2010. e-Pub 2010. PMID: 20627871.
- Lee JJ, Gu X, Liu S. Bayesian adaptive randomization designs for targeted agent development. Clin Trials 7(5):584-96, 2010. e-Pub 2010. PMID: 20571130.
- Fujimoto J, Kong M, Lee JJ, Hong WK, Lotan R. Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. Cancer Prev Res (Phila) 3(8):917-28, 2010. e-Pub 2010. PMID: 20663979.
- Benchekroun MT, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal Growth Factor Receptor Expression and Gene Copy Number in the Risk of Oral Cancer. Cancer Prev Res (Phila) 3(7):800-809, 2010. e-Pub 2010. PMID: 20570883.
- Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: A randomized phase III trial. J Natl Cancer Inst 102(12):859-65, 2010. e-Pub 2010. PMID: 20505152.
- Lee JJ, Feng L, Reshef DS, Sabichi AL, Williams B, Rinsurongkawong W, Wistuba II, Lotan R, Lippman SM. Mortality in the randomized controlled Lung Intergroup Trial of isotretinoin. Cancer Prev Res (Phila) 3(6):738-44, 2010. e-Pub 2010. PMID: 20501862.
- Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-63, 2010. e-Pub 2010. PMID: 20530716.
- William WN, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer 116(10):2401-08, 2010. e-Pub 2010. PMID: 20225327.
- Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 29(18):2616-27, 2010. e-Pub 2010. PMID: 20154724.
- William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer as Frontline and Second-Line Therapy. Am J Clin Oncol 33(2):148-52, 2010. e-Pub 2010. PMID: 19687727.
- Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 45(3):498-504, 2010. e-Pub 2010. PMID: 19633690.
- Clague J, Lippman SM, Yang H, Hildebrandt MA, Ye Y, Lee JJ, Wu X. Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog 49(2):183-9, 2010. e-Pub 2010. PMID: 19851984.
- Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, Jimenez CA, Eapen GA, Lotan R, Tang X, Newman RA, Wistuba II, Kurie JM. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) 3(2):148-59, 2010. e-Pub 2010. PMID: 20103722.
- Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 16(4):1289-97, 2010. e-Pub 2010. PMID: 20145187.
- Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 28(2):193-201, 2010. e-Pub 2010. PMID: 19949019.
- Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, Hong WK, Lotan R, Wistuba II. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res 16(1):34-44, 2010. e-Pub 2010. PMID: 20028769.
- Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 28(1):8-14, 2010. e-Pub 2010. PMID: 19917840.
- Kong M, Lee JJ. Applying Emax model and bivariate thin plate splines to assess drug interactions. Front Biosci (Elite Ed) 2:279-92, 2010. e-Pub 2010. PMID: 20036878.
- Lee JJ, Lin HY, Liu DD, Kong M. Emax model and interaction index for assessing drug interaction in combination studies. Front Biosci (Elite Ed) 2:582-601, 2010. e-Pub 2010. PMID: 20036904.
- Gu X, Lee JJ. A simulation study for comparing testing statistics in response-adaptive randomization. BMC Med Res Methodol 10(48):48, 2010. e-Pub 2010. PMID: 20525382.
- Cao J, Lee JJ, Alber S. Comparison of Bayesian sample size criteria: ACC, ALC, and WOC. J Stat Plan Inference 139(12):4111-4122, 2009. e-Pub 2009. PMID: 25554718.
- Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2(11):931-41, 2009. e-Pub 2009. PMID: 19892663.
- Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res 15(19):6284-91, 2009. e-Pub 2009. PMID: 19773378.
- Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, Feng L, Behrens C, Prudkin L, Miller YE, Lee JJ, Lippman SM, Hong WK, Wistuba II, Lee HY. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res 69(18):7439-48, 2009. e-Pub 2009. PMID: 19738076.
- Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15(17):5359-68, 2009. e-Pub 2009. PMID: 19706809.
- William WN, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting Stage IIIB and IV Non-small Cell Lung Cancer: Analysis of the Surveillance, Epidemiology, and End Results Data. Chest 136(3):701-709, 2009. e-Pub 2009. PMID: 19318668.
- Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) 2(8):702-11, 2009. e-Pub 2009. PMID: 19638491.
- Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, Wolff RA, Tortorice ML, Tansey P, Gonzalez-Moreno S, Lambert DH, Mansfield PF. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 16(8):2181-7, 2009. e-Pub 2009. PMID: 19475451.
- Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, Khuri FR, Kim E, Gu J, Lotan R, Hong WK. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) 2(7):617-24, 2009. e-Pub 2009. PMID: 19584075.
- Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas MD Anderson Cancer Center. Clin Trials 6(3):205-16, 2009. e-Pub 2009. PMID: 19528130.
- Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective Risk-Adjusted [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. J Clin Oncol 27(15):2509-15, 2009. e-Pub 2009. PMID: 19332725.
- Roblyer D, Kurachi C, Stepanek V, Williams MD, El-Naggar AK, Lee JJ, Gillenwater AM, Richards-Kortum R. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila) 2(5):423-31, 2009. e-Pub 2009. PMID: 19401530.
- Kim ES, Mauer AM, William WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancer. Cancer 115(8):1713-22, 2009. e-Pub 2009. PMID: 19208430.
- Schwarz RA, Gao W, Redden Weber C, Kurachi C, Lee JJ, El-Naggar AK, Richards-Kortum R, Gillenwater AM. Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer 115(8):1669-79, 2009. e-Pub 2009. PMID: 19170229.
- Pu X, Lippman SM, Yang H, Lee JJ, Wu X. Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. Cancer 115(7):1498-1506, 2009. e-Pub 2009. PMID: 19197984.
- Kajiwara Y, Panchabhai S, Liu DD, Kong M, Lee JJ, Levin VA. Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells. Technol Cancer Res Treat 8(2):163-76, 2009. e-Pub 2009. PMID: 19334798.
- Khuri FR, Holsinger FC, Kies MS, Diaz EM, Gillenwater AM, Lewin JS, Ginsberg LE, Glisson BS, Garden AS, Ark N, Lin HY, Lee JJ, El-Naggar AK, Ki Hong W, Shin DM, Khuri FR. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol 27(12):1976-82, 2009. e-Pub 2009. PMID: 19289628.
- William WN, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ES. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol 32(1):15-9, 2009. e-Pub 2009. PMID: 19194117.
- Lee JJ, Kong M. Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction. Stat Biopharm Res 1(1):4-17, 2009. e-Pub 2009. PMID: 20037663.
- Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized Trial of 13-cis Retinoic Acid Compared With Retinyl Palmitate With or Without Beta-Carotene in Oral Premalignancy. J Clin Oncol 27(4):599-604, 2009. e-Pub 2009. PMID: 19075276.
- William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) 2(1):22-6, 2009. e-Pub 2009. PMID: 19139014.
- Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila) 2(1):14-21, 2009. e-Pub 2009. PMID: 19139013.
- Zhang J, Liu B, Jiang X, Zhao H, Fan M, Fan Z, Lee JJ, Jiang T, Jiang T, Song SW. A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. PLoS One 4(7):e6274, 2009. e-Pub 2009. PMID: 19609451.
- Ye Y, Lippman SM, Lee JJ, Chen M, Frazier ML, Spitz MR, Wu X. Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer 113(9):2488-95, 2008. e-Pub 2008. PMID: 18823025.
- Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, Lotan R. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 14(19):6014-22, 2008. e-Pub 2008. PMID: 18829480.
- Zhang L, Lee JJ, Tang H, Fan YH, Xiao L, Ren H, Kurie J, Morice RC, Hong WK, Mao L. Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. Cancer Prev Res (Phila) 1(2):112-8, 2008. e-Pub 2008. PMID: 19138944.
- Kong M, Lee JJ. A semiparametric response surface model for assessing drug interaction. Biometrics 64(2):396-405, 2008. e-Pub 2008. PMID: 17900314.
- Bhutani M, Pathak AK, Fan YH, Liu DD, Lee JJ, Tang H, Kurie JM, Morice RC, Kim ES, Hong WK, Mao L. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila) 1(1):39-44, 2008. e-Pub 2008. PMID: 19138934.
- Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14(7):2095-101, 2008. e-Pub 2008. PMID: 18381950.
- Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis. Cancer 112(5):1058-1065, 2008. e-Pub 2008. PMID: 18186497.
- Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26(3):354-60, 2008. e-Pub 2008. PMID: 18202409.
- Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials 5(3):181-93, 2008. e-Pub 2008. PMID: 18559407.
- Lee JJ, Liu DD. A predictive probability design for phase II cancer clinical trials. Clin Trials 5(2):93-106, 2008. e-Pub 2008. PMID: 18375647.
- Qu A, Lee JJ, Lindsay BG. Model diagnostic tests for selection informative correlation structure in correlated data. Biometrika 95(4):891-905, 2008. e-Pub 2008.
- Yang H, Lippman SM, Huang M, Lee JJ, Wang W, Spitz MR, Wu X. Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. European Journal of Cancer 44(11):1603-1611, 2008. e-Pub 2008. PMID: 18579371.
- Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, Lotan D, Lotan R. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst 99(22):1668-82, 2007. e-Pub 2007. PMID: 18000218.
- Hittelman WN, Liu DD, Kurie JM, Lotan R, Lee JS, Khuri F, Ibarguen H, Morice RC, Walsh G, Roth JA, Minna J, Ro JY, Broxson A, Hong WK, Lee JJ. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst 99(21):1603-12, 2007. e-Pub 2007. PMID: 17971525.
- Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, Qiao Y, Clayman GL, Lee JJ, El-Naggar AK, Prieto VG, Duvic M, Lippman SM, Weber RS, Kripke ML, Wei Q. Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res 13(21):6532-9, 2007. e-Pub 2007. PMID: 17975167.
- Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-72, 2007. e-Pub 2007. PMID: 17620427.
- Wang Y, Spitz MR, Lee JJ, Huang M, Lippman SM, Wu X. Nucleotide excision repair pathway genes and oral premalignant lesions. Clin Cancer Res 13(12):3753-8, 2007. e-Pub 2007. PMID: 17575242.
- Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25(16):2164-70, 2007. e-Pub 2007. PMID: 17538160.
- Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol 25(15):1974-8, 2007. e-Pub 2007. PMID: 17513803.
- Lee JJ, Kong M, Ayers GD, Lotan R. Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat 17(3):461-80, 2007. e-Pub 2007. PMID: 17479394.
- Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107(11):2637-46, 2006. e-Pub 2006. PMID: 17078054.
- Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res 66(23):11194-206, 2006. e-Pub 2006. PMID: 17145864.
- Kong M, Lee JJ. A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics 62(4):986-95, 2006. e-Pub 2006. PMID: 17156272.
- Huang M, Spitz MR, Gu J, Lee JJ, Lin J, Lippman SM, Wu X. Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis 27(10):2034-7, 2006. e-Pub 2006. PMID: 16638786.
- Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24(25):4163-9, 2006. e-Pub 2006. PMID: 16943532.
- Wang J, Walsh G, Liu DD, Lee JJ, Mao L. Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer. Cancer Res 66(17):8361-6, 2006. e-Pub 2006. PMID: 16951144.
- Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107(3):563-9, 2006. e-Pub 2006. PMID: 16804930.
- Lee JJ, Bekele BN, Zhou X, Cantor SB, Komaki R, Lee JS. Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol 24(22):3597-603, 2006. e-Pub 2006. PMID: 16877726.
- Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev 15(8):1485-9, 2006. e-Pub 2006. PMID: 16896037.
- Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Lee JJ, Hong WK, Lee HY. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett 239(1):136-43, 2006. e-Pub 2006. PMID: 16181731.
- Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106(11):2428-36, 2006. e-Pub 2006. PMID: 16634096.
- Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 12(10):3109-14, 2006. e-Pub 2006. PMID: 16707609.
- Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98(7):441-50, 2006. e-Pub 2006. PMID: 16595780.
- Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 12(7 Pt 1):2178-84, 2006. e-Pub 2006. PMID: 16609032.
- Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-31, 2006. e-Pub 2006. PMID: 16640804.
- Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104(11):2430-6, 2005. e-Pub 2005. PMID: 16245318.
- Moore BA, Weber RS, Prieto V, El-Naggar A, Holsinger FC, Zhou X, Lee JJ, Lippman S, Clayman GL. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope 115(9):1561-7, 2005. e-Pub 2005. PMID: 16148695.
- Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T, Ostrander EA, Stanford JL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman ED, Clayman GL, Lippman SM, Lee JJ, Zheng W, Balmain A. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 26(8):1368-1373, 2005. e-Pub 2005. PMID: 15802297.
- Lee HY, Chang YS, Han JY, Liu DD, Lee JJ, Lotan R, Spitz MR, Hong WK. Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers. J Clin Oncol 23(19):4439-49, 2005. e-Pub 2005. PMID: 15994153.
- Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(11):2544-55, 2005. e-Pub 2005. PMID: 15753462.
- Xu XC, Lee JJ, Wu TT, Hoque A, Ajani JA, Lippman SM. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 14(4):826-9, 2005. e-Pub 2005. PMID: 15824151.
- Han JY, Liu DD, Lee JJ, Kurie J, Lotan R, Hong WK, Lee HY. 9-cis-retinoic acid treatment increases serum concentrations of alpha-tocopherol in former smokers. Clin Cancer Res 11(6):2305-11, 2005. e-Pub 2005. PMID: 15788681.
- Massarelli E, Brown E, Tran NK, Liu DD, Izzo JG, Lee JJ, El-Naggar AK, Hong WK, Papadimitrakopoulou VA. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer 103(5):952-9, 2005. e-Pub 2005. PMID: 15666322.
- Moon H, Ahn H, Lee JJ, Kodell RL. A weighted-adjusted Peto's test when cause of death is not assigned. Environmental and Ecological Statistics 12(1):95-113, 2005. e-Pub 2005.
- Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, Prieto VG, Altamirano E, Tucker SL, Strom SS, Kripke ML, Lippman SM. Mortality risk from squamous cell skin cancer. J Clin Oncol 23(4):759-65, 2005. e-Pub 2005. PMID: 15681519.
- Do KA, Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Spitz MR. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer 101(12):2837-42, 2004. e-Pub 2004. PMID: 15536619.
- Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, Hong WK, Mao L. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 10(18 Pt 1):6119-25, 2004. e-Pub 2004. PMID: 15447998.
- Tai SK, Lee JI, Ang KK, El-Naggar AK, Hassan KA, Liu D, Lee JJ, Ren H, Hong WK, Mao L. Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. Clin Cancer Res 10(16):5554-7, 2004. e-Pub 2004. PMID: 15328196.
- Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 22(16):3230-7, 2004. e-Pub 2004. PMID: 15310766.
- Maruya S, Kim HW, Weber RS, Lee JJ, Kies M, Luna MA, Batsakis JG, El-Naggar AK. Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. J Mol Diagn 6(3):180-90, 2004. e-Pub 2004. PMID: 15269293.
- Temam S, Casiraghi O, Lahaye JB, Bosq J, Zhou X, Julieron M, Mamelle G, Lee JJ, Mao L, Luboinski B, Benard J, Janot F. Tetranucleotide microsatellite instability in surgical margins for prediction of local recurrence of head and neck squamous cell carcinoma. Clin Cancer Res 10(12 Pt 1):4022-8, 2004. e-Pub 2004. PMID: 15217934.
- Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L, Hassan K, Feng L, Lee JJ, Lippman SM, Hong WK, Lotan R. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 10(5):1733-42, 2004. e-Pub 2004. PMID: 15014026.
- Rice D, Kim HW, Sabichi A, Lippman S, Lee JJ, Williams B, Vaporciyan A, Smythe WR, Swisher S, Walsh G, Putnam JB, Hong WK, Roth J. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg 76(4):1001-7; discussion 1007-8, 2003. e-Pub 2003. PMID: 14529975.
- Moon H, Ahn H, Kodell RL, Lee JJ. Estimation of k for the poly-k test with application to animal carcinogenicity studies. Stat Med 22(16):2619-36, 2003. e-Pub 2003. PMID: 12898548.
- Sabichi AL, Modiano MR, Lee JJ, Peng YM, Xu MJ, Villar H, Dalton WS, Lippman SM. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res 9(7):2400-5, 2003. e-Pub 2003. PMID: 12855611.
- Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer 5(1):40-5, 2003. e-Pub 2003. PMID: 14596703.
- Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Fu KK, Spitz MR. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol. Cancer Causes Control 14(2):131-8, 2003. e-Pub 2003. PMID: 12749718.
- Izzo JG, Papadimitrakopoulou VA, Liu DD, den Hollander PL, Babenko IM, Keck J, El-Naggar AK, Shin DM, Lee JJ, Hong WK, Hittelman WN. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 95(3):198-205, 2003. e-Pub 2003. PMID: 12569141.
- Kurie JM, Lotan R, Lee JJ, Lee JS, Morice RC, Liu DD, Xu XC, Khuri FR, Ro JY, Hittelman WN, Walsh GL, Roth JA, Minna JD, Hong WK. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 95(3):206-14, 2003. e-Pub 2003. PMID: 12569142.
- Soria JC, Xu X, Liu DD, Lee JJ, Kurie J, Morice RC, Khuri F, Mao L, Hong WK, Lotan R. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst 95(2):165-8, 2003. e-Pub 2003. PMID: 12529350.
- Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101, 2003. e-Pub 2003. PMID: 12538456.
- Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F, Herbst RS. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39(1):55-61, 2003. e-Pub 2003. PMID: 12499095.
- Papadimitrakopoulou VA, Liu DD, Mao L, Shin DM, El-Naggar A, Ibarguen H, Lee JJ, Hong WK, Hittelman WN. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev 11(12):1605-10, 2002. e-Pub 2002. PMID: 12496051.
- El-Naggar AK, Kim HW, Clayman GL, Coombes MM, Le B, Lai S, Zhan F, Luna MA, Hong WK, Lee JJ. Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. Oncogene 21(53):8206-19, 2002. e-Pub 2002. PMID: 12444558.
- Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097-105, 2002. e-Pub 2002. PMID: 12128107.
- Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 95(2):340-53, 2002. e-Pub 2002. PMID: 12124835.
- Wu X, Lippman SM, Lee JJ, Zhu Y, Wei QV, Thomas M, Hong WK, Spitz MR. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res 62(10):2813-8, 2002. e-Pub 2002. PMID: 12019158.
- Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20(8):2045-52, 2002. e-Pub 2002. PMID: 11956264.
- Shureiqi I, Jiang W, Fischer SM, Xu X, Chen D, Lee JJ, Lotan R, Lippman SM. GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res 62(4):1178-83, 2002. e-Pub 2002. PMID: 11861401.
- Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 20(2):364-70, 2002. e-Pub 2002. PMID: 11786562.
- Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong WK, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 62(2):351-5, 2002. e-Pub 2002. PMID: 11809677.
- Moon H, Lee JJ, Ahn H, Nikolova RG. Web-based simulator for sample size and power estimation in animal carcinogenesis studies. Journal of Statistical Software 7(13):1-36, 2002. e-Pub 2002.
- Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, Fu KK, Cooper JS, Vokes EE, Chamberlain RM, Williams B, Pajak TF, Goepfert H, Hong WK. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 10(8):823-9, 2001. e-Pub 2001. PMID: 11489748.
- Lee JJ, Tseng C. Uniform power method for sample size calculation in historical control studies with binary response. Control Clin Trials 22:390-400, 2001. e-Pub 2001. PMID: 11514040.
- Soria JC, Moon C, Wang L, Hittelman WN, Jang SJ, Sun SY, Lee JJ, Liu D, Kurie JM, Morice RC, Lee JS, Hong WK, Mao L. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 93(16):1257-63, 2001. e-Pub 2001. PMID: 11504771.
- Lee JJ, Liu D, Lee JS, Kurie JM, Khuri FR, Ibarguen H, Morice RC, Walsh G, Ro JY, Broxson A, Hong WK, Hittelman WN. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst 93:1081-8, 2001. e-Pub 2001. PMID: 11459869.
- Shin DM, Charuruks N, Lippman SM, Lee JJ, Ro JY, Hong WK, Hittelman WN. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev 10(6):603-9, 2001. e-Pub 2001. PMID: 11401909.
- Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7(4):861-7, 2001. e-Pub 2001. PMID: 11309334.
- Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91(7):1316-23, 2001. e-Pub 2001. PMID: 11283932.
- Khuri FR, Lee JS, Lippman SM, Lee JJ, Kalapurakal S, Yu R, Ro JY, Morice RC, Hong WK, Hittelman WN. Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers. Cancer Epidemiol Biomarkers Prev 10(4):311-8, 2001. e-Pub 2001. PMID: 11319170.
- Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer. J Natl Cancer Inst 93:605-18, 2001. e-Pub 2001. PMID: 11309437.
- Royce ME, Hoff PM, Dumas P, Lassere Y, Lee JJ, Coyle J, Ducharme MP, De Jager R, Pazdur R. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J Clin Oncol 19(5):1493-500, 2001. e-Pub 2001. PMID: 11230496.
- Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18(23):3904-11, 2000. e-Pub 2000. PMID: 11099319.
- Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res 6(10):3895-903, 2000. e-Pub 2000. PMID: 11051235.
- Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92(18):1511-6, 2000. e-Pub 2000. PMID: 10995806.
- Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Broxson A, Lippman SM, Ro JY, Kemp BL, Liu D, Fritsche HA, Xu X, Lotan R, Hong WK. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 6(8):2973-9, 2000. e-Pub 2000. PMID: 10955773.
- Khuri FR, Lotan R, Kemp BL, Lippman SM, Wu H, Feng L, Lee JJ, Cooksley CS, Parr B, Chang E, Walsh GL, Lee JS, Hong WK, Xu XC. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol 18(15):2798-804, 2000. e-Pub 2000. PMID: 10920126.
- Tae K, El-Naggar AK, Yoo E, Feng L, Lee JJ, Hong WK, Hittelman WN, Shin DM. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res 6(7):2821-8, 2000. e-Pub 2000. PMID: 10914730.
- Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, Lotan R, Fischer SM, Lippman SM. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 92(14):1136-42, 2000. e-Pub 2000. PMID: 10904086.
- Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 6:1702-10, 2000. e-Pub 2000. PMID: 10815888.
- Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB, Schrump DS, Shin DM, Walsh GL, Roth JA. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther 7(4):530-6, 2000. e-Pub 2000.
- Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 6(3):790-7, 2000. e-Pub 2000. PMID: 10741698.
- Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18(3):609-22, 2000. e-Pub 2000. PMID: 10653876.
- Zhou X, Kemp BL, Khuri FR, Liu D, Lee JJ, Wu W, Hong WK, Mao L. Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin Cancer Res 6(2):559-65, 2000. e-Pub 2000. PMID: 10690539.
- Shin DM, Mao L, Papadimitrakopoulou VM, Clayman G, El-Naggar A, Shin HJ, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst 92(1):69-73, 2000. e-Pub 2000. PMID: 10620636.
- Lee JJ, Hess KR, Dubin JA. Extensions and applications of event charts. American Statistician 54:63-70, 2000. e-Pub 2000.
- Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer 86(11):2291-300, 1999. e-Pub 1999. PMID: 10590370.
- Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res 27(5):362-7, 1999. e-Pub 1999. PMID: 10550525.
- Xu XC, Lee JS, Lee JJ, Morice RC, Liu X, Lippman SM, Hong WK, Lotan R. Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. J Natl Cancer Inst 91(15):1317-21, 1999. e-Pub 1999. PMID: 10433621.
- Thall PF, Lee JJ, Tseng CH, Estey EH. Accrual strategies for phase I trials with delayed patient outcome. Stat Med 18:1155-69, 1999. e-Pub 1999. PMID: 10363337.
- Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Jr, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91(9):763-71, 1999. e-Pub 1999. PMID: 10328106.
- Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17(3):976-83, 1999. e-Pub 1999. PMID: 10071292.
- Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, Plager C, Ross M, Lee JE, Mansfield P, Rice J, Ring S, Lee JJ, Strom E, Benjamin R. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 8(6):549-56, 1998. e-Pub 1998. PMID: 9918417.
- Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS, Hittelman WN, Lippman SM, Hong WK. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 90(20):1545-51, 1998. e-Pub 1998. PMID: 9790547.
- Wu X, Gu J, Hong WK, Lee JJ, Amos CI, Jiang H, Winn RJ, Fu KK, Cooper J, Spitz MR. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst 90:1393-9, 1998. e-Pub 1998. PMID: 9747870.
- Gershenwald JE, Tseng CH, Thompson W, Mansfield PF, Lee JE, Bouvet M, Lee JJ, Ross MI. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124(2):203-10, 1998. e-Pub 1998. PMID: 9706139.
- Zhou J, Mulshine JL, Ro JY, Avis I, Yu R, Lee JJ, Morice R, Lippman SM, Lee JS. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers. Clin Cancer Res 4(7):1631-40, 1998. e-Pub 1998. PMID: 9676837.
- Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, Balch CM, Ross MI. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16(6):2253-60, 1998. e-Pub 1998. PMID: 9626228.
- Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, Roth JA. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58(11):2288-92, 1998. e-Pub 1998. PMID: 9622060.
- Anderson CM, Buzaid AC, Sussman J, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Legha SS, Grimm EA. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res 8(2):149-55, 1998. e-Pub 1998. PMID: 9610868.
- Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha SS, Benjamin RS. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. Melanoma Res 8(2):145-8, 1998. e-Pub 1998. PMID: 9610867.
- Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, Lawhorn K, Gillenwater AM, Ang KK, Clayman GL, Callender DL, Hong WK, Lippman SM. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 16(4):1325-30, 1998. e-Pub 1998. PMID: 9552033.
- Spitz MR, Lippman SM, Jiang H, Lee JJ, Khuri F, Hsu TC, Trizna Z, Schantz SP, Benner S, Hong WK. Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst 90(3):243-5, 1998. e-Pub 1998. PMID: 9462683.
- Mitchell MF, Tortolero-Luna G, Lee JJ, Hittelman WN, Lotan R, Wharton JT, Hong WK, Nishioka K. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res 4(2):303-10, 1998. e-Pub 1998. PMID: 9516915.
- Staniswalis JG, Lee JJ. Nonparametric regression analyses of longitudinal data. J Am Stat Assoc 93:1403-1418, 1998. e-Pub 1998.
- Wu X, Hsu TC, Cao S, Lee JJ, Amos CI, Spitz MR. Deletion in poly(ADP-ribose)polymerase pseudogene and lung cancer risk. Carcinogenesis 19(1):93-8, 1998. e-Pub 1998. PMID: 9472699.
- El-Naggar AK, Lai S, Clayman G, Lee JK, Luna MA, Goepfert H, Batsakis JG. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 151(6):1767-74, 1997. e-Pub 1997. PMID: 9403727.
- Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukmanji F, Hortobagyi G, Lippman SM, Dhingra K, Lotan R. Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res 57(22):4992-6, 1997. e-Pub 1997. PMID: 9371489.
- Lee JJ, Tu ZN. A Versatile One-Dimensional Distribution Plot: The BLiP Plot. American Statistician 51(4):353-8, 1997. e-Pub 1997.
- Spitz MR, McPherson RS, Jiang H, Hsu TC, Trizna Z, Lee JJ, Lippman SM, Khuri FR, Steffen-Batey L, Chamberlain RM, Schantz SP, Hong WK. Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancer. Cancer Epidemiol Biomarkers Prev 6(9):687-92, 1997. e-Pub 1997. PMID: 9298575.
- Jung FA, Buzaid AC, Ross MI, Woods KV, Lee JJ, Albitar M, Grimm EA. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 15(8):2826-31, 1997. e-Pub 1997. PMID: 9256125.
- Konishi H, Steinbach G, Terry NH, Fujita K, Lee JJ, Ruifrok A, Spaulding D, Lynch PM, Dubin JA, Andreeff M, Goodacre AM, Hattori T, Hittelman WN. S phase determination in intact colonic crypts by histone H3 messenger RNA in situ hybridization and confocal microscopy. Cancer Epidemiol Biomarkers Prev 6(7):531-6, 1997. e-Pub 1997. PMID: 9232341.
- Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC, Kemp BL, Khuri FR, Walsh GL, Hittelman WN, Hong WK. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89(12):857-62, 1997. e-Pub 1997. PMID: 9196251.
- Shin DM, Xu XC, Lippman SM, Lee JJ, Lee JS, Batsakis JG, Ro JY, Martin JW, Hittelman WN, Lotan R, Hong WK. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 3(6):875-80, 1997. e-Pub 1997. PMID: 9815762.
- Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK, Lotan R. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst 89(9):624-9, 1997. e-Pub 1997. PMID: 9150186.
- Shin HJ, Kalapurakal SK, Lee JJ, Ro JY, Hong WK, Lee JS. Comparison of p53 immunoreactivity in fresh-cut versus stored slides with and without microwave heating. Mod Pathol 10(3):224-30, 1997. e-Pub 1997. PMID: 9071730.
- Papadimitrakopoulou VA, Dimery IW, Lee JJ, Perez C, Hong WK, Lippman SM. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the MD Anderson Cancer Center experience. Cancer J Sci Am 3:92-9, 1997. e-Pub 1997. PMID: 9099459.
- Papadimitrakopoulou VA, Hong WK, Lee JS, Martin JW, Lee JJ, Batsakis JG, Lippman SM. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 89(3):257-8, 1997. e-Pub 1997. PMID: 9017007.
- Lee JJ, Serachitopol DM, Brown BW. Likelihood weighted confidence intervals for the difference of two binomial proportions. Biom J 39:387-407, 1997. e-Pub 1997.
- Dimery IW, Hong WK, Lee JJ, Guillory-Perez C, Pham F, Fritsche HA, Jr, Lippman SM. Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Oncol 8(1):85-9, 1997. e-Pub 1997. PMID: 9093712.
- Mitchell MF, Tortolero-Luna G, Lee JJ, Hittelman WK, Lotan R, Wharton JT, Hong WK, Nishioka K. Polyamine measurements in the uterine cervix. J Cell Biochem Suppl 28-29:125-32, 1997. e-Pub 1997. PMID: 9589357.
- Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee JJ, Abbruzzese JL. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res 2(12):2015-22, 1996. e-Pub 1996. PMID: 9816161.
- Sim SJ, Glassman AB, Ro JY, Lee JJ, Logothetis CJ, Liu FJ. Serum calcitonin in small cell carcinoma of the prostate. Ann Clin Lab Sci 26(6):487-95, 1996. e-Pub 1996. PMID: 8908318.
- Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, Hittelman WN, Yu R, Lee JJ, Hong WK. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2(10):1787-93, 1996. e-Pub 1996. PMID: 9816131.
- Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2(9):985-91, 1996. e-Pub 1996. PMID: 8782455.
- Steinbach G, Lupton J, Reddy BS, Lee JJ, Kral JG, Holt PR. Calcium carbonate treatment of diarrhoea in intestinal bypass patients. Eur J Gastroenterol Hepatol 8(6):559-62, 1996. e-Pub 1996. PMID: 8823570.
- Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, Heyne K, Shin HJ, Ro JY, Goepfert H, Hong WK, Hittelman WN. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 88(8):519-29, 1996. e-Pub 1996. PMID: 8606380.
- Lee JJ, Trizna Z, Hsu TC, Spitz MR, Hong WK. A statistical analysis of the reliability and classification error in application of the mutagen sensitivity assay. Cancer Epidemiol Biomarkers Prev 5:191-7, 1996. e-Pub 1996. PMID: 8833619.
- Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14(2):503-13, 1996. e-Pub 1996. PMID: 8636764.
- Konishi H, Steinbach G, Terry NH, Lee JJ, Dubin JA, Glober GA, Fujita K, Spaulding D, Cass L, Hittelman WN. Histone H3 messenger RNA in situ hybridization correlates with in vivo bromodeoxyuridine labeling of S-phase cells in rat colonic epithelium. Cancer Res 56(3):434-7, 1996. e-Pub 1996. PMID: 8564947.
- Ehteshami M, Ro JY, Shin HJC, Lee JJ, Ordonez NG, Ayala AG. p53 expression and tumor proliferative activity in testicular germ cell tumors: An immunohistochemical and clinicopathologic study. Int J Oncol 9:787-793, 1996. e-Pub 1996.
- Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN. Design and results of phase I cancer clinical trials: three-year experience at MD Anderson Cancer Center. J Clin Oncol 14(1):287-95, 1996. e-Pub 1996. PMID: 8558210.
- Walsh GL, O'Connor M, Willis KM, Milas M, Wong RS, Nesbitt JC, Putnam JB, Jr, Lee JJ, Roth JA. Is follow-up of lung cancer patients after resection medically indicated and cost-effective?. Ann Thorac Surg 60(6):1563-70; discussion 1570-2, 1995. e-Pub 1995. PMID: 8787445.
- Xu XC, Zile MH, Lippman SM, Lee JS, Lee JJ, Hong WK, Lotan R. Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res 55:5507-11, 1995. e-Pub 1995. PMID: 7585623.
- Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1(10):1103-10, 1995. e-Pub 1995. PMID: 9815900.
- Buzaid AC, Tinoco LA, Jendiroba D, Tu ZN, Lee JJ, Legha SS, Ross MI, Balch CM, Benjamin RS. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 13(9):2361-8, 1995. e-Pub 1995. PMID: 7666095.
- Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelman WN, Hong WK. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 13:1893-903, 1995. e-Pub 1995. PMID: 7636531.
- Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 332(21):1405-10, 1995. e-Pub 1995. PMID: 7723796.
- Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55(2):237-41, 1995. e-Pub 1995. PMID: 7812951.
- Clayman GL, Chamberlain RM, Lee JJ, Lippman SM, Hong WK. Screening at a health fair to identify subjects for an oral leukoplakia chemoprevention trial. J Cancer Educ 10:88-90, 1995. e-Pub 1995. PMID: 7669540.
- Lippman SM, Shin DM, Lee JJ, Batsakis JG, Lotan R, Tainsky MA, Hittelman WN, Hong WK. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 55(1):16-9, 1995. e-Pub 1995. PMID: 7805028.
- Sinicrope FA, Hart J, Brasitus TA, Michelassi F, Lee JJ, Safa AR. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer 74(11):2908-17, 1994. e-Pub 1994. PMID: 7954255.
- Benner SE, Lippman SM, Wargovich MJ, Lee JJ, Velasco M, Martin JW, Toth BB, Hong WK. Micronuclei, a biomarker for chemoprevention trials: results of a randomized study in oral pre-malignancy. Int J Cancer 59(4):457-9, 1994. e-Pub 1994. PMID: 7960211.
- Lee JS, Lippman SM, Benner SE, Lee JJ, Ro JY, Lukeman JM, Morice RC, Peters EJ, Pang AC, Fritsche HA, Jr, Hong WK. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 12(5):937-45, 1994. e-Pub 1994. PMID: 8164045.
- Schag CA, Ganz PA, Wing DS, Sim MS, Lee JJ. Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Res 3(2):127-41, 1994. e-Pub 1994. PMID: 8044158.
- Trizna Z, Lee JJ, Hsu TC, Benner S, Fritsche HA, Pang A, Hong WK. Protective effects of in vivo 13-cis-Retinoic acid treatment against mutagen-induced genetic damage. Cancer Research Therapy and Control 4:81-85, 1994. e-Pub 1994.
- Lee JJ, Tu ZN. A better confidence interval for Kappa on measuring agreement between two raters with binary outcomes. Journal of Computational and Graphical Statistics 3:301-321, 1994. e-Pub 1994.
- Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg 79(2):210-6, 1993. e-Pub 1993. PMID: 8331402.
- Dimopoulos MA, Cabanillas F, Lee JJ, Swan F, Fuller L, Allen PK, Hagemeister FB. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol 11(6):1108-11, 1993. e-Pub 1993. PMID: 8501496.
- Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, Hays GL, Goepfert H, Hong WK. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328(1):15-20, 1993. e-Pub 1993. PMID: 8416267.
- Trizna Z, Schantz SP, Lee JJ, Spitz MR, Goepfert H, Hsu TC, Hong WK. In vitro protective effects of chemopreventive agents against bleomycin-induced genotoxicity in lymphoblastoid cell lines and peripheral blood lymphocytes of head and neck cancer patients. Cancer Detect Prev 17(6):575-83, 1993. e-Pub 1993. PMID: 7506126.
- Lee JJ, Li KC, Elashoff RM. On recensoring for censored paired data. J Am Stat Assoc 88:104-118, 1993. e-Pub 1993.
- Heyne KH, Lippman SM, Lee JJ, Lee JS, Hong WK. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol 10(10):1519-24, 1992. e-Pub 1992. PMID: 1328547.
- Ganz PA, Lee JJ, Sim MS, Polinsky ML, Schag CA. Exploring the influence of multiple variables on the relationship of age to quality of life in women with breast cancer. J Clin Epidemiol 45(5):473-85, 1992. e-Pub 1992. PMID: 1588353.
- Ganz PA, Schag AC, Lee JJ, Polinsky ML, Tan SJ. Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery?. Cancer 69(7):1729-38, 1992. e-Pub 1992. PMID: 1551058.
- Ganz PA, Schag CA, Lee JJ, Sim MS. The CARES: a generic measure of health-related quality of life for patients with cancer. Qual Life Res 1(1):19-29, 1992. e-Pub 1992. PMID: 1301111.
- Trizna Z, Hsu TC, Schantz SP, Lee JJ, Hong WK. Anticlastogenic effects of 13-cis-retinoic acid in vitro. Eur J Cancer 29A:137-40, 1992. e-Pub 1992. PMID: 1280151.
- Lee JJ. A note on the conditional approach to interval estimation in the calibration problem. Biometrics 47:1573-80, 1991. e-Pub 1991. PMID: 1786330.
- Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 67(12):3131-5, 1991. e-Pub 1991. PMID: 1710541.
- Cochran ST, Barbaric ZL, Lee JJ, Kashfian P. Percutaneous nephrostomy tube placement: an outpatient procedure?. Radiology 179(3):843-7, 1991. e-Pub 1991. PMID: 2028003.
- Clark GT, Adler RC, Lee JJ. Jaw pain and tenderness levels during and after repeated sustained maximum voluntary protrusion. Pain 45(1):17-22, 1991. e-Pub 1991. PMID: 1861875.
- Petrocik E, Wassman ER, Lee JJ, Kelly JC. Second trimester maternal serum pregnancy specific beta-1 glycoprotein (SP-1) levels in normal and Down syndrome pregnancies. Am J Med Genet 37:114-8, 1990. e-Pub 1990. PMID: 2146876.
- Lee JJ, Cochran ST. Rebuttal: evaluation of iopamidol and diatrizoate in excretory urography: a double-blind clinical study. Invest Radiol 25:1256-1257, 1990. e-Pub 1990.
- Elashoff RM, Lee JJ, Afifi AA. A note on confidence limits for quartiles with right censored data. Stat Med 8:1269-76, 1989. e-Pub 1989. PMID: 2814074.
- Gratt BM, Pullinger A, Sickles EA, Lee JJ. Electronic thermography of normal facial structures: a pilot study. Oral Surg Oral Med Oral Pathol 68(3):346-51, 1989. e-Pub 1989. PMID: 2771378.
- Clark GT, Jow RW, Lee JJ. Jaw pain and stiffness levels after repeated maximum voluntary clenching. J Dent Res 68(1):69-71, 1989. e-Pub 1989. PMID: 2910958.
- Jacobson JJ, Schweitzer S, DePorter DJ, Lee JJ. Chemoprophylaxis of dental patients with prosthetic joints: a simulation model. J Dent Educ 52:599-604, 1988. e-Pub 1988. PMID: 3183167.
- Cochran ST, Ballard JW, Katzberg RW, Barbaric ZL, Spataro R, Iwamoto K, Lee JJ. Evaluation of lopamidol and diatrizoate in excretory urography: a double-blind clinical study. Am J of Radiology 151:523-7, 1988. e-Pub 1988. PMID: 3044040.
- Afifi AA, Elashoff RM, Lee JJ. Simultaneous non-parametric confidence intervals for survival probabilities from censored data. Stat Med 5:653-62, 1986. e-Pub 1986. PMID: 3823672.
- Sayre J, Elashoff R, Wang HJ, Lee, JJ. The effective use of a local area network for the data management of clinical and nutritional data from a multicenter clinical trial. Controlled Clinical Trials 7:234, 1986. e-Pub 1986.
Invited Articles
- Lippman SM, Lee JJ. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 66(6):2893-903, 2006. e-Pub 2006. PMID: 16540634.
- Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Design considerations for efficient prostate cancer chemoprevention trials. Urology 57(4 - Suppl 1):205-12, 2001. e-Pub 2001. PMID: 11295629.
- Leiberman, R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology 57(4 Suppl 1):4-27, 2001. e-Pub 2001. PMID: 11295590.
- Lee JJ. ß-carotene may not prevent second head and neck cancer. Commentary to Mayne ST et al. Cancer Res 61:1457-1463, 2001. Evidence-based Oncology 2:200-201, 2001. e-Pub 2001.
Review Articles
- Hernandez M, Lee JJ, Yeap BY, Ye R, Foote RL, Busse P, Patel SH, Dagan R, Snider J, Mohammed N, Lin A, Blanchard P, Cantor SB, Teferra MY, Hutcheson K, Yepes P, Mohan R, Liao Z, DeLaney TF, Frank SJ. The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. Adv Radiat Oncol 6(2):100635, 2021. e-Pub 2021. PMID: 33732960.
- Yuan Y, Lee JJ, Hilsenbeck SG. Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923856.
- Le-Rademacher J, Dahlberg S, Lee JJ, Adjei AA, Mandrekar SJ. Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. J Thorac Oncol 13(11):1625-1637, 2018. e-Pub 2018. PMID: 30194034.
- Frank SJ, Blanchard P, Lee JJ, Sturgis EM, Kies MS, Machtay M, Vikram B, Garden AS, Rosenthal DI, Gunn GB, Fuller CD, Hutcheson K, Lai S, Busse PM, Lee NY, Lin A, Foote RL. Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Semin Radiat Oncol 28(2):108-113, 2018. e-Pub 2018. PMID: 29735186.
- Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol 33(32):3817-25, 2015. e-Pub 2015. PMID: 26304871.
- Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101(10):708-20, 2009. e-Pub 2009. PMID: 19436029.
- Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, Cancer Prevention ATFO. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 2006. e-Pub 2006. PMID: 16778094.
- Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 23(19):4450-7, 2005. e-Pub 2005. PMID: 15994154.
- Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol 23(9):1911-20, 2005. e-Pub 2005. PMID: 15774783.
- Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst 90:1514-28, 1998. e-Pub 1998. PMID: 9790544.
- Jacobson JJ, Schweitzer S, DePorter DJ, Lee JJ. Antibiotic prophylaxis for dental patients with joint prostheses? A decision analysis. Int J Technol Assess Health Care 6(4):569-87, 1990. e-Pub 1990. PMID: 2150670.
Professional Educational Materials
- Lee JJ. Clinical Trials and Biometric Methodology. ASCO Curriculum: Cancer Prevention, ASCO, 2007.
Other Articles
- Fu, C., Zhou, S., Lee, J. J. Posterior Predictive Design for Phase I Clinical Trials. Journal of the American Statistical Association:1-12, 2025.
- Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 639(8054):E19, 2025. PMID: 40016449.
- Ferrarotto R, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D, Frank SJ, Song X, Kupferman ME, Liu B, Lee JJ, Glisson BS, Zhang J, Aster JC, Lin SY, Futreal PA, Heymach JV, El-Naggar AK Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res 29(14):2737, 2023. PMID: 37449360.
- Moon, H, Anh, H, Lee, JJ A Fleming-Harrington type adjustment of the Peto Test for testing dose-related trend of a test drug in animal carcinogenicity studies. Proceedings of the Biometrics Section, American Statistical Association:70-75, 2001.
Editorials
- Gupta D, Lee JJ, Lin AY. A Randomized Clinical Trial on Anterior Approach vs Conventional Hepatectomy for Resection of Colorectal Liver Metastasis-To Terminate or Not to Terminate the Study. JAMA Surg 156(9):893-894, 2021. PMID: 34037707.
- Lu Y, Lee JJ, Ford JM. Statistical Methods in Precision Oncology. J Clin Oncol:JCO1903173. PMID: 31895607.
- Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R. Response. J Natl Cancer Inst 108(3)(3), 2016. PMID: 26912651.
- Lee JJ. Commentary on Hey and Kimmelman. Clin Trials 12(2):110-2, 2015. PMID: 25649110.
- Benjamin RS, Lee JJ. One step forward, two steps back. Lancet Oncol 15(4):366-7, 2014. PMID: 24694628.
- Jain RK, Lee JJ, Hong D, Kurzrock R. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst 105(11):833, 2013. PMID: 23628598.
- Jain RK, Lee JJ, Hong D, Kurzrock R. Reply to A. Levy et al. J Clin Oncol 31(3):396, 2013. PMID: 23451354.
- Lee JJ. Demystify statistical significance--time to move on from the p value to Bayesian analysis. J Natl Cancer Inst 103(1):2-3, 2011. PMID: 21131578.
- Lee JJ, Kong M. Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity—Response. Cancer Res 7(71):2794 - 95, 2011.
- Lee JJ, Kong M. Rebuttal to the Response of Chou. Cancer Res 7(71):2798-2800, 2011.
- Le Tourneau C, Lee JJ, Siu LL. Response: Re: Dose escalation methods in phase 1 cancer clinical trials. Journal of the National Cancer Institute, 2009.
- Lee JJ. Beta-carotene may not prevent second head and neck cancer. Evidencee-based Oncology, 2001.
- Jr MF, Lippman SM, Lee JJ, Sabichi AL. Re: Cancer chemoprevention: Progress and promise (3) multiple letters. Journal of the National Cancer Institute, 1999.
Abstracts
- Cascone T, Sepesi B, Lin H Y, Kalhor N, Zhang J, Fossella F V, Tsao A S, Lam V K, Lu C, Mott F, Simon G R, Antonoff M, Mehran R J, Rice D C, Vaporciyan A A, Godoy M, Lee JJ, Swisher S, William W N, Heymach J. A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC). American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
- Sicklick, J K, Shumei K, Schwaederle M C, Okamura R, Hahn M, Williams C B. Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
- Rodon J, Soria JC, Berger R, Miller W H, Lazar V, Rubin E, Tsimberidou A M, Saintigny P, Ackerstein A, Brana I, Loriot Y, Afshar M, Miller V A, Wunder F, Bresson C, Martini JF, Mendelsohn J, Schilsky R L, Lee JJ, Kurzrock R. WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
- Hu X, Fujimoto J, Chen R, Chow CW, Sun W, Song, X, Mao X, Scheet P, Kadara H, Behrens C, C-jiun W, Lee JJ, Antonoff M, Vaporciyan A A, Swisher S, Zhang J, Heymach J, Wistuba I, Futreal A, Zhang J. Genomic evolutions in the progression from lung preneoplasia to adenocarcinoma. American Society of Clinical Oncology Annual Meeting, Chicago, IL J Clin Oncol 36, 2018. e-Pub 2018.
- Parra E R, Jiang M, Zhang J, Behres C, Lee JJ, Heymach J V, Forget MA, Haymaker C, Bernatchez C, Moran C, Zhang J, Gibbons D, Wistuba I. Immunofluorescence profiling of co-expression of multiple immune checkpoints in malignant and tumor infiltrated lymphocytes in non-small cell lung carcinomas using image analysis system. American Association for Cancer Research Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
- Cruz AF, Parra ER, Jiang M, Fujimoto J, Chow C W, Rodriguez-Canales J, Behrens C, Kalhor N, Weissferdt A, Heymach J, Swisher S, Sepesi B, Lee JJ, Moran C, Futreal PA, Zhang J, Wistuba I. Characterization of the immunologic intra-tumor heterogeneity in early stages of non-small cell lung carcinoma using multiplex immunofluorescence and image analysis approaches. American Association for Cancer Research Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
- Cuentas ER, Behrens C, Rodriguez-Canales J, Jiang M, Pataer A, Correa A, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Zhang J, Lee J, Heymach J, Moran C, Zhang J, Gibbons D, Wistuba I. Neoadjuvant chemotherapy influence changes of the immune response in non-small cell lung carcinomas immune response in non-small cell lung carcinomas. Cancer Res (13 Supplement) 2934-2934, 2017. e-Pub 2017.
- Yasir E, Richard GD, Vassiliki P, Tran Hai T, Waree R, Jeff L, Lara L, Emily R, Jack LJ, Roth Jack A, Stephen S, Jianjun Z, John H. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small cell lung cancer (NSCLC). J Clin Oncol, 2017. e-Pub 2017.
- Ali J, Jing W, Won-Chul L, Jianhua Z, Chin WC, Lynn GD, XiMing T, Neda K, Julie I, Carmen B, Fossella Frank V, Tsao Anne S, Jack LJ, Stephen S, John H, Andrew F, Ivan WI, Herbst Roy S, Vassiliki P, Zhang J. Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. J Clin Oncol, 2017. e-Pub 2017.
- Kelly Q, Jun L, Junya F, Jianhua Z, Jinliang W, Chi-Wan C, Carmen B, Latasha L, Curtis G, Mara A, Neda K, Annikka W, William William N, Stephen S, Jack LJ, John H, Ivan WI, Andrew F, Jianjun Z, ITH Group EN. Intratumor heterogeneity of stage IA lung adenocarcinoma by multiregion whole exome sequencing and association with survival. J Clin Oncol, 2017. e-Pub 2017.
- Nassib WW, Naohiro U, Andrew PS, Jack LJ, El-Naggar Adel K, Roger Parra CE, Jaime R, Gillenwater Ann M, Lin Heather Y, Ivan WI, Jeffrey M, Gold Kathryn A, Patrick H, John H, Vassiliki P, Michael LS. Immune profiling of oral pre-malignant lesions (OPLs): An Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis. J Clin Oncol, 2017. e-Pub 2017.
- Jianjun Z, Dan S, Junya F, Lisa Y, Chi-Wan C, Wenyong S, Jianhua Z, Jinlin H, Carmen B, Mara A, Justin OE, Myrna G, William William N, Stephen S, Jack LJ, Ivan WI, Ki HW, Andrew FP, Rodriguez CJ, Marcus C, Curtis G, Jun L, Latasha L, Neda K, Xizeng M, R Parra CE, Xingzhi S, Rebecca T, Ara V, Annikka W, Chang-Jiun W, Jiexin Z. Multiregion whole exome seuquencing of pre- and early neoplastic lung lesions. J Clin Oncol, 2017. e-Pub 2017.
- Gustavo S, Andrew PS, Giorgios B, Jack LJ, Felipe Kuperman BM, Jianjun Z, Waree R, Jeff L, Emily R, Lara L, Roth Jack A, Stephen S, John H, Fossella Frank V, Nassib WW. Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC). J Clin Oncol, 2017. e-Pub 2017.
- Pai Sara I, Jack LJ, Carey Thomas E, Westra William H, Soldano F, Charles M, Moon SD, Ferris Robert L. Intact APM and PD-1:PD-L1 pathway upregulation in HIV-infected head and neck cancer patients. J Clin Oncol, 2017. e-Pub 2017.
- Ming T, Neda K, Maheshwari R, Junya F, Jianhua Z, Jun L, Chi-Wan C, Xizeng M, Xingzhi S, Latasha L, Curtis G, Carmen B, William William N, Annikka W, Jack LJ, Stephen S, John H, Ivan WI, Andrew F, Jianjun Z. Histology determination of lung cancers: A report on genomic profiling of lung cancer of mixing histology. J Clin Oncol, 2017. e-Pub 2017.
- Alexandre R, Rachel G, Jiexin Z, Erik Y, Chang-jiun W, Emerson Ryan O, Jianhua Z, Christopher T, Marissa V, Junya F, Jaime R, Stephen S, John H, Harlan R, Jack LJ, Andrew F, Ivan WI, Jianjun Z, Study Team NT. TCR repertoire sequencing of 254 resected non-small cell lung cancers to reveal TCR clonality in normal tissues compared to tumor tissues. J Clin Oncol, 2017. e-Pub 2017.
- Richard GD, Blumenschein George R, Jack LJ, Mike H, Ross CD, Charles DR, Gaspar Laurie E, Lynn GD, Karam Jose A, Kavanagh Brian D, Ritsuko K, Louie Alexander V, Palma David A, Tsao Anne S, Nassib WW, Jianjun Z, Stephen S, John H. Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study. J Clin Oncol, 2016. e-Pub 2016.
- Liao Zhongxing X, Jack LJ, Ritsuko K, Richard GD, Michael O, Pamela A, Fossella Frank V, John H, Blumenschein George R, Choi Noah C, Thomas D, Hahn Stephen M, Charles L, Cox James D, Radhe M. Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. J Clin Oncol, 2016. e-Pub 2016.
- Clemence SM, Zhao Melissa M, Jack LJ, Vladimir L, Brian L, Schilsky Richard L, John M, Razelle K. Impact of precision medicine in refractory malignancies: A meta-analysis of 13,203 patients in phase I clinical trials. J Clin Oncol, 2016. e-Pub 2016.
- Ruder D, Papadimitrakopoulou V, Shien K, Kalhor N, Lee J, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Hanson NE, Sun J, Miller V, Frampton G, Herbst RS, Wistuba II, Izzo JG. Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC). American Association of Cancer Research Annual Meeting, Philadelphia, PA 2015, 2015. e-Pub 2015.
- Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Lou Y, Gibbons DL, Heymach JV, Swisher SG, Weissferdt A, Kahlor N, Izzo J, Lee J, Kadara H, Moran C, Wistub I. High programmed cell death ligand 1 expression and low immune infiltrate score correlate with worse outcome in patients with lung adenocarcinoma. American Association of Cancer Research Annual Meeting, Philadelphia, PA 2015, 2015. e-Pub 2015.
- Shien K, Papadimitrakopoulou VA, Ruder D, Hanson NE, Kalhor N, Lee J, Hong WK, Tang X, Herbst RS, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG. Oncostatin M receptor activation leads to molecular targeted therapy resistance in non-small cell lung cancer. American Association of Cancer Research Annual Meeting, Philadelphia, PA 2015, 2015. e-Pub 2015.
- Lee J. We learn as we go: Bayesian adaptive designs for efficient and flexible clinical trials. American Association of Cancer Research Annual Meeting, Philadelphia, PA 2015, 2015. e-Pub 2015.
- Massarelli E, Haddad RI, Lee J, Lin HY, Garden AS, Blumenschein GR, William WN, Tishler RB, Glisson BS, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC). 2015 ASCO Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr 6001), 2015. e-Pub 2015.
- Kopetz S, Litzenburger B, Kinyua W, Sajan B, Subbiah V, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw KR, Lee J, Broaddus R. Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. 2015 ASCO Annual Meeting J Clin Oncol 33, 2015 (suppl; abstr 3608), 2015. e-Pub 2015.
- Schwaederle MC, Zhao MM, Lee J, Eggermont A, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials. 2015 ASCO Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr 11097), 2015. e-Pub 2015.
- Wheler JJ, Yelensky R, Stephen B, Hong DS, Zinner R, Subbiah V, Fu S, Karp DD, Falchook GS, Naing A, Tsimberidou AM, Piha-Paul SA, Janku F, Li Y, Lee J, Miller VA, Meric-Bernstam F, Kurzrock R. Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. 2015 ASCO Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr 11019), 2015. e-Pub 2015.
- Zhang J, Liu Y, Zhang J, Gomez DR, Fujimoto J, Behrens C, Zhang J, Correa AM, Gumbs C, Mao X, Seth S, Song X, Heymach J, Lee J, Swisher S, William WN, Hong WK, Gao Y, Wistuba II, Futreal A. Genomic heterogeneity of lung cancers and its potential clinical implications. 2015 ASCO Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr 7530), 2015. e-Pub 2015.
- Tang X, Cai Y, Behrens C, Lin H, Lee J, Wistuba II. Focal adhesion kinsase (FAK) protein overexpression and gene copy number gain correlate with better outcome in patients with surgically resected NSCLC tumors. American Association of Cancer Research Annual Meeting, San Diego, California 2014, 2014. e-Pub 2014.
- Min H, Yun HJ, Lee H, Hyun-Ji Jang JC, Kim KM, Kim W, Diane Liu SO, Lee J, Hong WK, Wistuba II, Lee H. Targeting the insulin-like growth factor receptor/Insulin receptor and Src signaling network for the treatment of non-small cell lung cancer. American Association of Cancer Research Annual Meeting, San Diego, California 2014, 2014. e-Pub 2014.
- Massarelli E, Haddad RI, Lee J, Garden AS, Blumenschein GR, William WN, Tishler RB, Glisson BS, Gold KA, Johnson FM, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma. 2014 ASCO Annual Meeting, J Clin Oncol 32:5s, 2014 (suppl; abstr TPS6102), 2014. e-Pub 2014.
- Weidhaas JB, Kim ES, Herbst RS, Yu J, Slack F, Blumenschein GR, Tsao AS, Wistuba II, Lee J, Papadimitrakopoulou V, Hong WK, Heymach J, Tran HT. The KRAS-variant and treatment response in BATTLE-1. 2014 ASCO Annual Meeting, J Clin Oncol 32:5s, 2014 (suppl; abstr 8135), 2014. e-Pub 2014.
- Wheler JJ, Janku F, Atkins JT, Moulder SL, Zinner R, Lee J, Falchook GS, Tsimberidou AM, Piha-Paul SA, Karp DD, Naing A, Fu S, Hong DS, Subbiah V, Stephens PJ, Yelensky R, Miller VA, Valero V, Kurzrock R, Meric-Bernstam F. PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. 2014 ASCO Annual Meeting, J Clin Oncol 32:5s, 2014 (suppl; abstr 2606), 2014. e-Pub 2014.
- Zhang H, Kim S, Chen Z, Nannapaneni S, Sica G, Carey TE, William WN, Nguyen ML, James Riddell IV, Pai SI, Walline HM, Lee J, Wolf GT, Grandis JR, Ferris RL, Chen ZG, Shin DM. Expression of tumor biomarkers in HIV-infected patients with head and neck cancer. 2014 ASCO Annual Meeting, J Clin Oncol 32:5s, 2014 (suppl; abstr 6086), 2014. e-Pub 2014.
- Fontes Jardim DL, Schwaederle MC, Lee J, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval. 2014 ASCO Annual Meeting, J Clin Oncol 32:5s, 2014 (suppl; abstr 11047), 2014. e-Pub 2014.
- Papadimitrakopoulou V, Lee J, Wistuba II, Tsao AS, Fossella FV, Heymach J, Kalhor N, Gupta S, Gettinger SN, Byers LA, Izzo J, Miller VA, Diao L, Wang J, Wei C, Coombes KR, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting, J Clin Oncol 32:5s, 2014 (suppl; abstr 8042), 2014. e-Pub 2014.
- William WN, Papadimitrakopoulou V, Lee J, Mao L, Lin H, Gillenwater AM, Martin JW, Cohen EE, Lingen MW, Boyle J, Shin DM, Vigneswaran N, Shinn N, Myers J, El-Naggar AK, Lippman SM. Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC). 2014 ASCO Annual Meeting, J Clin Oncol 32:5s, 2014 (suppl; abstr 11047), 2014. e-Pub 2014.
- Halperin DM, Lee J, Yao JC. Predictive value of phase II clinical trials in pancreatic cancer: Rethinking the road to progress. Pancreatic Cancer. 2013 ASCO Annual Meeting, 2013. e-Pub 2013.
- Saintigny P, Lingen MW, William Jr WN, Lang W, Feng L, Lee J, Kim ES, El-Naggar AK, Papadimitrakopoulou V, Lippman SM, Mao L, Hong WK. MET receptor tyrosine kinase is a potential novel target for prevention of oral cancer. AACR Annual Meeting, 2013. e-Pub 2013.
- Tang X, Xue Y, Su X, Harun N, Cai Y, Behrens C, Papadimitrakopoulou V, Blowers D, Moran C, Kalhor N, Rice DC, Beran G, Lee J, Kilgour E, Wistuba II. Fibroblast growth factor receptor 1 (FGFR1) gene copy number gain in adenocarcinoma and squamous cell carcinoma of the lung. ASCO Annual Meeting, 2013. e-Pub 2013.
- Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Ning Tapia EML, Wang X, Do K, Lee J, Vornik LA, Tangrea J, Parnes HL, Lippman SM, Thompson IM, Brown PH, Troncoso P, Logothetis CJ. A double-blind randomized controlled multisite trial evaluating tissue effects of preoperative finasteride in clinically organ-confined prostate cancer: Pathologic outcomes. AACR Annual Meeting, 2013. e-Pub 2013.
- Kim J, Min H, Yun HJ, Jang H, Kim ES, Liu D, Lee J, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee H. Preclinical evidence supporting cotargeting insulin-like growth factor receptor (IGF-1R) and Src in non-small cell lung cancer. AACR Annual Meeting, 2013. e-Pub 2013.
- Glisson BS, Tseng J, Marur S, Shin DM, Murphy BA, Cohen EE, Thomas CY, Willey R, Cosaert J, William WN, Harun N, Lee J, Haddad RI. Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN). ASCO Annual Meeting, 2013. e-Pub 2013.
- Gold KA, Byers LA, Fan YH, Fujimoto J, Tse WH, Lee J, Gupta S, Wistuba II, Stewart DJ, Gibbons DL. A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting, 2013. e-Pub 2013.
- Papadimitrakopoulou V, Wistuba II, Lee J, Tsao AS, Kalhor N, Fossella FV, Heymach J, Alden CM, Gettinger SN, Coombes KR, Saintigny P, Tang X, Duffield E, Boyer J, Davis SE, Powis G, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting, 2013. e-Pub 2013.
- William WN, Erickson HS, Wei C, Hanson N, Tang X, Rodriguez J, Kalhor N, Lee J, Hong WK, Kim ES, Wistuba II. Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC). ASCO Annual Meeting, 2013. e-Pub 2013.
- Xing Y, Zhang J, Lin H, Sturgis EM, Garden AS, Gold KA, Lee J, William WN. Relationship between level of lymph node metastasis (LNM) and survival in head and neck squamous cell carcinoma (HNSCC). ASCO Annual Meeting, 2013. e-Pub 2013.
- Min, Hye-Young, Yun, Jeong H, Jang, Hyun-Ji, Lee, Ho-Young, Kim, Jin-Soo, Kim, Edward S, Liu, Diane, Lee, Jack J, Behrens, Carmen, Lippman, Scott M, Hong, Ki W, Wistuba, Ignacio I. Preclinical evidence supporting cotargeting insulin-like growth factor receptor (IGF-1R) and Src in non-small cell lung cancer. AACR Annual Meeting, 2013. e-Pub 2013.
- Nicholas, Courtney, Nunez, Maria I, Harun, Nusrat, Lee, Jack J, Myers, Jeffrey, Wistuba, Ignacio I, Sen, Banibrata, El-Naggar, Adel K, Lai, Stephen Y, Johnson, Faye M, Jr W, William N. SOCS2 (suppressor of cytokine signaling protein 2) is a prognostic indicator of progression-free survival in head and neck squamous cell carcinoma (HNSCC) patients. AACR Annual Meeting, 2013. e-Pub 2013.
- Massarelli E, Ginsberg LE, Lin H, Tran HT, Lee J, Williams MD, Blumenschein GR, Lu C, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. ASCO Annual Meeting, 2013. e-Pub 2013.
- Johnson FM, Tang X, Tran HT, Intyre CM, Price J, Lee J, Harun N, Wistuba II, Gol KA. A phase I/II study combining dasatinib (D) and erlotinib (E) in non-small cell lung cancer. ASCO Annual Meeting, 2013. e-Pub 2013.
- Kim W, Prudkin L, Feng L, Kim E, Hennessy B, Lee J, Lee J J, Glisson B, Lippman S, Wistuba I, Hong, W K, Lee H. EGFR and K-Ras mutations and resistance of lung cancers to IGF-1R TKI. American Association for Cancer Research,Exhibit Hall F, Poster Section 33, 2012. e-Pub 2012.
- Galindo H, Solis L, Fujimoto J, Hanson N E, McDowell C, Riquelme E, Tang X, Behrens C, Lee J J, Kim E S, Wistuba I, Erickson H S. Formalin-fixed and paraffin-embedded (FFPE) DNA recovery for high-throughput genotyping of lung cancer tissues. American Association for Cancer Research, Exhibit Hall F, Poster Section 8, 2012. e-Pub 2012.
- Behrens C, Solis L, Heather L, Tang X, Yuan P, Kadara H, Riquelme E, Galindp H, Hong W K, Lee J J, Wistuba I I. Analysis of EZH2 and TTF-1 protein expression identifies a subset of lung adenocarcinomas with better prognosis. AACR Annual Meeting, Exhibit Hall F, Poster Section 25, 2012. e-Pub 2012.
- Saintigny P, Blumenschein G R JR, Dia L, Wang J, Coombes K, Liu S, Kim E, Tsao A, Herbst R, Alden C, Lee J J, Tang X, Stewart D, Kies M, Fossella F, Tran H, Mao L, Hicks M, Erasmus J, Gupta S, Girard L, Peyton M, Davis S, Lippman S, Hong W K, Minna J, Wistuba I, Heymach J. Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC). American Association for Cancer Reserach, Level 1, Room W 192, 2012. e-Pub 2012.
- Janku F, Garrido-Laguna I, Wheler J J, Hong D S, Naing A, Falchook G S, Fu S, Moulder S L, Luthra R, Lee J J, Tsimberidou A M, Kurzrock R. Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. 2011 Annual Meeting of the American Society for Clinical Oncology, Chicago , Illinois, 2011. e-Pub 2011.
- Tsao A S, Liu S, Lee J J, Alden C M, Kim E S, Blumenschein G R, Herbst R S, Lippman S M, Wistuba I I, Hong W K. Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. 2011 Annual Meeting of the American Society for Clinical Oncology, Chicago , Illinois, 2011. e-Pub 2011.
- Nunez M I, Suraokr M, Behrens C, Woods D M, Lin H, Lee J J, Mehran R J, Franklin W, Tsao A, Wistuba I I. Folate pathway in malignant pleural mesothelioma (MPM): Novel therapeutic opportunities due to folate receptor alpha overexpression. 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- Komaki R U, Wistuba I, Tang X M, Meyn R E JR, Lee J J, Wei X, Allen P K, O'Reilly M S, Welsh J, Hong W K. Phase II study of chemoradiation therapy and erlotinib for stage III non-small cell lung cancer. 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- Lu C, Stewart D J, Ji L, Ramesh R, Jayachandran G, Nunez M I, Wistuba I I, Erasmus J J JR, Lee J J, McMannis J D, Templeton N S, Roth J A. Systemic gene therapy with tumor suppressor TUSC2/FUS1 nanoparticles for recurrent/metastatic lung cancer. 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- Heymach J V, Saintigny P, Kim E S, Byers L A, Lee J J, Coombes K, Diao L, Wang J, Tran H, Fan Y H, Tsao A, Blumenschein GR JR, Papadimitrakopoulou V A, Tang X, Story M, Xie Y, Girard L, Weinstein J, Mao L, Minna JD, Herbst R, Lippman S M, Hong W K, Wistuba I I. Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination). 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- Saintigny P, Liu D, Lee JJ, Ping Y, Behrens C, Solis-Soto LM, Heymach JV, Kim ES, Hong WK, Kurie JM, Wistuba II, Koo JS. CXCR2 expression in tumor cells is associated with an adverse outcome in a large set of non-small-cell lung cancer (NSCLC). 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- Saintigny P, Jelinek J, Pickering C R, Lang W, Frederick M J, Zhang L, Ren H, Papadimitrakopoulou V, Lee J J, Kim E S, Fan Y H, El-Naggar A K, Hong W K, Myers J, Issa J J, Lippman S M, Mao L. DNA methyltransferase-3B (DNMT3B) in oral cancer (OC) development. 2011 Annual Meeting of the American Society of Clinical Oncology, 2011. e-Pub 2011.
- Kim J S, Kim E S, Liu D, Lee J J, Solis L, Behrens C, Lippman S, Hong W K, Wistuba I I, Lee H Y. Insulin receptor expression and survival of patients with non-small cell lung cancer. 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- Gold K A, Lee J J, Ping Y, Behrens C, Liu D, Lee H, Koo J S, Lotan R, Solis L, Rinsurongkawong W, Stewart D J, Hofstetter W L, Swisher S, Lippman S M, Wistuba I I, Hong W K, Kim E S. Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC). 2011 Annual Meeting of the American Society for Clinical Oncology, Chicago , Illinois, 2011. e-Pub 2011.
- Komaki R, Blumenschein G R, Wistuba I I, Lee J J, Allen P, Wei X, Welsh J, O'Reilly M, Herbst R S, Tang X, Meyn R, Liu D, Hong W K. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. 2011 Annual Meeting of the American Society for Clinical Oncology, Chicago , Illinois, 2011. e-Pub 2011.
- Fujimoto J, Kadara H, Behrens C, Liu D, Lee J J, Solis L M, Kim E, Sharafkhaneh A, Wistuba I I, Reuben L. Implication of GPRC5A loss in lung carcinogenesis in patients with and without chronic obstructive pulmonary disease. 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- Kadara H, Saintigny P, Fan Y, Chow C W, Chu Z, Lang W, Behrens C, Gold K, Liu D, Lee J J, Mao L, Kim E S, Hong W K, Wistuba I I. Gene expression analysis of field of cancerization in early stage NSCLC patients towards development of biomarkers for personalized prevention. 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- Saintigny P, Diao L, Wang J, Girard L, Lin S H, Coombes KR, Liu S, Lee JJ, Weinstein JN, Xie Y, Fan YH, Tang XM, Kim ES, Herbst RS, Tsao A, Blumenschein GR, Mao L, Lippman SM, Minna J D, Hong W K, Wistuba I I, Heymach J V. A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS. 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- Ihle N T, Herbst R S, Kim E S, Wistuba I I, Lee J J, Blumenschein GR JR, Tsao AS, Chen L, Zhang S, Alden C M, Tang X, Liu S, Stewart D J, Papadimitrakopoulou V, Heymach J V, Tran H T, Hicks M E, Erasmus J J, Gupta S, Minna J D, Larsen J, Lippman S M, Hong W K, Powis G. 1 Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer. 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- Hong W K, Kim E S, Lee J J, Wistuba I, Lippman S. The landscape of cancer prevention: Personalized approach in lung cancer. 2011 Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011. e-Pub 2011.
- William W N JR, Weber R S, Lee J J, Myers J, Ginsberg L E, El-Naggar A K, Sturgis E M, Sabichi A L, Kies M S, Hanna E Y, Hessel A C, Lu C, Lai C Y, Ayuste R, Lippman S M, Kim E S. Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes. 2011 Annual Meeting of the American Society for Clinical Oncology, Chicago , Illinois, 2011. e-Pub 2011.
- Liu, S, Lee JJ. Design, implementation, and results for a Bayesian adaptive randomization trial for targeted therapy in lung cancer. Joint Statistical Meetings, Vancouver, British Columbia, Canada, 2010. e-Pub 2010.
- Liu, D, Lee, JJ. The use and misuse of statistical methods reported in Clinical Cancer Research. Joint Statistical Meetings, Vancouver, British Columbia, Canada, 2010. e-Pub 2010.
- Lin HY, Lipsitz SR, Fitzmaurice G, Lipshutlz S, Lee JJ. Bayesian Extension of Fisher's Exact Test in the Presence of Missing Data. Joint Statistical Meetings, Vancouver, British Columbia, Canada, 2010. e-Pub 2010.
- Jiang F, Lee JJ, Mueller P. Application of Group Sequential Methods with Response Adaptive Randomization Design for Comparing the Treatment Effect with Binary Outcomes: An Evaluation of Bayesian Decision Theory Approach. Spring Meeting of the International Biometric Association, Eastern and North American Region (ENAR), New Orleans, LA, 2010. e-Pub 2010.
Book Chapters
- Lee JJ, Berry DA. Statistical Innovation in Cancer Research. In: In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons Ltd, 2023.
- Long JP, Lee JJ. Inferential Frameworks for Clinical Trials. In: Piantadosi S, Meinert CL (eds) Principles and Practice of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-52677-5_271-1, 2021.
- Lin R, Lee JJ. Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials. In: Andriëtte Bekker, (Din) Ding-Geng Chen, Johannes T. Ferreira (Editors): Computational and Methodological Statistics and Biostatistics: Contemporary Essays in Advancement (Emerging Topics in Statistics and Biostatistics) (Aug 10, 2020). Springer, 2020.
- Yuan Y, Zhou Y, Lee JJ. Early Phase Clinical Trials (Chapter 21). In: Cohen, E., Mell, L. K., Murphy, J. D., and Tran, P. T. Principles of Clinical Cancer Research. Springer Publishing Company, 2018.
- Lee JJ, Trippa L. Adaptive Clinical Trial Designs in Oncology. In: Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. Chapman and Hall/CRC. Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis, 365-408, 2016.
- Lee JJ, Berry DA. Statistical Innovation in Cancer Research. In: Holland-Frei Cancer Medicine. 9th Edition. John Wiley & Sons Ltd: United Kingdom, 2016.
- Kong M, Lee JJ. Confidence Interval for Interaction Index. In: Statistical Methods in Drug Combination Studies. Zhao W, Yang H. Chapman and Hall/CRC, 55-72, 2015.
- Lippman, SM, Lee JJ. The Molecular Basis of Cancer. In: Cancer Chemoprevention. Fourth Edition. Elsevier Inc, 809-824, 2014.
- Lee JJ, Chu C. Novel Statistical Models for NSCLC Clinical Trials. In: Lung Cancer. 4th edition. Roth JA et al. John Wiley and Sons, Inc, 488-504, 2014.
- Lee JJ, Chen N. Software for Design and Analysis of Clinical Trials. In: Handbook of Statistics in Clinical Oncology. 3rd Ed. J. Crowley, A. Hoering, Taylor and Francis Group, 305-324, 2012.
- Hobbs B, Lee JJ. Adaptive Trial Designs. In: Handbook of Statistics in Clinical Oncology. 3rd Ed. J. Crowley, A. Hoering, Taylor and Francis Group, 265-292, 2012.
- Gan HK, Lee JJ, Siu LL. Phase II Trials with Anticancer Agents. In: Principles of Anticancer Drug Development. Ed(s) M. Hidalgo, S.G. Eckhardt, E. Garrett-Mayer, N.J. Clendeninn. Springer, 141-62, 2011.
- Lippman SM, Lee JJ. Cancer chemoprevention. In: The Molecular Basis of Cancer. 3rd. Saunders-Elsevier, 711-720, 2008.
- Lee JJ. Clinical trial design for anticancer therapies. In: The Cancer Handbook. 2nd Ed. Wiley, 1330-44, 2007.
- Lee JJ. Design and Analysis of Clinical Trials. In: Cancer - Principles and Practice of Oncology Review, 98-103, 2005.
- Lee JJ, Moon H. Calibration. In: Encyclopedia of Biostatistics. 2nd Ed. John Wiley & Sons Ltd, 579-585, 2005.
- Lee JJ. Statistical Methods of Biomarker Analysis for Head and Neck Carcinogenesis and Prevention. In: Head & Neck Cancers, 287-303, 2002.
- Lee JJ. Calibration. In: Encyclopedia of Biostatistics. John Wiley & Sons Ltd, 461-466, 1998.
Books (edited and written)
- Yuan Y, Lin R, Lee JJ. Model-Assisted Bayesian Designs for Dose Finding and Optimization: Methods and Applications. CRC Press, 2022.
- Berry SM, Carlin BP, Lee JJ, and Mueller P. Bayesian Adaptive Methods for Clinical Trials. CRC Press, 2010.
Patient Reviews
CV information above last modified March 11, 2026